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ABSTRACT	  	  	   The	  Chfr	   checkpoint	   is	   a	  point	  at	  which	  a	   cell	   checks	  whether	   it	   is	   safe	   to	  enter	   mitosis.	   	   Chfr	   is	   a	   protein	   that	   functions	   at	   this	   particular	   checkpoint	   to	  ensure	  safe	  entry	  into	  mitosis,	  but	  the	  molecular	  mechanism	  by	  which	  this	  protein	  functions	  is	  not	  entirely	  clear.	  	  The	  hypothesis	  in	  this	  thesis	  is	  that	  Ubc13,	  Chfr,	  and	  Uev1/Mms2	  function	  together	   in	  mitosis	  during	  the	  Chfr	  checkpoint.	   	  The	  results	  were	   observed	   using	   immunocytochemistry,	   the	   mitotic	   shake	   off	   procedure,	  Western	  blot	  analysis,	  and	  coimmunoprecipitation.	   	  High	  Ubc13,	  Mms2,	  and	  Chfr-­‐Ub	   levels	  at	   the	   interphase-­‐early	  prophase	   transition	   indicate	   that	   these	  proteins	  function	   together	   at	   the	   Chfr	   checkpoint.	   	   Localization	   of	   Chfr	   to	   decondensed	  chromatin	   in	   interphase	   cells	   and	   to	   decondensing	   chromatin	   in	   telophase	   cells	  indicates	   a	   decondensing	   function	   for	   Chfr.	   Interaction	  between	  Chfr	   and	  Ubc13,	  Chfr	  and	  phosphorylated	  histone	  H3,	  as	  well	  as	  Ubc13	  and	  phosphorylated	  histone	  H3	   further	   indicates	   that	   these	   proteins	   may	   function	   together	   at	   the	   Chfr	  checkpoint,	   because	   phosphorylated	   histone	   H3	   is	   a	   mitotic	   protein	   at	   that	  particular	   point	   in	   mitosis.	   Localization	   of	   Chfr,	   Ubc13,	   and	   Mms2	   to	   the	  centrosomes	   indicates	   that	   they	   function	   together	   at	   these	   sites	   to	   target	  substrates	  important	  in	  centrosome	  maturation,	  separation,	  and	  spindle	  formation.	  	  Furthermore,	   there	   are	   two	  molecular	   states	   of	   Chfr:	   Chfr	   and	   Chfr-­‐Ub.	   	   Chfr	   is	  predominant	   at	   late	   prophase,	   whereas,	   Chfr-­‐Ub	   is	   predominant	   at	   interphase-­‐early	  prophase.	  Chfr	  increases	  in	  level	  upon	  nocodazole	  exposure	  at	  late	  prophase	  to	  counteract	  the	  mitotic	  stress;	  and	  it	  also	  looses	  its	  ubiquitin	  signal	  upon	  passage	  into	  mitosis.	  	  High	  Ubc13	  and	  Mms2	  levels	  coincide	  with	  high	  Chfr-­‐Ub	  levels	  at	  the	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interphase-­‐early	  prophase	  transition,	  indicating	  that	  they	  function	  together	  at	  the	  Chfr	  checkpoint.	  	  The	  ubiquitin	  signal	  could	  be	  either	  K-­‐48-­‐linked	  or	  K-­‐63-­‐linked	  in	  nature.	   We	   propose	   that	   the	   Chfr,	   Ubc13,	   and	   Mms2	   protein	   complex	   could	  function	   through	   an	   auto-­‐ubiquitination-­‐decondensation-­‐Chfr	   destruction-­‐recondensation	  mechanism.	   	   Furthermore,	   Chfr	   could	   bind	   to	   pH3	   and	   its	   auto-­‐ubiquitin	   signal	   to	   serve	   as	   a	   bulky	   modification	   that	   hinders	   chromosome	  condensation.	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CHAPTER	  1:	  INTRODUCTION	  	  	   During	  mitosis	  a	  cell	  must	  accurately	  divide	  itself	  and	  its	  two	  meters	  of	  genetic	  material	  into	  two	  daughter	  cells.	   	  The	  vulnerability	  of	  mitosis	  often	  manifests	  itself	  in	  the	  form	  of	  cancer.	   	  Mitotic	  inaccuracy	  threatens	  genetic	  instability,	  which	  could	  result	  not	  only	   in	   the	  demise	  of	   the	  cell	  containing	   that	   inaccuracy,	  but	  also	   in	   the	  demise	  of	  the	  organism	  as	  a	  whole.	  	  	  	   It	   is	   likely	   for	   this	   reason	   that	   cells	   employ	   molecular	   machines,	   called	  “mitotic	   checkpoint	   proteins,”	   to	   regulate	   their	   entry	   and	   progression	   through	  mitosis.	   	   If	   during	  mitosis	   cells	   encounter	   stress	   or	   detect	   a	   suspicious	   event	   that	  could	  pose	  a	  threat	  to	  accurate	  cell	  division,	  mitotic	  checkpoint	  proteins	  sense	  this	  threat,	   transduce	   a	   signal	   for	   help,	   and	   execute	   the	   appropriate	   response	   to	   that	  threat	  –	  giving	  a	  cell	  more	  time	  to	  cope	  with	  the	  stress.	  	   Chfr	   is	   one	   such	   mitotic	   molecular	   machine	   (Privette	   et	   al.,	   2008a).	   	   The	  function	   of	   Chfr	   is	   presumed	   to	   stop	   mitotic	   entry	   under	   conditions	   that	   could	  compromise	  genetic	   stability	  of	   the	   cell.	   	  This	  protein	   is	   considered	   to	  be	  a	   tumor	  suppressor	   and	   is	   frequently	   down-­‐regulated	   in	   human	   cancers	   by	   promoter	  hypermethylation,	   resulting	   in	   reduced	   Chfr	   protein	   levels,	   a	   high	   number	   of	  condensed	   chromosomes,	   and	   a	   high	  mitotic	   index	   (MI)	   following	   treatment	  with	  nocodazole	  (Earson	  and	  Petty,	  2004;	  Privette	  et	  al.,	  2008a,b;	  Yu	  et	  al.,	  2005).	   	  Cells	  containing	  Chfr	  frequently	  have	  a	  lower	  number	  of	  condensed	  chromosomes	  and	  a	  lower	  mitotic	  index	  following	  treatment	  with	  nocodazole.	  	  Nocodazole	  disassembles	  microtubules	   and	   is	   a	   form	  of	  mitotic	   stress.	   	   	  CHFR	   is	   composed	  of	   at	   least	   three	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functional	  domains:	   the	  N-­‐terminal	   forkhead-­‐associated	  (FHA)	  domain,	   the	  central	  RING	  finger	  domain,	  and	  the	  cysteine-­‐rich	  C-­‐terminal	  domain.	  	  	  	  
	  
1.1 Chfr	  domain	  structure	  and	  functions.	  
1.1.1	  The	  FHA	  domain	  of	  Chfr.	   	  The	  Chfr	  protein	  has	  three	  domains	  (Figure	  1-­‐1).	  	  Chfr	   has	   the	   ability	   to	   bind	   phosphorylated	   peptides	   through	   its	   FHA	   domain	  (Stavridi	  et	  al.,	  2002).	  	  A	  colony	  formation	  assay	  was	  used	  to	  show	  how	  expression	  of	  Chfr	  affects	  the	  growth	  of	  cells	  (Fukuda	  et	  al.,	  2008).	  	  Wild	  type	  Chfr,	  vector	  alone,	  or	  the	  Chfr	  FHA	  deletion	  mutant	  were	  expressed	  in	  HCT116	  and	  RKO	  cells.	  	  The	  cells	  expressing	  the	  Chfr	  FHA	  deletion	  formed	  a	  fewer	  number	  of	  colonies/dish	  than	  did	  cells	   expressing	   the	   vector	   alone,	   and	   cells	   containing	   wild	   type	   Chfr	   had	   a	  substantially	   smaller	   number	   of	   colonies/dish	   than	   did	   cells	   expressing	   Chfr	   that	  lacked	   the	   FHA	  domain.	   	   The	   cells	   used	   for	   this	   experiment	  were	  not	   expected	   to	  contain	  endogenous	  Chfr	  (Fukuda	  et	  al.,	  2008).	  	  This	  indicates	  that,	  in	  the	  absence	  of	  the	   FHA	   domain,	   Chfr	   still	   contains	   some	   anti-­‐proliferative	   activity,	   because	   this	  protein	   still	   reduces	   proliferation,	   but	   is	   not	   as	   efficient	   as	   wild	   type	   Chfr.	   	   In	  summary,	  the	  data	  demonstrate	  that	  the	  FHA	  domain	  affects	  the	  tumor	  suppressive	  quality	  of	  Chfr,	  perhaps	  because	  of	  its	  importance	  in	  substrate	  binding.	  	  Their	  results	  indicate	  that	  the	  FHA	  domain	  of	  Chfr	  plays	  a	  role	  in	  preventing	  mitotic	  progression,	  and	  when	  deleted	  partially	   reduces	  Chfr	   function,	   resulting	   in	   a	  higher	  number	  of	  mitotic	   cells.	   	   Absence	   of	   the	   FHA	   domain	   in	   Chfr	  may	   prevent	   proper	   binding	   of	  Chfr	  to	  its	  substrate.	   	  This	  could	  in	  turn	  interfere	  with	  proper	  ubiquitination	  of	  the	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substrate,	  causing	  inefficient	  stress	  signaling,	  inefficient	  mitotic	  delay,	  and	  a	  higher	  likelihood	  of	  proliferation.	  	   Using	  the	  mitotic	  index	  assay,	  one	  group	  showed	  that	  expression	  of	  the	  Chfr	  FHA	  deletion	  in	  SAOS2	  cells,	  which	  are	  expected	  to	  contain	  the	  Chfr	  checkpoint	  and	  endogenous	  Chfr	  protein	  expression,	  actually	  results	  in	  an	  increased	  mitotic	  index	  in	  SAOS2	  cells	   following	  nocodazole	  exposure	  (Scolnick	  and	  Halazonetis,	  2000).	   	  This	  indicates	   that	   the	   Chfr	   FHA	   deletion	   protein	   in	   cells	   expressing	   Chfr	  may	   actually	  compete	  with	  the	  functional	  form	  of	  the	  protein	  for	  binding	  to	  substrate,	  preventing	  functional	   Chfr	   from	   binding	   to	   substrate	   and	   generating	   the	   expected	   signal	   for	  reducing	  mitotic	  index.	  	  	   Expression	  of	  the	  Chfr	  FHA	  deletion	  mutant	  in	  control	  cells	  that	  either	  lacked	  Chfr	  expression	  (DLD-­‐1)	  or	  already	  expressed	  a	  Chfr	  mutant	  (U2OS),	  had	  no	  effect	  on	  mitotic	   index	   following	  nocodazole	   exposure	   as	   expected.	   	  Only	  wild	   type	  Chfr	  expression	  had	  a	  clear	  effect	  on	  mitotic	  index	  in	  these	  cells.	  	  This	  indicates	  that	  the	  FHA	  domain	  of	  Chfr	  is	  important	  for	  its	  function	  (Scolnick	  and	  Halazonetis,	  2000).	  	   Using	   the	   DIC	   microscopy	   assay,	   Matsusaka	   and	   Pines	   showed	   using	   DIC	  microscopy	   that	   cells	   expressing	   wild	   type	   Chfr	   clearly	   return	   to	   interphase	  following	   treatment	  with	   a	  microtubule	   poison	   such	   as	   colcemid	   	   (Matsusaka	   and	  Pines,	  2004).	   	  The	  wild	   type	  cells	  were	   then	  compared	   to	  cells	   that	  express	  a	  Chfr	  FHA	   deletion,	   and	   these	   particular	   cells	   were	   unable	   to	   return	   to	   interphase,	  progressing	  directly	   into	  mitosis	   (Matsusaka	  and	  Pines,	  2004).	   	  This	   suggests	   that	  the	  FHA	  domain	  of	  Chfr	  is	  required	  for	  early	  prophase	  checkpoint	  function.	  	  
	  	  

















Figure	  1-­‐1.	  	  A	  diagram	  showing	  the	  Chfr	  domains.	  	  There	  is	  the	  fork-­‐head	  associated	   (FHA)	   domain,	   the	   ring-­‐finger	   (RF)	   domain,	   and	   the	   C-­‐terminal	  cysteine	  rich	  (CR)	  domain.	  	  	   	  
FHA CR RF 
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   By	  using	   a	  metaphase	   spread	   assay,	   it	  was	   shown	   that	   the	  FHA	  deletion	   in	  Chfr	  generates	  aneuploidy	  (Yu	  et	  al.,	  2005).	  This	  data	  indicates	  that	  the	  FHA	  domain	  of	   Chfr	   is	   important	   for	   preventing	   cells	   from	   progressing	   into	   mitosis	   with	   an	  abnormal	   number	   of	   chromosomes.	   	   Using	   the	   ubiquitination	   assay,	   it	   was	  demonstrated	   that	  when	   the	  FHA	  and	  RING	   finger	  domain	  of	  Chfr	   is	  present,	  Chfr	  auto-­‐ubiquitinates	   itself	   lightly	   (Kang	   et	   al.,	   2002).	   	   The	   smaller	   constructs,	  which	  lack	  the	  FHA	  domain	  and	  contain	  only	  the	  RING	  finger	  domain,	  on	  the	  other	  hand,	  have	  more	  pronounced	  ubiquitin	  ligase	  activity.	   	  This	  indicates	  that	  the	  deletion	  of	  the	   FHA	   domain	   could	   increase	   the	   ability	   of	   Chfr	   to	   auto-­‐ubiquitinate	   itself,	  improving	  the	  kinetics	  of	  the	  ubiquitination	  reaction	  (Kang	  et	  al.,	  2002).	  
	  
1.1.2	  The	  C-­‐terminal	  cysteine-­‐rich	  Chfr	  domain.	   	  Aurora	  A	  is	  one	  potential	  Chfr	  substrate	  (Yu	  et	  al.,	  2005).	   	  The	  C-­‐terminal	  region	  of	  Chfr	   interacts	  with	  Aurora	  A,	  and	  is	  required	  for	  its	  ubiquitination.	  	  This	  group	  also	  showed	  that	  Chfr	  levels	  affect	  the	  levels	  of	  Aurora	  A	  in	  cells.	  	  Another	  potential	  substrate	  for	  Chfr	  is	  HDAC.	  	  Young	  et	  al.	  (2009)	  showed	  that	  the	  C-­‐terminus	  of	  Chfr	  is	  required	  for	  its	  interaction	  with	  HDAC	  and	  is	  required	  for	  its	  ubiquitination.	  	  Increasing	  Chfr	  levels	  results	  in	  HDAC	  decrease.	  	   Scolnick	  and	  Halazonetis	  (2000)	  detected	  a	  mutation	  in	  the	  Chfr	  protein	  that	  was	   naturally	   expressed	   in	   U2OS	   cells.	   	   The	   group	   generated	   cell	   lines	   stably	  expressing	  this	  mutation.	   	  The	  expression	  of	  this	  C-­‐terminal	  mutant	  in	  DLD-­‐1	  cells,	  which	  are	  not	  expected	  to	  contain	  Chfr	  or	  the	  checkpoint,	  did	  not	  have	  an	  effect	  on	  their	  mitotic	   index,	   as	   compared	   to	   the	  vector	   control.	   	  Only	  wild	   type	  expression	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had	  a	  prominent	  effect	  on	  mitotic	  index.	  	  This	  indicates	  that	  the	  C-­‐terminal	  region	  of	  Chfr	  is	  important	  in	  reducing	  mitotic	  index	  (Scolnick	  and	  Halazonetis,	  2000).	  	   Chaturvedi	  et	  al.	  (2002)	  also	  showed	  that	  the	  C-­‐terminal	  Chfr	  mutation	  was	  very	   similar	   to	   the	   vector	   in	   terms	   of	   MI,	   whereas	   wild	   type	   Chfr	   expression	  substantially	   reduced	   mitotic	   index.	   This	   indicates	   that	   the	   C-­‐terminal	   domain	   is	  involved	  in	  preventing	  mitotic	  progression.	  
	  
1.1.3	  The	  RING	  domain	  of	  Chfr.	  	  The	  RING	  finger	  domain	  gives	  Chfr	  its	  E3	  ubiquitin	  ligase	   activity,	   enabling	   the	   ligase	   to	   ubiquitinate	   itself,	   as	  well	   as	   other	   potential	  substrate	  proteins	  	  (Yu	  et	  al.,	  2005;	  Kang	  et	  al.,	  2002;	  Chaturvedi	  et	  al.,	  2002).	  	  	  The	  nature	   of	   the	   ubiquitination	   required	   to	   achieve	   the	   early	   prophase	   checkpoint	   is	  unclear.	  	  Some	  reports	  indicate	  that	  CHFR	  targets	  cell	  cycle	  promoting	  proteins	  such	  as	   Plk1	   or	   Aurora	   A,	   for	   degradation	   through	  K48-­‐linked	   poly-­‐ubiquitin	   chains	   to	  delay	  mitotic	  entry	  in	  response	  to	  microtubule	  damage	  (Yu	  et	  al.,	  2005;	  Kang	  et	  al.,	  2002).	   	   Other	   reports	   support	   the	   idea	   that	   CHFR	   functions	   through	   K63-­‐linked	  poly-­‐ubiquitin	   chains	   possibly	   by	   targeting	   the	   p38	   kinase	   pathway	   to	   achieve	  mitotic	  delay	  (Bothos	  et	  al.,	  2003;	  Matsusaka	  and	  Halazonetis,	  2004).	   	   	  K63-­‐linked	  poly-­‐ubiquitin	  chains	  are	  not	  used	  for	  degradation,	  but	  rather	  to	  alter	  the	  activity	  of	  a	  particular	  target	  protein.	  	  	  	  	  	   Wild	   type	  Chfr	   can	  ubiquitinate	   itself,	   but	  when	   the	  RING	   finger	  domain	  of	  Chfr	  is	  changed	  Chfr	  can	  no	  longer	  ubiquitinatinate	  itself	  (Kang	  et	  al.,	  2002).	   	  Thus	  the	  RING	   finger	  domain	   is	  necessary	   for	  Chfr	  auto-­‐ubiquitination.	   	  This	  group	  also	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showed	  that	  the	  presence	  or	  absence	  of	  the	  FHA	  domain	  influences	  the	  ability	  of	  the	  RING	  finger	  portion	  of	  Chfr	  to	  carry	  out	  the	  auto-­‐ubiquitination	  process.	  	  	  	   Wild	   type	  Chfr	   can	  ubiquitinate	   itself	  while	   the	  RING	   finger	  mutant	  of	  Chfr	  cannot	   ubiquitinate	   itself	   (Chaturvedi	   et	   al.,	   2002).	   	   Chfr	   lacking	   cells	   expressing	  vector	  alone	  or	  Chfr	  RING	  finger	  mutant	  cells	  have	  reduced	  survival	  than	  wild	  type	  Chfr	   containing	   cells.	   	   Expression	   of	   Chfr	   in	   this	   case	   improves	   viability	   of	   DLD-­‐1	  cells	   in	   taxol	   because	   the	   safety	   checkpoint	   is	   restored.	   	   Expression	   of	   the	   RING	  finger	  mutant	   or	   vector	   alone	   in	   these	   same	   cells	   decreases	   the	   viability	   because	  there	  is	  no	  safety	  checkpoint	  restored	  in	  this	  case.	  	   Bothos	  et	  al.	  (2003)	  showed	  that	  Chfr	  mutants	  that	  have	  lost	  ubiquitin	  ligase	  activity	  could	  not	  reduce	  mitotic	  index.	  	  Cells	  expressing	  wild	  type	  Chfr,	  on	  the	  other	  hand,	  can	  reduce	  their	  own	  mitotic	  index.	  	  	   According	   to	  Matsusaka	   and	   Pines	   (2004),	   U2OS	   cells	   expressing	   the	   RING	  finger	  mutant	  of	  Chfr	  progressed	  readily	  into	  mitosis,	  whereas	  cells	  expressing	  wild	  type	  Chfr	  did	  not	  progress	  into	  mitosis,	  remaining	  in	  an	  interphase-­‐early	  prophase	  like	  state.	  	   Kim	   et	   al.	   (2011)	   showed	   very	   clearly	   how	   the	  Chfr	   protein	   could	   function	  during	   the	   Chfr	   checkpoint.	   This	   group	   showed	   that	   when	   wild	   type	   Chfr	   is	  expressed	   in	   cells,	   Chfr	   levels	   decrease	   over	   time	   after	   release	   from	   the	   double	  thymidine	  block,	  while	  pH3	  levels	  rise.	  	  This	  is	  an	  inverse	  relationship	  between	  Chfr	  and	   pH3	   protein	   levels.	   	   This	   decrease	   in	   CHFR	   is	   probably	   due	   to	   a	   degradative	  auto-­‐ubiquitin	  signal,	  which	  allows	  cells	  to	  enter	  mitosis.	  	  	  Chfr	  level	  decreases	  here	  over	  time	  because	  the	  Chfr	  protein	  becomes	  less	  and	  less	  necessary	  as	  cells	  progress	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through	  mitosis.	   	   Kim	   et	   al.	   also	   points	   out	   here	   that	   wild	   type	   CHFR	   expression	  results	   in	   less	   pH3	  protein	   expression	   in	   comparison	   to	   cells	   expressing	  no	  CHFR	  protein.	   	   This	   is	   in	   line	   with	   Chfr	   preventing	   cells	   from	   entering	   mitosis	   as	   Chfr	  protein	  levels	  go	  up,	  pH3	  protein	  levels	  (mitotic	  indicators)	  go	  down.	  	  A	  Chfr	  mutant	  that	   contains	   ubiquitin	   ligase	   activity,	   but	   cannot	   auto-­‐ubiquitinate	   itself	   for	  destruction	  (FLAG-­‐Chfr	  K2A),	  on	  the	  other	  hand,	  remains	  stable	  over	  time	  in	  terms	  of	  protein	  level.	  	  Phospho-­‐histone	  H3	  levels	  do	  not	  increase	  over	  time	  in	  these	  cells,	  and	  remain	  much	  lower	  in	  comparison	  to	  wild	  type	  Chfr	  control	  cells,	  as	  Chfr	  level	  is	  high	  and	  prevents	  cells	  from	  entering	  mitosis	  (Kim	  et	  al.,	  2011).	  	  This	  indicates	  that	  auto-­‐ubiquitination	   of	   Chfr	   is	   degradative	   in	   nature,	   and	   functions	   to	   reduce	   Chfr	  levels	  in	  order	  to	  allow	  cells	  to	  go	  through	  the	  G2/M	  checkpoint	  gate.	  	  	   When	  Chfr	   cannot	   auto-­‐ubiquitinate	   itself	   for	   destruction,	   its	   levels	   remain	  high.	   	   Likewise,	   pH3	   levels	   are	   substantially	   reduced	   in	   the	   presence	   of	   such	   a	  protein.	   	   The	   FLAG-­‐Chfr	   K2A	   protein	   for	   example,	   is	   resistant	   to	   ubiquitination-­‐mediated	  degradation.	   	  It	  can	  ubiquitinate	  itself,	  but	  it	  cannot	  effectively	  reduce	  its	  own	  level.	  	  pH3	  levels	  are	  substantially	  lower	  in	  cells	  expressing	  FLAG-­‐Chfr	  K2A,	  in	  comparison	  to	  pH3	  levels	  in	  cells	  expressing	  wild	  type	  FLAG-­‐Chfr.	  	  The	  modification	  on	   the	   FLAG-­‐Chfr	   K2A	   protein	   appears	   to	   improve	   the	   ability	   of	   this	   particular	  protein	   to	   keep	   chromosomes	   in	   a	   decondensed	   state.	   	   A	   possible	   explanation	   for	  this	  is	  that	  FLAG-­‐Chfr-­‐K2A	  binds	  to	  pH3	  directly,	  auto-­‐ubiquitinates	  itself	  or	  pH3	  at	  this	   location,	   and	   the	   stabilized	   ubiquitin	   signal	   results	   in	   stearic	   hindrance	   that	  either	   prevents	   the	   chromosomes	   from	   compacting	   or	   prevents	   further	   access	   to	  pH3.	  	  In	  this	  way,	  pH3	  levels	  could	  be	  kept	  low,	  and	  mitosis	  is	  prevented.	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1.2.	  Roles	  of	  Chfr	   in	  the	  early	  prophase	  checkpoint	  and	  the	  spindle	  assembly	  
checkpoints.	  
Several	   lines	   of	   evidence	   support	   the	   notion	   that	   CHFR	   is	   involved	   in	   two	  distinct	   mitotic	   checkpoints:	   the	   antephase	   or	   early	   prophase	   checkpoint,	   which	  guards	   entry	   into	   mitosis,	   and	   spindle	   assembly	   checkpoint,	   which	   guards	   the	  metaphase	   to	   anaphase	   transition.	   	   Both	   checkpoints	   are	   induced	   in	   response	   to	  microtubule	  damage.	  	  
	   The	  G2/M	  checkpoint	  and	  the	  spindle	  checkpoint	  should	  work	  together,	  with	  the	  G2/M	  checkpoint	  preventing	  damaged	  cells	  from	  progressing	  through	  the	  G2/M	  transition	   (lowering	   the	   EPI)	   and	   the	   spindle	   checkpoint	   catching	   anything	   that	  manages	  to	  squeeze	  through	  the	  G2/M	  checkpoint	  gate	  (increasing	  the	  MI).	  	  Unable	  to	  divide,	  these	  cells	  should	  then	  undergo	  apoptosis.	  	  	  
	   	  
1.2.1	   Chfr	   in	   the	   early	   prophase	   checkpoint.	   	   During	   microtubule	   damage	  induced	  by	  nocodazole,	   colcemid,	  or	   taxanes,	  CHFR	  has	  been	  shown	   to	   transiently	  delay	   the	   G2-­‐to-­‐M	   transition	   by	   mitotic	   index	   assay	   and	   immunocytochemistry	  (Scolnick	  and	  Halazonetis,	  2000).	  	  The	  mitotic	  index,	  which	  is	  the	  percentage	  of	  cells	  with	   condensed	   chromosomes,	   is	   reduced	   in	   CHFR-­‐expressing	   cells	   treated	   with	  microtubule	  poisons	  	  (Scolnick	  and	  Halazonetis,	  2000;	  Summers	  et	  al.,	  2005;	  Ogi	  et	  al.,	   2005).	   	   Scolnick	   and	   Halazonetis	   (2000)	   analyzed	   DLD-­‐1-­‐neo	   and	   DLD-­‐1-­‐Chfr	  cells	   that	   were	   synchronized	   using	   the	   double	   thymidine	   block,	   and	   treated	   with	  nocodazole	  for	  2	  hours,	  12	  hours	  after	  release	  from	  the	  S	  phase	  block.	  	  The	  MI	  assay	  and	  immunocytochemistry	  was	  then	  done	  on	  both	  cell	  types	  to	  determine	  the	  effect	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of	   Chfr	   expression.	   	   Colcemid-­‐treated	   cells	   lacking	   Chfr	   (DLD-­‐1-­‐neo)	   progressed	  readily	  into	  mitosis	  like	  untreated	  cells,	  with	  no	  delay	  into	  mitosis	  upon	  nocodazole	  treatment.	  	  The	  mitotic	  index	  increased	  as	  cells	  progressed	  through	  mitosis,	  just	  like	  in	  untreated	  cells,	  and	  cells	  condensed	  their	  chromosomes	  faster	  than	  DLD-­‐1-­‐CHFR	  cells.	  	  These	  were	  also	  more	  prone	  to	  death	  during	  nocodazole	  exposure.	  	  Colcemid-­‐treated	  cells	  over-­‐expressing	  Chfr	  (DLD-­‐1-­‐Chfr),	  on	  the	  other	  hand,	  remained	  in	  an	  interphase-­‐like	  state	  for	  several	  hours,	  with	  no	  chromosome	  condensation	  and	  low	  MI	   in	   comparison	   to	  untreated	   cells	   (Scolnick	   and	  Halazonetis,	   2000).	  DLD-­‐1	   cells	  were	  also	  less	  prone	  to	  death	  during	  nocodazole-­‐exposure.	  	  This	  indicates	  that	  Chfr	  may	   be	   involved	   in	   sensing	   microtubule	   damage	   at	   the	   G2/M	   transition,	   and	  signaling	   a	   response	   that	   allows	   cells	   to	   delay	   their	   entry	   into	   mitosis	   under	  conditions	  that	  could	  compromise	  genetic	  stability	  (Scolnick	  and	  Halazonetis,	  2000).	  	  This	  transient	  delay	  was	  further	  characterized	  by	  Matsusaka	  and	  Pines	  (2004),	  who	  showed	   that	   cells	   not	   only	   could	   inhibit	   chromosome	   condensation	   but	   could	  actually	  decondense	  their	  chromosomes	  and	  enter	  back	  into	  an	  interphase-­‐like	  state	  following	  treatment	  with	  colcemid	  during	  early	  prophase.	  	   Kim	  et	  al.	  (2011)	  showed	  that	  when	  cells	  express	  an	  empty	  FLAG-­‐vector,	  they	  are	  more	  likely	  to	  contain	  a	  strong	  anti-­‐phospho-­‐histone	  H3	  signal	  after	  nocodazole	  treatment.	  	  When	  Chfr	  is	  expressed,	  however,	  the	  amount	  of	  phospho-­‐histone	  H3	  is	  less	   in	   comparison	   to	   the	   Chfr-­‐lacking	   control.	   	   This	   indicates	   that	   Chfr	   prevents	  chromosome	  condensation	  during	  nocodazole	  exposure.	  These	  authors	  also	  showed	  that	   entry	   through	   the	   G2/M	   gate	   is	   associated	   with	   auto-­‐ubiquitination,	   which	  could	  degrade	  the	  Chfr	  protein	  as	  cells	  enter	  mitosis.	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1.2.1.1	   Chfr,	   Cyclin	   B1-­‐Cdc2,	   and	   Plk1.	   	  When	  microtubules	   are	   damaged,	   Chfr	  delays	   the	   cell	   cycle	   transiently	   by	   preventing	   Cyclin	   B1-­‐Cdc2	   from	   entering	   the	  nucleus,	   keeping	   it	   in	   the	   cytoplasm	   where	   it	   remains	   inactive	   (Summers	   et	   al.,	  2005).	   	   Cyclin	  B1-­‐Cdc2	   is	   the	  mitosis	   promoting	   factor	   (MPF).	   	  Kang	   et	   al.	   (2002)	  further	  showed	  that	  Chfr	  can	  inhibit	  the	  activation	  of	  Cyclin	  B1-­‐Cdc2,	  and	  that	  Chfr	  can	  ubiquitinate	  Plk1	  in	  X.	  laevis	  extracts.	  	  Their	  finding	  suggests	  that	  Chfr	  may	  delay	  entry	   into	  mitosis	  by	  ubiquitinating	  and	  reducing	  Plk1	   levels,	  which	   in	  turn	  delays	  the	  activation	  of	  Cdc25c	  phosphatase	  and	  the	  inactivation	  of	  Wee-­‐1	  kinase,	  which	  in	  turn	  leads	  to	  a	  delay	  in	  Cdc2	  activation	  (Cdc2	  is	  part	  of	  the	  MFP	  complex),	  and	  delay	  in	  mitotic	  entry.	  	   Furthermore,	   cells	   from	   Chfr	   knockout	   mice	   have	   been	   shown	   to	   over-­‐express	  Plk1	  in	  comparison	  to	  cells	  from	  wild	  type	  mice,	  which	  suggests	  that	  Plk1	  is	  ubiquitinated	  by	  Chfr	  for	  degradation	  (Yu	  et	  al.,	  2005).	  	  This	  study,	  however,	  did	  not	  do	   any	   tests	   with	   nocodazole,	   which	   is	   supposed	   to	   activate	   the	   Chfr	   checkpoint.	  	  Other	  research,	  on	  the	  other	  hand,	  has	  not	  found	  a	  relationship	  between	  Chfr	  over-­‐expression	  and	  reduced	  Plk1	  protein	   levels	  (Matsusaka	  and	  Pines,	  2004;	  Summers	  et	  al.,	  2005).	  	  Summers	  et	  al.	  (2005)	  show	  that	  Plk1	  localizes	  to	  the	  centrosomes.	  	  
1.2.1.2	   Chfr	   and	   Aurora	   A	   at	   early	   prophase.	   	   Another	   possible	   ubiquitination	  target	  for	  Chfr	  is	  Aurora	  A	  as	  this	  protein	  is	  capable	  of	  recruiting	  Cyclin	  B1	  into	  the	  centrosomes	   	   (Hirota	   et	   al.,	   2003).	   	   Summers	   et	   al.	   (2005)	   found	   no	   relationship	  between	   Chfr	   over-­‐expression	   and	   decreased	   Aurora	   A	   protein	   levels	   in	   HCT116	  cells.	  	  	  However,	  they	  showed	  that	  when	  HCT116	  cells	  expressing	  Chfr	  were	  treated	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with	  nocodazole,	  cells	  that	  remained	  in	  interphase,	  and	  were	  presumably	  delayed	  by	  the	   CHFR	   checkpoint,	   did	   not	   contain	   active	   Aurora	  A	   at	   their	   centrosomes.	   	   This	  active	   form	   of	   Aurora	   A	  was	   only	   present	   in	   cells	   that	   had	   already	   overcome	   the	  checkpoint	  and	  were	  in	  late	  prophase.	  	  This	  data	  indicates	  that	  CHFR	  may	  function	  by	   inactivating	   Aurora	   A,	   a	   mitosis	   promoting	   protein,	   at	   the	   centrosomes	   at	  interphase.	   Chfr	   here	   may	   function	   through	   K-­‐48-­‐linked	   degradative	   poly-­‐ubiquitination	   to	   inactivate	  Aurora	  A	   at	   interphase,	   and	  activate	   the	   same	  protein	  after	  the	  Chfr	  checkpoint	  is	  complete	  through	  K-­‐63-­‐linked	  poly-­‐ubiquitination.	  
	   Yu	   et	   al.	   (2005)	   found	   that	  Aurora	  A	   is	   over-­‐expressed	   in	   cells	   that	   have	   a	  CHFR	  knockout,	  indicating	  that	  Chfr	  may	  function	  to	  reduce	  Aurora	  A	  protein	  level	  and	  to	  keep	  this	  protein	  at	  a	  functional	  level.	  	  They	  also	  found	  that	  the	  C-­‐terminus	  of	  Chfr	   interacts	   with	   Aurora	   A	   and	   that	   this	   interaction	   is	   required	   for	   Aurora	   A	  ubiquitination.	   These	   findings	   support	   the	   idea	   that	   Chfr	   functions	   through	  degradative	  K48-­‐linked	  poly-­‐ubiquitination.	   	  Privette	  et	  al.	  (2008b)	  also	  found	  that	  depletion	  of	  Chfr	  by	  siRNA	  results	  in	  Aurora	  A	  over-­‐expression.	  	  This	  indicates	  that	  Chfr	  regulates	  Aurora	  A	  by	  degradation.	  	  	  	  
1.2.1.3	   Chfr	   and	   p38	   stress	   kinase.	   	   Another	  way	   in	  which	  Chfr	  may	  be	   able	   to	  induce	  delayed	  entry	   into	  mitosis	   in	   response	   to	  nocodazole	   treatment	   is	   through	  the	  p38	  stress	  kinase	  pathway.	  	  	  The	  p38	  stress	  kinase	  pathway	  has	  been	  shown	  to	  be	  activated	  by	  ubiquitination	  through	  K63-­‐linked	  polyubiquitin	  chains	  (Wang	  et	  al.,	  2001).	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   Furthermore,	  treatment	  of	  cells	  with	  anisomycin	  or	  nocodazole	  activates	  the	  p38	   stress	   kinases	   and	   results	   in	   a	   reduced	   mitotic	   index	   (Cano	   et	   al.,	   1994;	  Takeneka	  et	  al.,	  1998).	   	  Anisomicin	  is	  a	  p38	  kinase	  activator.	   	  Matsusaka	  and	  Pines	  (2004)	   found	  that	   treatment	  of	  cells	  with	  anisomycin,	  colcemid,	  or	  nocodazole	  not	  only	  reduced	  the	  number	  of	  prophase	  cells	  but	  also	  caused	  cells	  in	  mid	  prophase	  to	  return	   to	   interphase.	   	   Inhibition	   of	   p38	  with	   p38	   kinase	   inhibitors	   abrogated	   this	  colcemid-­‐induced	   checkpoint:	   cells	   entered	   mitosis	   in	   spite	   of	   the	   presence	   of	  microtubule	   stress,	   and	   they	   became	   arrested	   by	   the	   spindle	   checkpoint	   at	   the	  metaphase-­‐to-­‐anaphase	   transition.	   	   Injecting	   p38a	   and	   p38b	   stress	   kinases	   into	  early	   prophase	   cells	   resulted	   in	   the	  majority	   of	   cells	   returning	   to	   interphase,	   but	  injecting	   p38δand	   Erk2	   had	   no	   such	   effect	   on	   the	   progression	   of	   these	   cells	  through	   prophase	   	   (Matsusaka	   and	   Pines,	   2004).	   	  When	   the	   FHA∆-­‐Chfr	   dominant	  negative	  mutant	  was	   introduced	   into	   normal	   cells,	   the	   checkpoint	  was	   abrogated,	  but	   could	   be	   restored	   by	   injecting	   p38a	   into	   cells,	   causing	   them	   to	   return	   to	  interphase.	   	  This	   indicates	   that	  p38	  probably	   acts	  downstream	  of	  Chfr	   in	   the	  Chfr	  checkpoint	  pathway.	  	   The	  work	  done	  by	  Matsusaka	  and	  Pines	  (2004)	  also	  clearly	  points	  out	  that	  K-­‐63-­‐linked	   poly-­‐ubiquitin	   chains	   may	   be	   involved	   over	   the	   more	   expected	   K-­‐48-­‐linked	   poly-­‐ubiquitination	   during	   the	   G2/M	   checkpoint	   delay	   induced	   by	  microtubule	   stress.	   	   This	   group	   shows	   that	   ubiquitination	   is	   necessary	   for	  mitotic	  delay,	  but	  that	  degradative	  ubiquitination	  is	  not	  necessary	  for	  such	  a	  mitotic	  delay.	  	  They	   do	   this	   by	   inhibiting	   proteasomal	   degradation.	   	   In	   the	   presence	   of	   such	  inhibition,	   the	   chromosomes	   still	   delay	   their	   entry	   into	  mitosis.	   	   This	  means	   that	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degradative	   ubiquitination	   is	   not	   necessary	   for	   the	   Chfr	   checkpoint.	   	   	   General	  ubiquitination,	  on	  the	  other	  hand,	  is	  necessary,	  for	  Chfr	  checkpoint	  delay.	  	  	  	  	  
	  
1.2.2	   Chfr	   in	   the	   spindle	   checkpoint.	   	  Aside	   from	  regulating	   the	  early	  prophase	  stage	  of	  mitosis,	  CHFR	  also	  appears	  to	  play	  a	  role	  in	  the	  later	  stage	  of	  mitosis,	  at	  the	  metaphase-­‐to-­‐anaphase	  transition,	  making	  sure	  that	  all	  chromosomes	  are	  properly	  attached	   to	   the	   mitotic	   spindle	   before	   the	   onset	   of	   anaphase.	   	   This	   transition	   is	  governed	   by	   the	   spindle	   checkpoint	   and	   regulates	   chromosome	   segregation	   and	  genetic	  instability	  (Yu	  et	  al.,	  2005).	  	  	  	   CHFR	  deficient	  mouse	  cells,	   for	  example,	  spent	  a	  prolonged	  amount	  of	   time	  not	   only	   in	   prophase	   but	   also	   in	   anaphase.	   	   These	   cells	   were	   multinucleated,	  displayed	  increased	  aneuploidy,	  lagging	  chromosomes	  and	  failed	  cytokinesis	  (Yu	  et	  al.,	  2005).	  	   Scolnick	   and	   Halazonetis	   (2000)	   distinguish	   clearly	   the	   early	   prophase	  checkpoint	  from	  the	  spindle	  checkpoint.	   	  Their	  data	  shows	  that	  DLD1-­‐neo	  cells	  are	  stopped	   by	   the	   spindle	   checkpoint	   after	   exposure	   to	   nocodazole,	   whereas	   DLD1-­‐Chfr	  cells	  are	  stopped	   initially	  by	   the	  early	  prophase	  checkpoint	  and	   then	   later	  by	  the	  spindle	  assembly	  checkpoint.	  	  This	  data	  shows	  a	  delay	  in	  cells	  expressing	  Chfr	  in	  comparison	  to	  those	  that	  do	  not	  express	  Chfr.	  	  
	   	   	  
1.2.2.1	   	   Chfr,	   BUBR1,	   and	   MAD2.	   	   In	   another	   study,	   cells	   treated	   with	   siRNA	  specific	  for	  Chfr	  also	  resulted	  in	  mitotic	  spindle	  checkpoint	  defects,	  including	  lagging	  anaphase	   chromosomes,	   multipolar	   mitotic	   spindles,	   tetraploid,	   binucleated	   giant	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cells	  and	  misaligned	  chromosomes	  at	   the	  metaphase	  plate	   (Privette	  et	  al.,	  2008b).	  	  Furthermore,	  Chfr	  depletion	  by	  siRNA	  in	  these	  cells	  caused	  BUBR1	  and	  MAD2,	  two	  mitotic	   spindle	   checkpoint	   proteins,	   to	   localize	   abnormally	   to	   the	   kinetochores	  during	   metaphase,	   causing	   impaired	   MAD2/CDC20	   complex	   formation	   during	  microtubule	   stress.	   	   The	  MAD2/CDC20	   complex	   prevents	   the	   APC	   from	   initiating	  anaphase	  prematurely,	  making	  sure	  that	  all	  of	  the	  sister	  chromatids	  are	  attached	  to	  the	   mitotic	   spindle	   apparatus	   (Privette	   et	   al.,	   2008b).	   Chfr,	   therefore,	   appears	   to	  function	   in	   the	  proper	  recruitment	  and	  activation	  of	   important	  spindle	  checkpoint	  proteins	   to	   the	   kinetochores.	   	   This	   is	   in	   line	  with	  K-­‐63	   linked	  poly-­‐ubiquitination,	  which	  can	  act	  as	  a	  stress	  signal	  to	  alter	  protein	  localization	  or	  function	  (Newton	  et	  al,	  2008).	  	   So	   basically,	   taking	   the	   review	   of	   the	   literature	   into	   perspective,	   the	   G2/M	  checkpoint	   and	   the	   spindle	   assembly	   checkpoint	   should	   work	   together,	   with	   the	  G2/M	   checkpoint	   preventing	   damaged	   cells	   from	   progressing	   through	   the	   G2/M	  transition	  (lowering	  the	  EPI)	  and	  the	  spindle	  assembly	  checkpoint	  catching	  anything	  that	   manages	   to	   squeeze	   through	   the	   G2/M	   checkpoint	   gate	   (increasing	   the	   MI).	  	  Unable	  to	  divide,	   these	  cells	  should	  then	  undergo	  apoptosis	  or	  delay	  their	  division	  until	  conditions	  are	  favorable.	  	  A	  summary	  of	  the	  literature	  is	  presented	  in	  Figure	  1-­‐
2.	  	  	  	  	  
	   	  
1.2.2.2	   	   Chfr	   and	  Aurora	  A.	   	  Chfr	  may	  also	  regulate	  proper	  spindle	   formation	  by	  regulating	   Aurora	   A	   protein	   levels.	   	   Aurora	   A	   is	   a	   mitosis	   promoting	   protein,	  localizing	  to	  the	  centrosomes,	  and	  is	  involved	  in	  centrosome	  maturation	  and	  spindle	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formation	   (Privette	  et	  al.,	  2008b).	   	   If	   these	   structures	  do	  not	  mature	  and	  separate	  correctly,	  this	  could	  result	  in	  abnormal	  spindle	  formation	  and	  chromosome	  division.	  	  Privette	  et	  al.	  (2008b)	  showed	  that	  when	  Chfr	  levels	  are	  down,	  Aurora	  A	  levels	  are	  increased.	   Thus,	   abnormally	   low	   Chfr	   levels	   increase	   Aurora	   A	   levels,	   which	  increases	   centrosome	   number.	   	   Centrosomes	   are	   microtubule-­‐organizing	   centers	  required	  for	  proper	  mitotic	  spindle	  formation.	  This	  means	  that	  abnormal	  Aurora	  A	  and	   Chfr	   protein	   levels	   could	   result	   in	   abnormal	   multipolar	   mitotic	   spindle	  structures,	  and	  aneuploidy.	  	  	  	  	   Interestingly,	   one	   article	   showed	   that	   Aurora	   A	   could	   potentially	   recruit	  Ubc13	  to	  the	  centrosomes	  during	  mitosis	  (Toland	  et	  al.,	  2003).	  	  This	  group	  showed	  that	  Ubc13	  cannot	  localize	  to	  the	  centrosomes	  in	  the	  presence	  of	  mutated	  Aurora	  A,	  Ile31	  variant	  of	  STK15.	   	  The	  article	  did	  not	  mention	  Chfr.	   	  Chfr,	  however,	   could	   in	  this	  way	  function	  by	  localizing	  to	  the	  centrosomes	  with	  Ubc13	  and	  Aurora	  A	  to	  alter	  the	  behavior	  or	  stability	  of	  Aurora	  A	  by	  activation	  of	  that	  protein.	  	  The	  signal	  could	  be	  either	  K63-­‐linked	  or	  K-­‐48	  linked	  in	  nature.	  	  The	  degradative	  signal	  could	  function	  first	  to	  reduce	  or	  inactivate	  Aurora	  A	  at	  the	  centrosomes,	  and	  the	  K63-­‐linked	  signal	  could	   function	   to	   reactivate	   Aurora	   A	   at	   the	   centrosomes	   to	   allow	   mitotic	  progression	  to	  continue.	  	  Summers	  et	  al.	  (2005)	  showed	  that	  Aurora	  A	  is	  inactivated	  at	  the	  centrosomes	  in	  interphase	  in	  the	  presence	  of	  Chfr,	  and	  that	  the	  active	  form	  of	  Aurora	   A	   is	   only	   present	   in	   late	   prophase	   cells	   that	   have	   overcome	   the	   G2/M	  transition	   and	   progressed	   into	   mitosis.	   	   K-­‐63	   linked	   poly-­‐ubiquitin	   chains	   could	  potentially	  be	  involved	  in	  such	  activation	  of	  Aurora	  A	  because	  a)	  Chfr	  can	  formulate	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K63-­‐linked	  polyubiquitin	  chains	  with	  Ubc13-­‐Mms2;	  and	  b)	  Ubc13	  can	  be	  recruited	  by	  Aurora	  A	  to	  the	  centrosomes	  	  (Toland	  et	  al.,	  2003).	  	  
	  
1.2.2.3	  Chfr	  and	  alpha-­‐tubulin.	  	  Alpha-­‐tubulin	  levels	  and	  acetylated	  alpha-­‐tubulin	  levels	  may	  also	  be	  regulated	  by	  CHFR.	  	  Interestingly,	  when	  CHFR	  protein	  levels	  are	  reduced	  by	  CHFR	  siRNA	  knockdown,	  alpha-­‐tubulin	  levels	  and	  especially	  acetylated	  alpha-­‐tubulin	   levels	   are	   increased	   in	   expression.	   	   Furthermore,	   a	   ubiquitin	   signal	  appears	  to	  be	  associated	  with	  reduced	  alpha-­‐tubulin	  levels	  and	  the	  presence	  of	  Chfr.	  	  This	   ubiquitin	   signal	   is	   reduced	   when	   CHFR	   is	   knocked	   down	   using	   the	   siRNA	  knockdown	   technique,	   and	   alpha-­‐tubulin	   levels	   become	   noticeably	   higher	   during	  this	   knockdown.	   	   The	   signal	   appears	   to	   be	   a	   diubiquitin	   (Privette	   et	   al.,	   2008b).	  	  	  This	   supports	   the	   idea	   that	   Chfr	   can	   ubiquitinate	   other	   proteins,	   and	   that	   alpha-­‐tubulin	   could	   possibly	   be	   yet	   another	   substrate	   for	   CHFR.	   	   Alpha-­‐tubulin	   is	   an	  important	  component	  of	  the	  mitotic	  spindle.	   	   	  So	  Chfr	  in	  this	  case	  could	  reduce	  the	  level	  of	  this	  mitotic	  spindle	  component	  to	  guard	  proper	  spindle	  formation.	  	  	  	  
1.3	  Reasoning	  behind	  thesis.	  
1.3.1	   Introduction	   to	   Ubiquitination.	   	   Bothos	   et	   al.	   (2003)	   proposed	   that	   Chfr	  might	   delay	   entry	   into	  mitosis	   by	   ubiquitination,	   specifically	   by	   using	   the	   Ubc13-­‐Mms2	   ubiquitin-­‐conjugating	   enzyme	   complex	   to	   catalyze	   the	   formation	   of	   K63-­‐linked	  poly-­‐ubiquitin	  chains.	  	  	  
	  	  
















Figure	  1-­‐2.	  	  Some	  possible	  molecular	  pathways	  by	  which	  Chfr	  can	  attain	  the	  mitotic	  delay	  induced	  in	  response	  to	  microtubule	  poisons.	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Ubiquitination	  is	  an	  enzymatic	  cascade	  that	  can	  alter	  the	  stability,	  behavior,	  or	  intracellular	  localization	  of	  a	  particular	  substrate	  protein	  (Newton	  et	  al.,	  2008).	  	  This	  control	   is	   achieved	   through	   the	   covalent	   attachment	   of	   a	   small	   molecule	   called	  ubiquitin	  (Ub)	  to	  the	  target’s	  surface.	   	  The	  ubiquitination	  cascade	  consists	  of	  a	  Ub-­‐activating	  enzyme	  (E1),	  a	  Ub-­‐conjugating	  enzyme	  (E2),	  and	  a	  Ub-­‐ligase	  enzyme	  (E3).	  	  Chfr,	   in	   this	   context,	   would	   be	   an	   example	   of	   an	   E3	   enzyme,	   while	   Ubc13-­‐Mms2	  would	  be	  an	  example	  of	   an	  E2	  enzyme	  complex.	   	  The	  E1	  enzyme	  activates	   the	  Ub	  molecule,	  and	  passes	  it	  onto	  the	  E2	  enzyme.	  	  The	  E2	  enzyme	  can	  then	  attach	  the	  Ub	  molecule	  directly	  onto	  a	   target	  protein,	  with	   the	  E3	  enzyme	  serving	  as	  an	  adaptor	  between	  the	  E2	  and	  the	  target.	  	  	  
Alternatively,	  the	  E2	  can	  also	  pass	  the	  Ub	  molecule	  onto	  the	  E3	  enzyme,	  which	  can	  then	  pass	  the	  Ub	  molecule	  onto	  the	  target.	  	  Either	  way,	  the	  ultimate	  result	  is	  the	  ubiquitination	   of	   a	   particular	   substrate	   protein,	   which	   results	   either	   in	   protein	  degradation	   or	   in	   protein	   signaling.	   	   Target	   proteins	   can	   be	   mono-­‐ubiquitinated,	  multiply	  mono-­‐ubiquitinated	  on	  different	  lysine	  residues,	  or	  poly-­‐ubiquitinated. The	  two	  most	   characterized	   types	   of	   poly-­‐ubiquitin	   chains	   are	   the	  K63-­‐linked	   and	   the	  K48-­‐linked	   poly-­‐ubiquitin	   chains.	   	   K48-­‐linked	   chains	   mark	   faulty	   or	   unwanted	  proteins	   for	   destruction	   in	   the	   proteasome,	   whereas	   K63-­‐linked	   chains	   mark	   a	  protein	  for	  cellular	  signaling	  and	  can	  alter	  protein	  activity.	  	  	  
	   	  Researchers	  are	  debating	  whether	  Chfr	  delays	  entry	  into	  mitosis	  through	  K-­‐48	   linked	   or	   K-­‐63	   linked	   poly-­‐ubiquitin	   chains	   (Yu	   et	   al.	   2005;	   Kang	   et	   a,	   2002;	  Bothos	  et	  al.,	  2003).	  	  This	  ubiquitination	  could	  be	  either	  K-­‐48	  linked	  or	  K-­‐63-­‐linked	  in	   nature,	   with	   the	   majority	   of	   the	   literature	   leaning	   towards	   K-­‐48	   linked	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degradative	   ubiquitination.	   	   Two	   reports	   support	   the	   K-­‐63	   linked	   poly-­‐ubiquitination	  of	  Chfr.	   	  Bothos	  et	  al.	  (2003)	  proposed	  that	  the	  Chfr	  protein	  and	  the	  Ubc13-­‐Mms2	   protein	   complex	   work	   together	   to	   mark	   a	   particular	   substrate	   for	  cellular	  signaling	  via	  K-­‐63	  linked	  poly-­‐ubiquitin	  chains,	  resulting	  in	  delayed	  mitotic	  entry	  following	  microtubule	  damage.	   	  Matsusaka	  and	  Pines	  (2004)	  further	  showed	  that	   degradative	   ubiquitination	   is	   not	   necessary	   for	   the	   Chfr	   checkpoint	   delay,	  indicating	  K-­‐63	  linked	  poly-­‐ubiquitin	  chains	  may	  be	  involved	  in	  this	  process	  instead.	  	  Kim	  et	  al.	  (2011)	  provided	  an	  alternative	  hypothesis,	  that	  K-­‐48	  linked	  poly-­‐ubiquitin	  chains	  are	  involved	  instead.	  	  The	  bottom	  line	  is	  that	  Chfr	  accumulates	  in	  the	  nucleus	  and	   interacts	  with	  DNA	   to	   somehow	   influence	   chromosome	  dynamics.	   	  The	   signal	  that	  is	  generated	  must	  somehow	  result	  in	  decondensed	  chromatin.	  	  
1.3.2	  Hypothesis	  and	  rationale	  behind	  the	  hypothesis.	   	  Based	  on	  the	  literature,	  the	  hypothesis	  of	  this	  project	  is	  that	  Ubc13,	  Mms2/Uev1	  and	  Chfr	  function	  in	  mitosis	  at	  the	  G2/M	  transition,	  and	  that	  these	  proteins	  regulate	  entry	  into	  mitosis	  through	  ubiquitination.	  	  	  Chfr	   predominantly	   appears	   to	   be	   a	   nuclear	   protein,	   localizing	   to	   interphase	  nuclei.	   	  This	  nuclear	  localization	  is	  in	  line	  with	  the	  reported	  Chfr	  function,	  which	  is	  that	   of	   chromosome	   decondensation,	   because	   an	   interphase	   nucleus	   has	  decondensed	   chromatin.	   Chfr	   could	   potentially	   bind	   to	   DNA	   directly	   and	   interact	  with	  proteins	  that	  define	  the	  transition	  from	  interphase	  (G2)	  to	  early	  prophase	  (M),	  and	   are	   important	   for	   proper	   mitotic	   entry.	   	   At	   this	   point,	   Chfr	   could	   bind	   to	  condensing	  chromatin	  and	  use	  Ubc13-­‐Mms2/Uev1	  to	  conjugate	  K48-­‐linked	  or	  K-­‐63-­‐
	  	  
	  	   	   21	  
linked	  poly-­‐ubiquitin	  chains.	  The	  ubiquitin	  signal	  on	  Chfr	  could	  physically	  interfere	  with	  chromosome	  compaction.	  	  Though	  potentially	  degradative	  in	  nature,	  the	  signal	  could	   also	   contain	   an	   immediate	   bulky	   property	   that	   temporarily	   interferes	   with	  DNA	  condensation,	  increasing	  the	  likelihood	  of	  a	  more	  decondensed	  form	  of	  DNA	  at	  the	   interphase-­‐early	   prophase	   stage,	   resulting	   in	   temporary	   chromosome	  decondensation	   at	   interphase.	   	  When	   not	   necessary,	   Chfr	   could	   auto-­‐ubiquitinate	  itself	   for	  destruction	  at	   the	   interphase/early	  prophase	  stage	  to	  allow	  cells	   to	  enter	  mitosis,	  or	  mark	  important	  cell	  cycle	  promoting	  proteins	  for	  destruction.	   	  Either	  at	  the	  kinetochores,	  where	  microtubules	  attach	  to	  DNA,	  or	  at	  the	  centrosomes	  where	  microtubules	  originate	  from.	  	  Following	  mitotic	  delay,	  Chfr,	  Ubc13,	  and	  Mms2/Uev1	  could	   then	   generate	   K63-­‐linked	   poly-­‐ubiquitin	   chains	   to	   activate	   important	   cell	  cycle	  promoting	  proteins,	  either	  at	  the	  DNA	  site	  or	  at	  the	  centrosomes.	  
The	  main	  objectives	  of	   this	  project	  were	   to	  develop	  a	  hypothetical	  model	  by	  which	   Chfr,	   Ubc13,	   and	   Mms2/Uev1	   could	   function	   during	   mitosis,	   analyzing	  protein	   interactions,	   protein	   localization,	   protein	   level,	   protein	   modification,	   and	  detection	  of	  protein	  function.	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CHAPTER	  2:	  MATERIALS	  &	  METHODS	  
	  
2.1	  Immunocytochemistry.	  SAOS2	   cells	   were	   fixed	   and	   permeabilized	   with	   -­‐20°C	   methanol	   for	   5	  minutes,	   and	   were	   then	   incubated	   with	   the	  mouse	   4E11	   Ubc13-­‐specific	   antibody	  and	   the	   rabbit	   Chfr-­‐CR	   antibody	   (sc-­‐28263;	   Santa	   Cruz	   Biotechnology)	   overnight.	  	  The	   DAPI	   stain	  was	   not	   applied.	   	   The	   photos	   show	   an	   early	   prophase	   cell,	   and	   a	  metaphase	   cell,	   and	   a	   telophase	   cell,	   all	   of	   which	   have	   chromosomes	   with	   4E11	  immunoreactivity	  stronger	  than	  their	  surroundings.	  	  Alternatively,	  SAOS2	  cells	  were	  washed	  with	  PBS,	   fixed	  with	  4%	   formaldehyde	   for	  30	  minutes,	  and	  permeabilized	  with	   methanol	   for	   5	   minutes,	   after	   which	   they	   were	   stained	   with	   the	   Chfr-­‐CR	  antibody	  and	  the	  mouse	  Ubc13	  antibody.	  	  	  	  
	  
2.2	  siRNA	  knockdown.	  
iRNA	   specific	   for	   Ubc13	   (5575;	   GenePharma)	  was	   dissolved	   in	   RNAse-­‐free	  water.	  	  iUbc13	  with	  an	  optical	  density	  of	  1	  OD	  was	  added	  to	  150	  μl	  of	  water	  to	  get	  a	  stock	   solution	  od	  20	  nM.	   	   Control	   iRNA	  had	   an	  optical	   density	   of	   0.5	  OD	  and	  was	  added	  to	  7.5	  μl	  of	  water	  to	  get	  a	  stock	  concentration	  of	  20	  nM.	  	  The	  solutions	  were	  frozen	   in	   10	   μl	   alliquotes	   and	   refrozen	   a	   few	   times	   only.	   	   The	   RNAiMAX	   reagent	  protocol	   was	   followed	   by	   knockdown	   of	   Ub13.	   	   Cells	   were	   seeded	   into	   a	   35	  mm	  tissue	  culture	  dish,	  with	  1.5	  ml	  of	  media	  at	  a	  50	  %	  confluency.	  	  Cells	  should	  be	  plated	  at	   a	   confluency	  of	   50%	   if	   they	   grow	  quickly	   and	   a	  higher	   confluency	   if	   they	   grow	  slowely.	   	  5	  ml	  of	  media	  was	  removed	  the	  next	  day	   leaving	  1.0	  ml	  of	  media.	   	  Fresh	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media	   should	   not	   be	   added.	   	   1.5	   μl	   of	   Ubc13	   siRNA	   was	   mixed	   with	   250	   μl	   of	  OPTIMEM	  and	  the	  solution	  was	  allowed	  to	  sit	  for	  5	  minutes	  at	  room	  temperature.	  	  4	  μl	  of	  RNAiMAX	  Reagent	  was	  mixed	  with	  250	  μl	  of	  OPTIMEM,	  and	  the	  solution	  was	  allowed	   to	   sit	   for	  5	  minutes	  at	   room	  temperature.	   	   siRNA	  and	  RNAiMAX	  solutions	  were	   allowed	   to	   sit	   for	   20	   minutes.	   	   500	   μl	   of	   the	   Ubc13	   siRNA-­‐iMAX	   Reagent	  solution	  was	  then	  added	  to	  the	  1	  ml	  culture,	  leaving	  a	  final	  volume	  of	  1.5	  ml.	  	  Cells	  were	  then	  incubated	  overnight.	  	  Alternatively,	  media	  can	  be	  removed	  after	  6	  hours.	  	  Maximum	   activity	   of	   the	   Ubc13	   siRNA	   appears	   to	   be	   at	   about	   3	   days	   after	  transfection.	  
	  
2.3	  Coimmunoprecipitation	  and	  Western	  blot	  analysis.	  
	   Preparing	  the	  cell	  lysate:	  Four	  10	  cm	  dishes	  of	  SAOS2	  cells,	  grown	  in	  10ml	  of	   SIGMA	  DMEM	  +	  10%	  FBS,	  were	   rinsed	  with	  PBS	  and	   lysed	  with	  300	  μl	   of	   lysis	  solution.	  	  Cell	  lysates	  were	  sonicated,	  clarified	  by	  centrifugation	  on	  maximum	  speed	  for	   20	  minutes	   to	   remove	   cell	   debris,	   and	   pre-­‐absorbed	  with	   sepharose	   beads	   to	  reduce	   non-­‐specific	   binding.	   	   For	   pre-­‐absorption,	   the	   lysate	  was	   diluted	   1:5	   in	   IP	  diluent,	   and	   the	   PBST-­‐washed	   beads	   were	   added	   to	   the	   diluted	   cell	   lysate.	   	   The	  diluted	  lysate	  and	  bead	  mixture	  was	  then	  incubated	  for	  4-­‐6	  hours.	  	  The	  beads	  used	  for	  clarification	  were	  then	  removed	  by	  centrifugation	  at	  2000	  x	  g	  for	  2	  minutes.	  	  
	   Making	   the	   bead-­‐antibody	   complex:	   A	   fresh	   batch	   of	   beads	   was	   then	  washed	  several	   times	  with	  PBST	  and	  the	  beads	  were	  blocked	  for	  1hr	  with	  a	  50mg	  BSA	   powder/1ml	   of	   PBST	   solution	   while	   rotating	   at	   4°C.	   	   2-­‐5	  μl	   of	   mouse	   4E11	  antibody	   and	   10	   μl	   of	   1%	   thimerosal	   was	   then	   put	   into	   the	   appropriate	   bead-­‐
	  	  
	  	   	   24	  
containing	   tubes.	   	   The	   blocked	   beads	   were	   then	   incubated	   with	   the	   antibody	   for	  approximately	   4-­‐6hrs	   to	   form	   a	   complex.	   	   The	   bead-­‐antibody	   complex	   was	   then	  further	  washed	  with	  more	  blocking	  solution	  to	  remove	  excess	  antibody.	  	  	  	   Application	  of	  cell	   lysate	  to	  bead-­‐antibody	  complex:	  Clarified	  lysate	  was	  then	  applied	  to	  the	  bead-­‐antibody	  complex;	  and	  the	  tubes	  were	  placed	  horizontally	  on	   a	   gently	   rocking	  platform	  on	   ice	   overnight	   at	   4°C. Samples	  were	   then	   spinned	  down	  at	  2000xg	  for	  2	  minutes	  and	  washed	  with	  PBST	  at	  least	  8	  times.	  	  	  	   Preparation	  of	  sample	  for	  Western	  blot	  analysis:	  Elution	  buffer	  was	  then	  added	  to	  the	  bead-­‐antibody	  complex,	  samples	  were	  boiled	  for	  5	  minutes,	  and	  6μl	  of	  iodoacetamide	  was	   added	   to	   each	   tube	   after	   boiling.	   	   Samples	  were	   then	   spinned	  down	   on	   maximum	   speed	   to	   compact	   the	   beads,	   and	   the	   supernatant	   was	  transferred	  to	  fresh	  tubes.	  	  10μl	  of	  sample	  was	  then	  loaded	  in	  each	  well	  of	  a	  1.0mm,	  12%	   gel.	   	   The	   samples	   on	   the	   gel	   were	   then	   transferred	   onto	   a	  membrane.	   	   The	  membrane	  was	  blocked	  with	  a	  5%	  skim	  milk/PBST/0.01%	  thimerosal	  solution	  and	  probed	  with	  the	  mouse	  4E11	  antibody	  (1:5000)	  for	  at	  least	  4	  hours.	  	  The	  membrane	  was	   then	  washed	  4	   times	   for	   10	  minutes	  with	  PBST.	   	   A	   goat	   anti-­‐mouse	   IgG	  HRP	  conjugate	  (1:10,000)	  was	  used	  as	  the	  secondary	  antibody.	  	  	  
	   Lysis	   Solution:	  200	  μl	  of	  phosphate	  buffer	   (0.2	  g	  KCl,	  0.2	  g	  KH2PO4,	  1.15	  g	  Na2HPO4,	  50	  ml	  ddH2O);	  54.8	  μl	  5M	  NaCl;	  20	  μl	  of	  phosphate	  inhibitory	  cocktail;	  20	  
μl	  1M	  NEM	  in	  DMSO;	  40	  μl	  10%	  SDS;	  40	  μl	  10%	  deoxycholate;	  1625ml	  water.	  	  	  	   IP	   diluent:	   1000	   μl	   of	   phosphate	   buffer	   (0.2	   g	   KCl,	   0.2	   g	   KH2PO4,	   1.15	   g	  Na2HPO4,	  50	  ml	  ddH2O);	  274	  μl	  5	  M	  NaCl;	  100	  μl	  phosphate	  inhibitory	  cocktail;	  100	  
μl	  1M	  NEM	  dissolved	  in	  DMSO;	  8526	  ml	  of	  water.	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   Elution	  buffer:	  125	  μl	  loading	  buffer;	  25	  μl	  phosphate	  buffer	  (0.2	  g	  KCl,	  0.2	  g	  KH2PO4,	  1.15	  g	  Na2HPO4,	  50	  ml	  ddH2O);	  50	  μl	  10%	  SDS	  (1%	  final);	  5	  μl	  1M	  DTT;	  295	  
μl	  autoclaved	  ddH2O;	  6	  μl	  0.5	  M	  iodoacetamide	  per	  tube.	  
	  
2.4	  Mitotic	  shake	  off	  procedure.	  	  
	   A	  mitotic	   shake-­‐off	   experiment	   was	   carried	   out	   in	   nocodazole-­‐treated	   and	  untreated	   HeLa-­‐Chfr	   cells.	   	   Cells	   were	   either	   treated	   with	   or	   left	   untreated	   with	  nocodazole	   (for	   O/N),	   and	   the	   rounded	   cells	   were	   shaken	   off,	   separating	   the	   flat	  cells	  from	  the	  rounded	  cells.	  	  The	  rounded	  cells	  are	  cells	  in	  a	  late	  prophase-­‐like	  stage	  of	   mitosis	   (fraction	   2+4;	   corresponding	   to	   lanes	   2	   and	   4),	   whereas	   the	   flat	   cells	  represent	   cells	   that	   are	   either	   in	   interphase	   or	   in	   early	   prophase	   (fractions	   1+3;	  corresponding	   to	   lanes	   1	   and	   3),	   with	   some	   possible	   late-­‐prophase-­‐like	   cell	  contamination.	   	   Cells	   were	   lysed,	   and	   lysates	   analyzed	   by	   Western	   blot	   analysis.	  	  Ubc13,	   Mms2,	   and	   Chfr	   protein	   levels	   were	   compared	   in	   each	   of	   the	   four	   cells	  fractions:	  treated	  cell	  fraction	  1	  and	  2,	  untreated	  cell	  fraction	  3	  and	  4.	  	  The	  Western	  blots	  were	  probed	   for	  Chfr	  using	   the	  Myc-­‐tag	  antibody.	  For	  Ubc13	  using	   the	  4E11	  antibody,	  and	  for	  Mms2/Uev1	  using	  the	  2H11	  antibody.	  	   Four	  10	  cm	  dishes	  of	  95%	  confluent	  HeLa-­‐Chfr	  cells	  grown	  in	  10	  ml	  of	  SIGMA	  DMEM	  +	  10%	  FBS	  were	  used	  for	  the	  mitotic	  shake	  off	  experiment.	  	  Nocodazole	  was	  added	  at	  a	  concentration	  of	  0.5	  μg/ml	  to	  one	  of	  the	  10	  cm	  dishes.	  	  The	  nocodazole-­‐treated	   cells	   were	   then	   divided	   into	   interphase-­‐early	   prophase	   (INT/EP)	   cell	  fractions	  and	   late	  prophase	  (LP)	  cell	   fractions,	  which	  were	  rounded	  in	  shape.	   	  The	  three	   untreated	   plates	   were	   also	   divided	   into	   the	   same	   two	   cell	   fractions:	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interphase-­‐early	  prophase	   and	   late	  prophase.	   	   Rounded	   cells	   representing	   cells	   in	  late	  prophase	  were	  dislodged	  from	  the	  monolayer	  by	  using	  a	  pipette.	  	  The	  four	  cell	  fractions	  were	  then	  washed	  with	  PBS	  and	   lysed	  with	  300	  μl	  of	   lysis	  solution.	   	  The	  samples	   were	   then	   analyzed	   by	   Western	   blot	   analysis	   using	   a	   1.0	   mm,	   12%	  acrylamide	  gel.	  	  The	  membrane	  was	  probed	  using	  a	  mouse	  antibody	  that	  recognizes	  both	   Mms2	   and	   Uev1a	   (2H11,	   4:5000),	   a	   mouse	   antibody	   specific	   for	   Ubc13	  (3:10,000),	  and	  a	  rabbit	  myc-­‐tag	  antibody	  (06-­‐549,	  UPSTATE,	  3:10,000)	  specific	  for	  myc-­‐tagged	  Chfr.	  	  	  	  	  	  	  	  
	   Lysis	   solution:	  125	  μl	  of	  phosphate	  buffer	   (0.2	  g	  KCl,	  0.2	  g	  KH2PO4,	  1.15	  g	  Na2HPO4,	  50	  ml	  ddH2O);	  50	  μl	  of	  1M	  NEM;	  50	  μl	  of	  protease	  inhibitory	  cocktail;	  62.5	  
μl	  of	  10%	  SDS;	  125	  μl	  10%	  deoxycholate;	  4.525	  ml	  PBS.	  	  
	  
2.5	  Cell	  Culture	  and	  Synchronization.	  
	   Cells	   were	   cultured	   in	   SIGMA	   DMEM	   +	   10%	   FBS.	   	   U2OS	   cells	   were	  synchronized	  using	  the	  double	  thymidine,	  single	  R03306	  block.	   	  Cells	  were	  treated	  with	   2mM	   thymidine	   for	   21	   hours,	   released	   for	   12	   hours,	   treated	   with	   2mM	  thymidine	   for	   21	   hours.	   	   The	   thymidine	   was	   then	   removed	   and	   cells	   were	  immediately	  treated	  with	  10	  μM	  of	  R03306	  for	  22	  hours.	  R03306	  is	  a	  Cdk1	  inhibitor	  and	  blocks	  cells	  at	  the	  G2/M	  gate.	  	  The	  R03306	  drug	  was	  then	  removed	  and	  the	  cells	  were	   released	   from	   the	   G2/M	   block	   for	   0	  min,	   10	  min,	   and	   45	  minutes	   to	  watch	  progression	   through	   the	   early	   prophase	   stage	   of	   mitosis.	   	   Most	   U2OS	   cells	   enter	  early	  prophase	  10	  minutes	  after	  release	   from	  the	  G2/M	  block.	   	  Photos	  were	   taken	  under	   the	   red	   and	  blue	   fluorescent	   filter	   and	  merged	  with	  phase	   contrast	   photos.	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Lipofectamine	   RNAiMAX	   Reagent	   (13778-­‐030;	   Invitrogen)	   and	   OPTI-­‐MEM®1	  (31985-­‐062;	  GIBCO	  Invitrogen)	  were	  used	  for	  the	  transfections.	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CHAPTER	  3:	  RESULTS	  
	  
3.1	  Chfr	  expression	  in	  HeLa	  cells.	  
The	  first	  objective	  was	  to	  determine	  whether	  HeLa-­‐Chfr	  cells,	  which	  should	  contain	   a	  myc-­‐tagged	   Chfr	   vector,	   do	   indeed	   over-­‐express	   the	   Chfr	   protein.	   	   Chfr	  expression	   in	   these	   cells	   was	   confirmed	   using	   Western	   blot	   analysis	   (WBA)	   and	  immunocytochemistry	  (ICC)	  (Figure	  3-­‐1).	  	  HeLa-­‐Chfr	  cells	  express	  myc-­‐tagged	  Chfr,	  whereas	  HeLa	  control	  cells	  do	  not	  express	  this	  protein.	  	  The	  actin	  control	  indicates	  equal	   loading.	   	   	   Another	   possible	   control	   that	   could	   be	   useful	   for	   this	   experiment	  could	  be	  a	  HeLa	  cell	  line	  expressing	  only	  a	  Myc-­‐tag	  containing	  vector.	  	  The	  Myc-­‐tag	  antibody	  localizes	  predominantly	  in	  the	  nucleus.	  	   	  Cells	  in	  interphase	  had	  Myc-­‐Chfr	  in	  the	  nucleus.	  
	  
3.2	  Protein-­‐Protein	  interaction	  between	  Chfr	  and	  Ubc13.	  













Figure	   3-­‐1.	   	   Western	   blot	   (A)	   and	   immunocytochemistry	   (B)	   showing	   over-­‐
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Figure	  3-­‐2.	   	  Myc-­‐tagged	  Chfr	   coimmunoprecipitates	  with	  Ubc13	   in	  HeLa-­‐Chfr	  
cells.	  	  	  Ubc13	  was	  pulled	  out	  of	  HeLa	  cells	  over-­‐expressing	  Myc-­‐tagged	  Chfr	  using	  a	  Ubc13-­‐specific	  antibody	  conjugated	  to	  protein	  G-­‐sepharose	  beads,	  and	  the	  blot	  was	  probed	   for	   Myc-­‐tagged	   CHFR,	   followed	   by	   a	   secondary	   HRP-­‐conjugated	   rabbit	  antibody.	   	   (Lane	   1)	  Beads;	  no	   lysate;	  Ubc13	  antibody.	   	   (Lane	   2)	  HeLa-­‐Chfr	  whole	  cell	   lysate.	   	  (Lane	  3)	  Beads;	  HeLa-­‐Chfr	  whole	  cell	   lysate;	  Ubc13	  antibody	  (Lane	  4)	  Beads;	  HeLa-­‐Chfr	  whole	  cell	  lysate;	  no	  Ubc13	  antibody.	  	  The	  coimmunoprecipitation	  indicates	  that	  the	  Chfr	  and	  Ubc13	  proteins	  interact	  together	  in	  cells	  expressing	  Myc-­‐tagged	  Chfr.	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coimmunoprecipitates	  with	  Ubc13	   indicating	   these	   two	  proteins	   interact	   together.	  	  	  	  The	  interaction	  is	  faint.	  	  	  
	  
3.3	  A	  potential	  method	  for	  Chfr	  checkpoint	  detection.	  	  	  
3.3.1	  	  Early	  prophase	  index	  assay.	  	  Another	  part	  of	  the	  project	  was	  focused	  on	  the	  early	   prophase	   index	   (EPI)	   assay	   tailored	   for	   Chfr	   checkpoint	   analysis.	   	   The	   Chfr	  checkpoint	  is	  measured	  either	  by	  live	  microscopy	  in	  individual	  cells	  or	  by	  using	  the	  mitotic	  index	  assay	  (Matsusaka	  and	  Pines,	  2004;	  Bothos	  et	  al.,	  2003).	  Mitotic	  index	  assay	  is	  an	  indirect	  way	  of	  detecting	  Chfr	  checkpoint	  activity.	  In	  order	  to	  unravel	  the	  molecular	   mechanism	   by	   which	   any	   protein	   functions,	   one	   must	   first	   detect	   an	  effective	  way	  of	  detecting	  its	  activity.	  	  This	  was	  done	  by	  developing	  an	  effective	  way	  of	  detecting	  cells	  at	   the	  early	  prophase	  (EP)	  stage	  of	  mitosis	   -­‐-­‐	  because	   that	   is	   the	  point	   at	  which	  Chfr	   has	  been	   thought	   to	   specifically	   exert	   its	   effects.	   	   The	   general	  idea	   behind	   the	   assay	   is	   that	   a	   high	   number	   of	   EP	   cells	   following	   microtubule	  damage	  means	  failure	  to	  delay	  mitosis	  and	  indicates	  the	  absence	  of	  Chfr	  checkpoint	  activity.	  	  A	  low	  number	  of	  EP	  cells	  following	  microtubule	  damage,	  on	  the	  other	  hand,	  indicates	  effective	  mitotic	  delay,	  and	  Chfr	  activity	  presence.	   	  Currently,	  researchers	  are	  detecting	  Chfr	  checkpoint	  activity	  by	  counting	  the	  entire	  mitotic	   index	  of	  a	  cell	  population.	  	  This	  is	  an	  indirect	  way	  of	  assessing	  Chfr	  checkpoint	  activity	  because	  it	  focuses	   on	   the	   entire	  mitotic	   cell	   population	   (arrested	   by	   the	   spindle	   checkpoint)	  instead	  of	  looking	  exclusively	  at	  the	  EP	  stage	  of	  mitosis	  where	  Chfr	  specifically	  exerts	  its	  effects.	  	  In	  other	  words,	  the	  mitotic	  index	  is	  the	  percentage	  of	  cells	  that	  squeeze	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through	  the	  checkpoint.	  	  The	  early	  prophase	  index	  (EPI)	  assay	  is	  thus	  a	  more	  direct	  way	  of	  assessing	  Chfr	  checkpoint	  activity	  and	  could	  provide	  resolution	  between	  the	  early	  prophase	  checkpoint	  and	  the	  spindle	  assembly	  checkpoint.	  
	  
3.3.2	  Visually	  defining	  the	  early	  prophase	  stage	  of	  mitosis.	  Using	  DAPI	  staining	  is	  ineffective	  at	  detecting	  early	  prophase	  (EP)	  cells	  as	  cells	  at	  this	  stage	  have	  not	  yet	  fully	   condensed	   their	   chromosomes	   and	   may	   appear	   as	   though	   they	   are	   still	   in	  interphase	  (Figure	  3-­‐3).	  	  To	  efficiently	  detect	  EP	  cells,	  and	  to	  distinguish	  them	  from	  interphase	  and	   late	  prophase	   (LP)	   cells,	   I	  used	   the	  α-­‐phospho-­‐histone	  H3	   (α-­‐pH3)	  antibody	  and	  the	  α-­‐nucleolin	  antibody	  (Figure	  3-­‐4).	  	  
The	  α-­‐pH3	  antibody	  is	  a	  useful	  marker	  for	  identifying	  mitotic	  cells	  because	  it	  detects	   phosphorylated	   histone	   H3.	   	   The	   phosphorylation	   of	   this	   histone	   is	  necessary	   for	   chromosome	  condensation	  and	  occurs	   rapidly	  during	   the	  very	  early	  stages	  of	  mitosis,	   even	  before	   the	  chromatin	   is	   fully	   condensed.	   	  This	  allows	  us	   to	  detect	  EP	  cells	  and	  to	  distinguish	  these	  cells	  from	  interphase	  cells.	  	  The	  α-­‐nucleolin	  antibody,	  on	  the	  other	  hand,	  stains	  the	  nucleoli	  of	  cells.	  	  Nucleoli	  disappear	  as	  cells	  enter	  into	  the	  late	  prophase	  (LP)	  stage	  of	  mitosis.	  	  Being	  able	  to	  detect	  the	  presence	  or	  absence	  of	  nucleoli,	  therefore,	  allows	  one	  to	  distinguish	  early	  prophase	  cells	  from	  late	  prophase	  cells.	  	  Used	  in	  combination,	  these	  two	  markers	  helped	  to	  clearly	  define	  the	  EP	  stage	  of	  mitosis	  and	  the	  point	  at	  which	  Chfr	  functions	  (Figure	  3-­‐5).	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3.3.3	   Sensitization	   by	   synchronization.	   	   Though	   the	   EPI	   assay	   appears	   to	   be	  applicable	   to	  SAOS2	  and	  U2OS	  cells,	   it	   is	  not	  very	  sensitive,	  and	  will	  not	  be	  better	  than	  the	  mitotic	   index	  (MI)	  assay	  unless	  we	  can	  effectively	  increase	  the	  number	  of	  early	  prophase	  cells	  for	  analysis	  in	  each	  cell	  population.	  
To	   improve	  the	  assay,	   I	  needed	  a	  synchronization	  method	  that	  would	  allow	  me	  sensitive	  control	  over	  the	  G2/M	  entry	  gate,	  so	  that	  upon	  release,	  the	  cells	  would	  enter	  mitosis	  rapidly	  together.	  	  	  	  
This	   task	   was	   a	   challenge	   because	   currently	   there	   are	   no	   effective	  synchronization	  methods	  out	   there	   for	   studying	  mitotic	  entry	   in	  mammalian	  cells.	  	  There	   are	  methods	   in	   the	   literature	   that	   block	   cells	   at	   the	   G1/S	   gate,	   such	   as	   the	  thymidine-­‐aphidicolin	  or	  thymidine-­‐cytidine	  block	  (Scolnick	  and	  Halazonetis,	  2000;	  Summers	  et	  al.,	  2005).	   	  There	  are	  also	  methods	   in	  the	   literature	  that	  block	  cells	   in	  the	  middle	   of	  mitosis,	   by	   using	   nocodazole	   or	   a	   combination	   of	   the	   R03306	   drug	  with	   nocodazole	   (Vassilev	   et	   al.,	   2006).	   	   For	   the	   study	   of	   early	   mitotic	   entry,	  however,	  there	  does	  not	  appear	  to	  be	  any	  effective	  methods	  of	  synchronization.	  	  The	  R03306	  drug	  can	  be	  used	  alone	  to	  synchronize	  cells	  at	  the	  G2/M	  gate	  (Vassilev	  et	  al.,	  2006)	  but	   this	  method	  does	  not	  always	  synchronize	  cells	  as	  effectively	  as	   I	  would	  like	  (approximately	  15-­‐30%).	  	  	  
For	  this	  reason,	  a	  method	  for	  synchronizing	  mammalian	  cells	  was	  developed,	  referred	   to	   here	   as	   the	   “double	   thymidine,	   single	   R03306	   block”	   (2xThymidine-­‐1xR03306).	   	   This	   technique	   is	   essentially	   a	   double	   G1/S,	   single	   G2/M	   block.	   	   To	  synchronize	  cells,	  cells	  are	  treated	  with	  2mM	  thymidine	  for	  21	  hours,	  released	  for	  	  
	  	  





Figure	  3-­‐3.	   	  DAPI	  used	   in	   combination	  with	   the	   anti-­‐phospho-­‐histone	  H3	   (α-­‐
pH3)	  rabbit	  antibody	  is	  more	  effective	  at	  detecting	  early	  prophase	  cells	  than	  
the	   DAPI	   stain	   alone.	   	   The	   α-­‐pH3	   antibody	   detects	   early	   prophase	   cells	   more	  accurately	   than	  the	  DAPI	  stain	  (A,	  B),	  which	  results	   in	  a	  higher	  and	  more	  accurate	  early	  prophase	   index	  (EPI)	   in	  untreated	  SAOS2	  and	  U2OS	  cells	  (C,	  D).	   	  SAOS2	  cells	  are	  expected	  to	  express	  the	  Chfr	  protein,	  and	  U2OS	  cells	  are	  not	  expected	  to	  express	  the	  Chfr	  protein,	  in	  comparison	  to	  SAOS2	  cells.	  Arrows	  point	  to	  early	  prophase	  cells,	  which	  can	  be	  easily	  overlooked	  by	  staining	  only	  with	  DAPI.	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12	  hours,	  and	  treated	  with	  2mM	  thymidine	  for	  21	  hours.	   	  This	  should	  synchronize	  them	  at	  the	  G1/S	  phase	  of	  the	  cell	  cycle.	  	  The	  thymidine	  is	  then	  removed	  and	  cells.	  For	  this	  reason,	  a	  method	  for	  synchronizing	  mammalian	  cells	  was	  developed,	  referred	   to	   here	   as	   the	   “double	   thymidine,	   single	   R03306	   block”	   (2xThymidine-­‐1xR03306).	   	   This	   technique	   is	   essentially	   a	   double	   G1/S,	   single	   G2/M	   block.	   	   To	  synchronize	  cells,	  cells	  are	   treated	  with	  2mM	  thymidine	   for	  21	  hours,	   released	   for	  12	  hours,	  and	  treated	  with	  2mM	  thymidine	  for	  21	  hours.	   	  This	  should	  synchronize	  them	  at	  the	  G1/S	  phase	  of	  the	  cell	  cycle.	   	  The	  thymidine	  is	  then	  removed	  and	  cells	  are	   immediately	   treated	  with	   10	   μM	   of	   R03306	   for	   22	   hours.	   	   R03306	   is	   a	   Cdk1	  inhibitor	  and	  blocks	  the	  cells	  at	  the	  G2/M	  gate	  (Vassilev	  et	  al.,	  2006).	  	  This	  way,	  cells	  that	  have	  accumulated	  at	   the	  G1/S	  boundary	  can	  now	  progress	  and	  accumulate	  at	  the	  G2/M	  boundary.	   	  R03306	   is	   then	  removed,	   cells	  are	  released,	  and	  should	  now	  progress	  synchronously	  through	  the	  early	  stages	  of	  mitosis.	  	  	  
HeLa,	   HeLa-­‐Chfr,	   SAOS2,	   and	   U2OS	   cells	   were	   then	   synchronized	   by	   using	  this	  method.	  	  U2OS	  cells	  synchronized	  the	  best.	  	  In	  one	  experiment,	  50.8%	  of	  U2OS	  cells	   entered	   mitosis	   within	   45	   minutes	   of	   release	   from	   the	   G2/M	   block;	   and	   in	  another	  experiment,	  64.6%	  of	  cells	  entered	  mitosis	  upon	  release	  (Figure	  3-­‐6).	  	  The	  mitotic	   index	   was	   scored	   as	   the	   percentage	   of	   rounded	   cells	   in	   a	   cell	   population	  using	  phase	   contrast	  microscopy.	   	  As	   a	   control,	  U2OS	   cells	  were	   also	   treated	  with	  R03306	   alone.	   	   Upon	   release	   from	   the	   G2/M	   block,	   only	   27.4%	   of	   cells	   entered	  mitosis	   in	   one	   experiment;	   and	   in	   another	   experiment,	   28.3%	   percent	   of	   cells	  entered	   mitosis	   upon	   release.	   	   To	   look	   at	   early	   prophase	   cells	   specifically,	   the	  experiment	  was	  then	  repeated	  and	  the	  cells	  released	  for	  0	  minutes,	  10	  minutes,	  and	  
	  	  
	  	   	   38	  
45	  minutes	   from	   the	  2xThymidine-­‐1xR03306	  block	   and	   stained	   the	   cells	  with	   the	  anti-­‐phospho-­‐histone	  H3	  antibody,	  which	  detects	  mitotic	  cells	  (Figure	  3-­‐7).	  	  At	  the	  0	  minute	  time	  point,	  very	  little	  cells	  are	  in	  mitosis.	  	  The	  phase	  contrast	  photo	  in	  the	  0	  minute	   panel	   shows	   clearly	   that	   the	   nucleoli	   of	   these	   cells	   have	   not	   yet	   broken	  down,	  which	   indicates	   that	   they	  are	  blocked	  at	   a	   stage	  where	   the	  Chfr	   checkpoint	  should	  still	  be	  active	  according	  to	  Matsusaka	  and	  Pines	  (2004).	  
After	   10	   minutes	   of	   release	   from	   the	   G2/M	   block,	   many	   U2OS	   cells	   were	  visible	   at	   the	   early	   prophase	   stage	   of	  mitosis.	   	   At	   the	   45-­‐minute	   time	   point,	  most	  cells	  were	  in	  late	  prophase.	  	  The	  next	  step	  will	  be	  to	  try	  and	  optimize	  the	  condition	  for	   this	  U2OS	  cell	   line	  as	   I	  noticed	  some	  dead	  cells	  and	   fragmented	  nuclei	   in	   the	  0	  min	  control	  (Figure	  3-­‐8).	  
Synchronized	  HeLa-­‐Chfr	  cells	  had	  44.7%	  and	  54.4%	  of	  cells	  entering	  mitosis	  upon	  release	  from	  the	  2xThymidine-­‐1xR03306	  block	   in	  two	  separate	  experiments.	  Following	  release	  from	  treatment	  with	  R03306	  alone,	  resulted	  in	  14.7%	  and	  35.7%	  of	   cells	   entering	   mitosis.	   Synchronization	   of	   HeLa	   cells	   with	   the	   2xThymidine-­‐1xR03306	  block	  was	  also	  efficient,	  with	  33.9%,	  35.1%,	  and	  30.7%	  of	  cells	  entering	  mitosis	   in	   three	   separate	  experiments	  upon	  release.	  These	  numbers,	  however,	  did	  not	   vary	   greatly	   when	   compared	   to	   the	   percentage	   of	   HeLa	   cells	   treated	   with	  R03306	  alone	  (27.4%,	  26.2%).	  	  
SAOS2	  cells	  were	  the	  least	  effective	  at	  synchronization	  by	  the	  2xThymidine-­‐1xRO3306	   block,	   but	   the	   method	   still	   managed	   to	   increase	   the	   number	   of	   cells	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entering	  mitosis	  to	  28.7%.	  	  The	  single	  R03306	  control	  treatment	  for	  SAOS2	  cells	  has	  not	  yet	  been	  done.	  	  	  	  
The	   2xThymidine-­‐1xR03306	   synchronization	   method	   could	   prove	   to	   be	   a	  superior	  method	  of	  synchronizing	  cells	  for	  the	  study	  of	  mitotic	  events.	  
Firstly,	   the	   method	   gives	   a	   sensitive	   control	   over	   the	   G2/M	   entry	   gate,	  allowing	  for	  rapid	  entry	  into	  mitosis	  within	  10-­‐45	  minutes	  of	  release	  from	  the	  G2/M	  block.	   	  Secondly,	   the	  method	  allows	  rapid	  entry	  of	  a	  significantly	   larger	  number	  of	  cells	  to	  enter	  mitosis.	  	  Thirdly,	  the	  method	  appears	  to	  be	  better	  than	  a	  single	  R03306	  block	   alone,	   as	   far	   as	   U2OS	   cells	   are	   concerned.	   	   Fourthly,	   the	   2xThymidine-­‐1xR03306	  block	  is	  better	  than	  a	  mere	  2xThymidine-­‐G1/S	  block,	  which	  synchronizes	  cells	   at	   an	  undesirable	   stage	  of	   the	   cell	   cycle	   for	   the	   study	  of	   early	  mitotic	  events.	  Fifthly,	   the	   2xThymidine-­‐1xR03306	   block	   does	   not	   require	   nocodazole	   for	  synchronization.	  	  Many	  researchers	  use	  the	  2xThymidine	  block	  in	  combination	  with	  nocodazole,	  to	  get	  a	  large	  (90%)	  population	  of	  cells	  in	  “mitosis.”	   	  This	  combination	  method,	   however,	   will	   synchronize	   cells	   in	   the	   middle	   of	   mitosis,	   not	   at	   the	  beginning,	  and	  for	  this	  reason	  is	  not	  useful	  for	  studying	  early	  mitotic	  events,	  such	  as	  the	  early	  prophase	  Chfr	  checkpoint.	   	  Secondly,	  nocodazole	  is	  a	  microtubule	  poison,	  so	   it	   is	   undesirable	   for	   synchronization	   if	   you	   are	   trying	   to	   study	   events	   that	   are	  induced	   by	   microtubule	   stress	   in	   the	   first	   place,	   such	   as	   the	   Chfr	   checkpoint.	  	  Thirdly,	   cells	   “synchronized”	   with	   nocodazole,	   do	   not	   necessarily	   progress	  “synchronously”	   or	   normally	   through	   the	   rest	   of	  mitosis	  (Cooper	   et	   al.,	   2006)	   For	  these	   reasons,	   the	   2xThymidine-­‐1xR03306	  block	  may	  be	   a	   useful	   synchronization	  technique	  for	  studying	  early	  mitotic	  events.	  
	  	  






Figure	  3-­‐6.	  U2OS	  cells	   synchronized	  by	   the	  double	   thymidine,	   single	  R03306	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Figure	  3-­‐7.	   	   Synchronization	  of	  U2OS	   cells	   at	   the	   early	  prophase	   stage	  using	  
the	  double	  thymidine,	  single	  R03306	  block.	  	  U2OS	  cells	  were	  synchronized	  using	  the	  double	  thymidine,	  single	  R03306	  block.	  	  Cells	  were	  treated	  with	  2mM	  thymidine	  for	  21	  hours,	  released	  for	  12	  hours,	  treated	  with	  2mM	  thymidine	  for	  21	  hours.	  	  The	  thymidine	   was	   then	   removed	   and	   cells	   were	   immediately	   treated	   with	   10	   μM	   of	  R03306	  for	  22	  hours.	  R03306	  is	  a	  Cdk1	  inhibitor	  and	  blocks	  cells	  at	  the	  G2/M	  gate.	  	  The	   R03306	   drug	  was	   then	   removed	   and	   the	   cells	   were	   released	   from	   the	   G2/M	  block	   for	   0	  min,	   10	  min,	   and	   45	  minutes	   to	  watch	   progression	   through	   the	   early	  prophase	  stage	  of	  mitosis.	   	  Most	  U2OS	  cells	  enter	  early	  prophase	  10	  minutes	  after	  release	  from	  the	  G2/M	  block.	  	  Photos	  were	  taken	  under	  the	  red	  and	  blue	  fluorescent	  filter	  and	  merged	  with	  phase	  contrast	  photos.	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Figure	  3-­‐8.	   	   Synchronization	  of	  U2OS	   cells	   at	   the	   early	  prophase	   stage	  using	  
the	  double	   thymidine,	   single	  R03306	  block.	   	  Cells	  were	  synchronized	  as	  above.	  	  Photos	   were	   taken	   under	   the	   red	   (anti-­‐phospho-­‐histone	   H3	   antibody)	   and	   blue	  (DAPI)	  fluorescent	  filters,	  and	  the	  images	  were	  then	  merged	  together.	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One	   worry	   for	   this	   particular	   study	   is	   that	   blocking	   cells	   at	   the	   G2/M	  transition	  using	  the	  RO3306	  Cdk1	  inhibitor	  (Vassilev	  et	  al.,	  2006)	  stops	  cells	  too	  late	  in	   the	   cell	   cycle.	   	   So	   by	   the	   time	   that	   the	   cells	   reach	   this	   particular	   point	   in	   their	  cycle,	  Chfr	  may	  no	  longer	  be	  able	  to	  act	  on	  them,	  as	  they	  could	  have	  already	  passed	  through	  the	  Chfr	  checkpoint	  gate.	  	  The	  phase	  contrast	  photo	  in	  Figure	  3-­‐7,	  however,	  indicates	  that,	  this	  method	  should	  synchronize	  cells	  effectively	  for	  G2/M	  checkpoint	  analysis	  because	  the	  cells	  blocked	  at	  the	  0	  minute	  time	  point	  contain	  intact	  nucleoli.	  	  The	  checkpoint	   functions	  when	  colcemid	   is	  added	  before	  the	  nucleoli	  break	  down,	  but	   is	   no	   longer	   functional	   after	   the	   nucleoli	   break	   down	   (Matsusaka	   and	   Pines,	  2004).	   	   If	   this	   method	   of	   synchronization	   cannot	   be	   applied	   to	   the	   study	   of	   Chfr	  checkpoint	  activity	  at	  the	  EP	  stage	  of	  mitosis,	  it	  could	  still	  be	  a	  useful	  and	  superior	  method	  of	  synchronization	  for	  other	  early	  mitotic	  studies,	  such	  as	  nuclear	  envelope	  breakdown,	   nucleolar	   breakdown,	   phosphorylation	   of	   histone	   H3,	   chromosome	  condensation,	  centrosome	  separation,	  and	  spindle	  formation.	  	  This	  synchronization	  could	   also	   be	   used	   to	   collect	   cells	   at	   later	   stages	   of	  mitosis	  without	   the	   damaging	  effects	  of	  microtubule	  poisons.	  
	  
3.4	  Detecting	  Chfr	  checkpoint	  activity	  in	  various	  cell	  lines.	  
3.4.1	  HeLa	   and	  HeLa-­‐Chfr	   cells.	   	  The	  mitotic	   index	  assay	  was	  used	  to	  determine	  whether	  HeLa-­‐Chfr	  cells	  contain	  Chfr	  checkpoint	  activity.	  	  One	  experiment	  was	  done	  using	  unsynchronized	  cells	  and	  another	  was	  done	  after	  synchronization.	  	  Figure	  3-­‐
9a	  shows	  that	  the	  MI	  of	  unsynchronized	  HeLa-­‐Chfr	  cells	  was	  very	  similar	  to	  that	  of	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HeLa	   control	   cells	   following	   nocodazole	   treatment.	   	   The	   effect	   of	   nocodazole	  was	  very	  similar	  on	  both	  cell	  types.	  	  Synchronized	  HeLa	  and	  HeLa-­‐Chfr	  cells	  showed	  the	  same	   profile,	   with	   both	   cell	   types	   entering	  mitosis	   rapidly	   upon	   release	   from	   the	  G2/M	  block,	  in	  the	  absence	  of	  nocodazole	  (Figure	  3-­‐9b).	   	  The	  effect	  of	  nocodazole	  presence	  reduced	  the	  mitotic	  index	  slightly.	  	  	  
	  
3.4.2	   U2OS,	   U2OS-­‐GFP,	   U2OS-­‐EGFP,	   and	   U2OS-­‐EGFP-­‐Chfr.	   	   U2OS	   cells	   stably	  expressing	  EGFP-­‐Chfr	  were	  also	  generated.	  	  This	  has	  previously	  been	  done	  (Scolnick	  and	  Halazonetis,	  2000;	  Bothos	  et	  al.,	  2003)	  where	  HA-­‐tagged	  Chfr	  was	   transfected	  into	  U2OS	  cells,	  resulting	  in	  a	  significant	  decrease	  of	  mitotic	  index	  after	  nocodazole	  treatment.	  	  Fluorescent	  clones	  were	  selected	  using	  geneticin	  and	  a	  Western	  blot	  was	  run	  to	  determine	  which	  selected	  clones	  are	  expressing	  a	  protein	  of	  the	  correct	  size	  
(Figure	  3-­‐10a).	   	  From	  the	  11	  putative	  clones,	  Clone	  7	  and	  8	  contained	  bands	  with	  an	  expected	  size	  between	  75	  and	  100	  kDa,	  so	  these	  two	  clones	  were	  selected	  to	  do	  the	  MI	  assay.	   	  U2OS,	  U2OS-­‐GFP,	  and	  U2OS-­‐EGFP-­‐Chfr	   cells	  were	   then	   treated	  with	  nocodazole	   (Figure	   3-­‐10b).	   U2OS-­‐EGFP-­‐Chfr	   clone	   8	   has	   a	   smaller	   MI	   in	  comparison	   to	   the	   untransfected.	   U2OS	   control	   cell	   line	   	   (Figure	   3-­‐10b).	   	   U2OS-­‐EGFP-­‐Chfr	  Clone	  7	  also	  had	  a	  smaller	  MI	  in	  comparison	  to	  the	  untransfected	  U2OS	  control	   cell	   line.	   	   This	   reduction	   indicates	   possible	   Chfr	   checkpoint	   activity.	  	  	  However,	   the	   mitotic	   indexes	   of	   Clone	   7	   and	   8	   were	   higher	   than	   the	   U2OS-­‐GFP	  control,	  indicating	  no	  effect	  of	  Chfr	  presence	  on	  mitotic	  index.	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   Even	   though	   the	   U2OS-­‐GFP	   control	   did	   not	   work	   for	   this	   experiment,	   it	  should	  be	  noted	  that	  Clone	  7	  had	  a	  much	  higher	  EGFP-­‐Chfr	  expression	  than	  Clone	  8.	  	  These	  results	  are	  in	  line	  with	  the	  Western	  blot	  (Figure	  3-­‐10a).	  	  When	  compared	  to	  clone	   8,	   the	   mitotic	   index	   of	   Clone	   7	   is	   reduced	   here,	   and	   is	   much	   smaller	   in	  comparison	   to	   the	   MI	   of	   Clone	   8.	   The	   more	   Chfr	   expression	   there	   is,	   the	   more	  reduced	  the	  MI	  should	  should	  reduce	  MI	  and	  entry	  into	  mitosis.	  	  This	  indicates	  that	  the	  EGFP-­‐Chfr	  protein	  expressed	  in	  these	  cells	  (Clone	  7)	  may	  be	  functional.	  	  	  
Localization	   to	   either	   decondensing	   chromosomes	   in	   telophase	   cells	   or	   to	  decondensed	  chromatin	  in	  interphase	  cells	  helps	  to	  confirm	  Chfr	  function.	  Figure	  3-­‐
10c	   shows	   Chfr	   accumulating	   in	   the	   interphase	   nucleus,	   with	   Chfr	   promoting	  decondensation.	  By	  accumulation	  of	  Chfr	  in	  telophase,	  helps	  to	  confirm	  the	  potential	  decondensing	  activity	  that	  this	  protein	  could	  have	  in	  the	  EP	  Chfr	  checkpoint.	  
	   In	   control	   cells	   expressing	   only	   EGFP	   (Clone	   4),	   the	   EGFP	   protein	   localizes	  throughout	  the	  cell,	  and	  not	  specifically	  to	  interphase	  or	  telophase	  DNA	  (Figure	  3-­‐
10c,	  3-­‐10d).	   	  Cells	  lacking	  EGFP-­‐Chfr	  protein	  expression	  are	  abnormally	  elongated	  and	  have	  abnormally	  elongated	  chromosomes	  in	  mitosis	  indicating	  a	  defect	  either	  in	  the	  G2/M	  checkpoint	  or	  the	  spindle	  assembly	  checkpoint.	  	  
	  
3.4.3	  	  SAOS2	  and	  U2OS	  cells.	  	  The	  mitotic	  index	  (MI)	  assay	  and	  the	  early	  prophase	  index	  (EPI)	  assay	  had	  previously	  been	  used	  with	  success	  to	  detect	   the	  presence	  of	  Chfr	   checkpoint	   activity	   in	   SAOS2	  and	  U2OS	   cells.	   	  Figure	   3-­‐11	   demonstrates	   the	  difference	   between	   the	   mitotic	   index	   assay	   and	   the	   early	   prophase	   index	   assay.	  	  U2OS	  cells,	  which	  express	  mutant	  Chfr,	  were	  shown	  to	  have	  a	  high	  MI	  following	  	  
	  	  










Figure	  3-­‐9a.	  	  Effect	  of	  nocodazole	  on	  the	  mitotic	  index	  of	  unsynchronized	  HeLa	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Figure	  3-­‐9b.	   	  Effect	  of	  nocodazole	  on	  the	  mitotic	  index	  of	  G2/M	  synchronized	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microtubule	   damage,	   indicating	   reduced	   Chfr	   checkpoint	   activity,	   whereas	   SAOS2	  cells,	   which	   express	   wild	   type	   Chfr	   were	   shown	   to	   have	   a	   lower	   MI	   following	  microtubule	  damage,	  indicating	  Chfr	  checkpoint	  activity	  presence.	  	  	  This	  experiment	  was	  done	  only	  once.	  
	  
3.4.4	   U2OS-­‐WTChfr	   and	   U2OS-­‐RING∆Chfr	   cells.	   	   U2OS	   WTChfr	   and	   U2OS-­‐RING∆Chfr	  cell	   lines	  have	  been	  shown	  by	  Matsusaka	  and	  Pines	   	   (2004)	   to	  contain	  and	  not	  to	  contain	  the	  Chfr	  checkpoint,	  respectively.	  	  The	  two	  cell	  lines	  are	  isogenic,	  unlike	  the	  SAOS2	  and	  U2OS	  cell	   lines.	   	  Their	  tendency	  to	  enter	  mitosis	  is	  shown	  in	  (Figure	  3-­‐15	  and	  Table	  3-­‐1).	  	  	  
	  
3.4.4.1	   	   A	   G2/M	   checkpoint	   induced	   by	   colcemid	   in	   U2OS	   cells.	   	   U2OS	   cells	  expressing	   wild	   type	   Chfr	   (U2OS-­‐WTChfr)	   and	   RING	   finger	   mutant	   Chfr	   (U2OS-­‐RING∆Chfr)	   cells	   can	   express	   the	   Chfr	   protein	   from	   a	   tetracycline-­‐inducible	  promotor	   (Matsusaka	   and	   Pines,	   2004).	   	   These	   proteins	   are	   tagged	   with	   a	   green	  fluorescent	  X-­‐press	  tag.	  WTChfr	  expression	  in	  U2OS	  cells	  was	  confirmed	  by	  Western	  blot	   (Figure	   3-­‐12).	   	   Immunocytochemistry	   showed	   wild	   type	   Chfr	   expression	   in	  U2OS	   cells	   using	   the	   Xpress	   antibody	   and	   the	   Chfr-­‐CR	   antibody.	   	   Both	   antibodies	  localized	  to	  spotted	  areas,	  some	  of	  which	  could	  possibly	  be	  centrosomes,	  which	  are	  indicated	   by	   arrows.	   The	   spotted	   areas	   are	   mainly	   in	   the	   interphase	   nucleus.	  	  Approximately	  2-­‐10%	  of	  cells	  express	  WTChfr	  in	  the	  U2OS-­‐WTChfr	  cell	  population	  and	   approximately	   30-­‐40%	   express	   RING∆Chfr	   in	   the	   U2OS-­‐RING∆Chfr	   cell	  population	  via	  immunocytochemistry.	  	  This	  makes	  their	  analysis	  more	  difficult.	  	  The	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Figure	  3-­‐10a.	   	  Western	  blot	  showing	  U2OS-­‐EGFP-­‐Chfr	  clones	  (lanes	  2-­‐12)	  and	  
the	   U2OS-­‐GFP	   control	   (lane	   1).	   	   	   Lanes	   2-­‐12,	   Clones	   11-­‐1.	   Lane	   6,	   for	   example,	  contains	  U20S	  cell	  extracts	  expressing	  the	  EGFP-­‐Chfr	  clone	  7	  protein,	  and	  has	  high	  EGFP-­‐Chfr	  expression	   in	   comparison	   to	   lane	  5,	  which	  contains	  U2OS	  cells	  extracts	  expressing	  EGFP-­‐Chfr	  protein	  clone	  8.	   	  Clone	  8	  has	  medium	  EGFP-­‐Chfr	  expression.	  	  Clone	   3,	   in	   lane	   10	   has	   even	   less	   EGFP-­‐Chfr	   expression	   than	   clone	   7	   and	   clone	   8.	  	  Clone	  4,	  in	  lane	  9,	  expresses	  only	  EGFP	  and	  is	  localized	  to	  the	  nucleus	  as	  well	  as	  to	  the	  cytoplasm.	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Figure	   3-­‐10b.	   	   Mitotic	   index	   of	   U2OS	   EGFP-­‐Chfr	   clones	   following	  
nocodazole	   treatment.	   	   U2OS,	   U2OS-­‐EGFP	   control	   cells,	   and	   U2OS-­‐EGFP-­‐Chfr	   cells	   stably	   expressing	   EGFP-­‐Chfr	   were	   treated	   with	   0.5	   μg/ml	  nocodazole	  for	  15	  hours.	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Figure	  3-­‐10c.	  	  Expression	  of	  EGFP-­‐Chfr	  in	  U2OS	  cells.	  	  Many	  cells	  are	  rounded	  in	  the	   presence	   of	   nocodazole.	   	   Arrows	   point	   to	   rounded	   cells.	   	   EGFP-­‐Chfr	   is	   either	  cytoplasmic	   or	   localizes	   to	   the	   nucleus.	   EGFP-­‐Chfr	   is	   noticeable	   in	   decondensing	  chromatin	   in	   telophase	   cells.	   	   EGFP-­‐Chfr	   is	   also	   present	   in	   interphase	   nuclei	  with	  decondensed	   chromatin.	   	   Unlike	   the	   EGFP	   control	   cell	   line,	   this	   cell	   line	   could	   be	  more	   resistant	   to	   nocodazole	   and	   less	   prone	   to	   cell	   death	   because	   it	   has	   less	  abnormally	  elongated	  and	  fragmented	  cells.	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Figure	   3-­‐10d.	   	   Expression	   of	   EGFP	   in	   U2OS	   cells.	   	  Many	   U2OS	   cells	   (Clone	   4)	  expressing	   only	   the	   EGFP	   protein	   are	   abnormally	   elongated	   and	   fragmented	   in	  nocodazole	  presence.	  	  Arrow	  points	  to	  abnormally	  elongated	  cell.	  	  The	  EGFP	  protein	  is	  cytoplasmic.	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Figure	  3-­‐11.	  	  A	  comparison	  of	  the	  current	  MI	  assay	  and	  the	  EPI	  assay	  tailored	  







































































































1 = Cells were treated with nocodazole overnight.
2 = Cells were synchronized with RO3306, treated for 
2 hrs with nocodazole, and then released for 30 
minutes into mitosis.
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Figure	   3-­‐12.	   	   (A)	   Induction	   of	   Xpress-­‐WTChfr	   protein	   from	   a	   tetracycline-­‐
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3.4.4.2	  Effect	  of	  Chfr	  expression	  on	  mitotic	  index.	  	  Two	  more	  similar	  experiments	  were	  carried	  out	  using	  immunocytochemistry	  instead	  of	  phase	  contrast	  (Figures	  3-­‐
13	   and	   3-­‐14).	   	  U2OS-­‐WTChfr	   cells	  were	   compared	   to	   cells	   that	   express	   a	  mutant	  version	   of	   the	   same	   protein	   (U2OS-­‐RING∆Chfr).	   	   U2OS-­‐WTChfr	   cells	   have	   the	  following	  mitotic	  indexes:	  27.1%	  in	  uninduced,	  untreated	  cells,	  8.9%	  in	  uninduced,	  treated	  cells,	  18.5%	  in	   induced,	  untreated	  cells,	  and	  5.5%	  in	   induced,	   treated	  cells.	  	  Uninduced	  cells	  treated	  with	  colcemid	  reduced	  their	  MI	  by	  3.0%,	  whereas	  induced	  cells	   treated	   with	   colcemid	   reduced	   their	   MI	   by	   3.4%.	   	   This	   suggests	   that	   Chfr	  expression	   does	   not	   significantly	   affect	   the	   ability	   of	   this	   cell	   population	   to	   delay	  mitotic	   entry.	   	   However,	   a	   complete	   conclusion	   cannot	   be	   made	   because	   of	   low	  overall	  WTChfr	   expression	   (~2-­‐10%).	   	   There	   is	   a	   colcemid-­‐induced	   checkpoint	   in	  these	  cells,	  but	  WTChfr	  does	  not	  seem	  to	  affect	  the	  response	  of	  cells	  to	  colcemid.	  
Instead	  of	  comparing	  the	  effect	  of	  WTChfr	  expression	  to	  U2OS	  cells	  that	  have	  not	  yet	  been	  induced	  to	  express	  the	  WTChfr	  protein,	  cells	  expressing	  WT-­‐Chfr	  were	  then	   compared	   to	   cells	   expressing	   a	   mutant	   version	   of	   the	   same	   protein.	   U2OS-­‐RING∆Chfr	  cells	  have	  the	  following	  mitotic	  indexes:	  18.3%	  for	  uninduced,	  untreated	  cells,	  5.1%	  for	  uninduced	  treated	  cells,	  (18.3%;	  5.1%)	  23.2%	  for	  induced,	  untreated	  cells,	  and	  11.8%	  for	  induced,	  treated	  cells	  (23.2%;	  11.8%).	  	  Uninduced	  cells	  treated	  with	   colcemid	   reduced	   their	   MI	   by	   3.6	   folds,	   whereas	   induced	   cells	   treated	   with	  colcemid	  reduced	  their	  MI	  by	  2.0	  folds.	   	  We	  found	  that	  cells	  expressing	  the	  mutant	  version	   of	   the	   protein	  were	   less	   effective	   at	   reducing	   their	  mitotic	   index	   and	   less	  efficient	   at	   mitotic	   delay	   in	   response	   to	   colcemid.	   These	   numbers	   could	   become	  more	  significant	  with	  a	  homogeneous	  clone.	  
	  	  




Figure	   3-­‐13.	   	   Effects	   of	   colcemid	   on	   the	   mitotic	   index	   of	   uninduced	   and	  
induced	  U2OS-­‐WTChfr	   cells.	   	  Cells	  were	  synchronized	  with	  RO3306	  at	  the	  G2/M	  entry	  gate,	   treated	  or	   left	  untreated	   for	  2	  hours,	   and	   then	  released	   into	  mitosis	   to	  observe	  early	  mitotic	  progression.	  Only	  approximately	  2-­‐10	  %	  of	  cells	  in	  the	  U2OS-­‐WTChfr	  cell	  population	  express	  Xpress-­‐WTChfr	   (lower	  panel),	   although	  some	  may	  have	   low	  or	  visually	  undetectable	  Chfr	  expression.	   	  Chfr	  expression	  affects	  mitotic	  index	   by	   reducing	   mitotic	   index.	   	   For	   example,	   in	   the	   absence	   of	   colcemid,	   the	  mitotic	  index	  of	  cells	  is	  reduced	  from	  27.1%	  to	  18.5%	  when	  tetracycline	  is	  removed	  from	  the	  cell	  population	  to	  induce	  Chfr	  expression.	  	  This	  indicates	  that	  expression	  of	  Chfr	   affects	   entry	   into	  mitosis.	   	   This	   is	   in	   agreement	   with	   some	   of	   the	   published	  findings.	   	   The	   response	   of	   the	   cell	   population	   to	   colcemid	   does	   not	   seem	   to	   be	  greatly	  affected	  by	  Chfr	  expression:	  	  cells	  that	  have	  no	  Chfr	  induction	  (27.1%;	  8.9%)	  reduce	  their	  mitotic	   index	  by	  approximately	   the	  same	  amount	  than	  cells	   that	  have	  Chfr	  induced	  (18.5%;	  5.5%).	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Figure	  3-­‐14.	  	  Effect	  of	  colcemid	  on	  the	  mitotic	  index	  of	  uninduced	  and	  induced	  
U2OS-­‐RING∆Chfr	  cells.	   	   	  Cells	  were	  synchronized	  with	  RO3306	  at	  the	  G2/M	  entry	  gate,	  treated	  or	  left	  untreated	  for	  2	  hours,	  and	  then	  released	  into	  mitosis	  to	  observe	  early	   mitotic	   progression.	   Only	   approximately	   30-­‐40%	   of	   cells	   in	   the	   U2OS-­‐RING∆Chfr	   cell	   population	   express	   Xpress-­‐RING∆Chfr	   (lower	   panel).	   	   RINGΔChfr	  expression	  affects	  mitotic	  index	  by	  increasing	  mitotic	  index.	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3.4.4.3	   WT-­‐Chfr	   over-­‐expression	   prevents	   mitotic	   entry.	   	   Since	   the	   cell	  populations	  are	  not	  homogeneous,	  individual	  green	  cells	  expressing	  the	  appropriate	  protein	   in	   the	   induced	   cell	   population	   were	   observed	   upon	   entry	   into	   mitosis	  
(Figure	  3-­‐15	  and	  Table	  3-­‐1).	  	  U2OS-­‐WTChfr	  cells	  have	  reduced	  entry	  into	  mitosis	  in	  comparison	  to	  U2OS-­‐RING∆Chfr	  cells	  regardless	  of	  colcemid	  presence	  or	  absence	  
(Table	  3-­‐1).	  	  The	  data	  indicates	  that	  cells	  expressing	  wild	  type	  Chfr	  are	  less	  likely	  to	  enter	  mitosis	   than	  are	   cells	   expressing	  mutant	  Chfr.	   	  Cells	   expressing	  mutant	  Chfr	  lacking	   the	   ubiquitinating	   domain	   progress	   into	   mitosis	   more	   readily,	   possibly	  because	   they	   are	   unable	   to	   carry	   out	   the	  decondensing	   function.	   	   This	   indicates	   a	  mitotic	  function	  for	  the	  U2OS-­‐WT-­‐Chfr	  protein.	  	  It	  also	  indicates	  the	  function	  of	  the	  portion	   of	   Chfr	   required	   for	   ubiquitination,	   indicating	   that	   ubiquitination	   is	  important	  at	  the	  G2/M	  transition.	  	  Aside	  from	  the	  Chfr	  RING	  domain	  mutant	  control,	  Ubc13	  or	  Chfr	  knockdown	  would	  also	  serve	  as	  an	  efficient	  control	   to	  confirm	  Chfr	  checkpoint	  activity	  in	  this	  cell	  line.	  
	  
3.5	  Ubc13	   levels	   in	   the	   early	   prophase	   stage	   of	  mitosis.	  HeLa	  cells	  expressing	  Myc-­‐tagged	   Chfr	   (HeLa-­‐Chfr;	   Figure	   3-­‐16a)	   were	   synchronized	   with	   the	   R03306	  reagent,	  which	  blocks	  cells	  at	   the	  G2/M	  entry	  gate.	   	  The	  cells	  were	  then	  either	   left	  untreated	   or	   treated	   with	   nocodazole	   for	   2	   hours	   before	   release	   from	   the	   G2/M	  block.	  	  The	  cells	  were	  released	  for	  0,	  15,	  or	  40	  minutes	  into	  mitosis	  (Figure	  3-­‐16).	  	  
Chfr	  levels	  did	  not	  change	  significantly	  as	  cells	  entered	  mitosis,	  and	  a	  2	  hour	  
	  	  















Figure	  3-­‐15.	  The	  effect	  of	  WTChfr	  and	  RING∆Chfr	  protein	  expression	  on	  entry	  
into	  mitosis	  in	  U2OS	  cells.	  	  	  The	  anti-­‐Xpress	  antibody	  was	  used	  to	  detect	  wild	  type	  and	  mutant	  Chfr	  (green).	  	  The	  phospho-­‐histone	  H3	  (anti-­‐pH3	  antibody	  was	  used	  to	  detect	   cells	   that	   have	   entered	   mitosis	   (red).	   	   There	   is	   more	   mitotic	   cells	   in	   the	  RING∆Chfr–expressing	   cell	   population	   than	   there	   are	   mitotic	   cells	   in	   the	   U2OS-­‐WTChfr	   population.	   	   	   These	   observations	   may	   change	   but	   indicate	   that	   over-­‐expression	   of	   WTChfr	   decreases	   mitotic	   entry	   whereas	   RING∆Chfr	   protein	  expression	   increases	   mitotic	   entry.	   	   WTChfr-­‐expressing	   cells	   are	   less	   likely	   to	  contain	  pH3.	  	  This	  also	  indicates	  that	  the	  RING	  domain	  of	  Chfr,	  which	  is	  required	  for	  the	  poly-­‐ubiquitination	  of	  target	  proteins,	  may	  be	  required	  for	  efficient	  delay	  at	  the	  G2/M	  checkpoint.	  	  Arrows	  point	  to	  Chfr-­‐expressing,	  mitotic	  cells.	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Table	  3-­‐1.	  	  Effects	  of	  Chfr	  protein	  on	  cell	  entry	  of	  U2OS	  cells	  
	   -­‐Colcemid	  
U20S-­‐WTChfr	   0/80	   0.0%	  
U2OS-­‐RINGΔChfr	   10/213	   4.7%	  
	  
	   -­‐Colcemid	  
U2OS-­‐WTChfr	   0/78	   0.0%	  
U2OS-­‐RINGΔChfr	   14/138	   10.1%	  
	  
Effect	  of	  Chfr	  protein	  on	  cell	  entry	  in	  colcemid	  presence:	  
	   +Colcemid	  
U2OS-­‐WTChfr	   0/49	   0.0%	  
U2OS-­‐RINGΔChfr	   1/239	   0.42%	  
	  
	   +Colcemid	  
U2OS-­‐WTChfr	   1/81	   1.2%	  
U2OS-­‐RINGΔChfr	   4/90	   4.4%	  
	  This	   table	   showing	   the	  effect	  of	   the	  wild	   type	  Chfr	  protein	  on	   the	  mitotic	  entry	  of	  U2OS	  cells	  in	  the	  presence	  or	  absence	  of	  colcemid.	  Cells	  were	  RO3306-­‐synchronized	  at	  the	  G2/M	  gate,	  and	  treated	  with	  colcemid	  for	  2	  hours	  before	  release	  into	  mitosis.	  	  Colcemid	   has	   a	   beneficial	   effect	   on	   cells	   expressing	   RING∆Chfr,	   as	   it	   reduces	   the	  mitotic	   index	  of	   the	   cell	   population.	   	   Colcemid	  has	   very	   little	   effect	   on	   the	  mitotic	  index	   of	   the	  wild	   Chfr	   cell	   population,	  most	   possibly	   because	   cells	   expressing	   the	  wild	  type	  Chfr	  protein	  have	  not	  yet	  entered	  mitosis.	  	  Cells	  expressing	  the	  wild	  type	  Chfr	  protein	  enter	  mitosis	   less	   frequently	  than	  RING∆Chfr	  protein	  expressing	  cells,	  regardless	  of	  colcemid	  presence	  or	  absence.	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nocodazole	   treatment	  did	  not	  affect	   this	  pattern.	   	  Ubc13	   levels,	  on	  the	  other	  hand,	  
increased	  as	  cells	  entered	  into	  early	  prophase.	  	  This	  pattern	  was	  also	  not	  affected	  by	  nocodazole	  treatment.	  	  A	  similar	  experiment	  was	  also	  carried	  out	  using	  a	  	  
2xthymidine-­‐1xRO3306	  block	  and	  similar	  results	  were	  observed,	  where	  Ubc13	  
protein	   levels	   increased	   within	   45	   minutes	   after	   release	   from	   the	   G2/M	   block	  
(Figure	  3-­‐16b).	  	  This	  indicates	  a	  role	  for	  Ubc13	  in	  mitosis.	  	  The	  actin	  control	  here	  is	  a	  little	  better	  than	  in	  Figure	  16a.	  	  Figure	  3-­‐16a	  is	  similar	  to	  Figure	  3-­‐16b	  in	  that	  Ubc13	   is	   increased	  upon	  entry	   into	  mitosis.	   	  This	   includes	   the	   interphase	  or	  early	  prophase	  time	  point,	  and	  a	  45	  minute	  time	  point	   following	  release	   from	  the	  G2/M	  block.	  	  
	  
3.6	  Chfr,	  Ubc13,	  Uev1a/Mms2	  levels	  at	  the	  G2/M	  transition.	  
A	  mitotic	   shake-­‐off	   experiment	   was	   carried	   out	   in	   nocodazole-­‐treated	   and	  untreated	   HeLa-­‐Chfr	   cells	   to	   study	   the	   relative	   levels	   of	   Chfr,	   Ubc13,	   and	  Mms2/Uev1a.	   Cells	   were	   either	   treated	   or	   left	   untreated	   with	   nocodazole	   for	  overnight,	  and	  the	  rounded	  cells	  were	  shaken-­‐off,	  separating	  the	  flat	  cells	  from	  the	  rounded	  cells.	  	  The	  rounded	  cells	  are	  cells	  in	  the	  late	  prophase	  stage	  of	  mitosis	  (LP	  cell	  fraction),	  whereas	  the	  flat	  cells	  represent	  cells	  that	  are	  either	  in	  interphase	  or	  in	  early	  prophase	  (INT/EP	  cell	  fraction).	  Cells	  were	  then	  lysed,	  and	  lysates	  analyzed	  by	  Western	  blot	  analysis.	  	  Ubc13,	  Uev1/Mms2,	  and	  Chfr	  protein	  levels	  were	  compared	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Figure	  3-­‐16a.	  	  Ubc13	  levels	  upon	  release	  from	  the	  single	  RO3306	  block.	  	  HeLa-­‐Chfr	  cells	  were	  treated	  with	  10	  μM	  of	  RO3306	  for	  24	  hours.	  	  0.5	  μg/ml	  of	  nocodazole	  was	   added	   for	   2	   hours	   before	   release	   from	   the	   RO3306-­‐induced	   G2/M	   block	   for	  various	  times.	   	  A	  Western	  blot	  was	  carried	  out	  to	  look	  at	  the	  levels	  of	  Ubc13,	  Myc-­‐Chfr,	   and	   actin	   levels	   upon	   release	   into	  mitosis.	   	   The	  mouse	   4E11	   Ubc13-­‐specific	  antibody	  was	  used	  to	  detect	  Ubc13	  levels,	  and	  a	  rabbit	  Myc-­‐tag	  antibody	  was	  used	  to	  detect	   Myc-­‐Chfr	   levels.	   	   Immunocytochemistry	   was	   done	   to	   complement	   the	  Western	  blot,	  showing	  cells	  before	  and	  after	  release	  from	  the	  G2/M	  block.	  	  	  Lane	  1 = 
0 min – nocodazole;	   Lane	  2 = 15 min – noccodazole;	   Lane	  3 = 40 min – nocodazole;	  Lane	   4 = 0 min + nocodazole;	   Lane	   5 = 15 min + nocodazole; Lane 6 = 40 min + 
nocodazole.	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Figure	   3-­‐16b.	   	   Ubc13	   levels	   upon	   release	   from	   a	   2xThymidine-­‐1xRO3306	  
block.	   	  HeLa-­‐Chfr	  cells	  were	  blocked	  at	  the	  G2/M	  transition	  and	  then	  released	  into	  mitosis.	  	  The	  blot	  was	  probed	  with	  a	  Ubc13-­‐specific	  mouse	  4E11	  antibody.	  	  	  Ubc13	  levels	   rise	   during	   the	   G2/M	   transition	   without	   nocodazole.	   Lane	   1	   =	   0	   minutes	  release	  from	  G2/M	  block.	   	  Lane	  2	  =	  15	  minutes	  release	  from	  G2/M	  block.	  Lane	  3	  =	  30	  minutes	  release	  from	  G2/M	  block.	  	  Lane	  4	  =	  45	  minutes	  release	  from	  G2/M	  block.	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in	   each	   of	   the	   four	   cell	   fractions:	   untreated	   INT/EP,	   untreated	   LP,	   treated	  INT/EP,	  and	  treated	  LP	  (Figure	  3-­‐17).	  Ubc13	  and	  Mms2/Uev1	  levels	  were	  highest	  in	   the	   INT/EP	   cell	   fractions	   and	   lowest	   in	   the	   LP	   cell	   fractions	   in	  HeLa-­‐Chfr	   cells.	  	  This	   pattern	   was	   not	   affected	   by	   nocodazole	   treatment.	   This,	   along	   with	   the	  evidence	  discussed	  above,	  supports	  a	  role	  for	  the	  Ubc13-­‐Mms2	  complex	  during	  the	  interphase	  or	  early	  prophase	  stage	  of	  mitosis,	  regardless	  of	  the	  presence	  or	  absence	  of	  microtubule	  damage.	  	  	  
	   Chfr	  levels,	  on	  the	  other	  hand,	  were	  highest	  in	  the	  nocodazole-­‐treated	  LP	  cell	  fractions.	   	   This	   pattern	   was	   affected	   by	   nocodazole	   presence,	   with	   the	   Chfr	   level	  being	  higher	  in	  the	  nocodazole-­‐treated	  LP	  cell	  fraction	  and	  lower	  in	  the	  nocodazole-­‐treated	   INT/EP	  cell	   fraction,	   the	  untreated	   INT/EP	  cell	   fraction,	  and	   the	  untreated	  LP	  cell	  fraction.	  	  This	  indicates	  that	  Chfr	  levels	  increase	  in	  the	  late	  prophase	  stage	  of	  mitosis	   only	   upon	   extensive	   nocodazole	   treatment.	   	   The	   cells	   in	   the	   nocodazole-­‐treated	   late	  prophase	  cell	   fraction	  are	  most	   likely	  cells	   that	  have	  been	  arrested	  by	  the	   spindle	   checkpoint,	  which	   is	   induced	  at	   the	  metaphase-­‐anaphase	   transition	  by	  microtubule	   poisons.	   	   The	   more	   mitotic	   stress	   there	   is,	   the	   more	   Chfr	   protein	   is	  produced	  by	  these	  (HeLa-­‐Chfr)	  cells.	  	  Thus,	  an	  increase	  in	  Chfr	  protein	  levels	  in	  this	  cell	   fraction	   indicates	   a	   role	   for	   Chfr	   in	   the	   spindle	   checkpoint.	   	   There	   is	   also	   a	  modification	   of	   Myc-­‐Chfr	   in	   the	   INT/EP	   cell	   fraction,	   and	   this	   modification	   is	  completely	   reduced	   in	   the	   LP	   cell	   fraction.	   	   This	   figure	   indicates	   that	   Chfr	   could	  possibly	   auto-­‐ubiquitinate	   itself	   using	   Ubc13	   and	   Mms2/Uev1	   at	   the	   G2/M	  transition	  (Figure	  3-­‐17).	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Figure	  3-­‐17	  also	   shows	  a	  clear	  division	  between	  the	  Chfr	  modification	  and	  no	  Chfr	  modification	  at	  the	  G2/M	  and	  at	  the	  LP	  stage,	  respectively.	  Nocodazole	  does	  not	  appear	  to	  affect	  the	  modification	  on	  Chfr.	   	  Thus,	   the	  shift	   from	  Chfr-­‐Ub	  to	  Chfr	  appears	   to	   be	   cell	   cycle	   dependent,	   with	   the	   ubiquitin	   signal	   serving	   at	   the	  interphase-­‐to-­‐early	   prophase	   transition	   to	   patrol	   mitotic	   entry.	   	   Figure	   3-­‐18a	  shows	  similar	  results.	  	  Wherever	  the	  nocodazole	  is	  highest,	  Chfr	  protein	  level	  is	  also	  highest,	  to	  counteract	  the	  mitotic	  stress.	  	  Where	  nocodazole	  is	  lowest,	  Chfr	  becomes	  less	   necessary,	   and	   is	   more	   likely	   to	   become	   reduced	   in	   level	   through	   auto-­‐ubiquitination.	  	  
Western	   blot	   in	   Figure	   3-­‐18b	   further	   indicates	   how	   mitotic	   stress	   in	   the	  form	   of	   nocodazole	   can	   modulate	   such	   modification	   in	   a	   cell	   population.	   	   In	   the	  absence	   of	   nocodazole,	   Chfr	   is	  most	   ubiquitinated.	   	   As	   exposure	   to	  mitotic	   stress	  increases,	  the	  modification	  on	  Chfr	  is	  reduced	  and	  Chfr	  protein	  levels	  increase	  in	  a	  cell	  population.	  	  Under	  less	  nocodazole	  exposure,	  the	  Chfr-­‐Ub	  protein	  becomes	  more	  predominant,	  because	  Chfr	  becomes	  less	  necessary	  under	  such	  conditions.	  	  Perhaps	  this	   modification	   is	   a	   signal	   for	   Chfr	   protein	   degradation,	   with	   Chfr	   being	  unnecessary	  in	  the	  absence	  of	  microtubule	  damage.	  
	  
3.7	  The	  ubiquitin	  modification	  on	  Chfr.	  
3.7.1	   Effect	   of	   nocodazole	   on	   the	   Chfr	   modification.	   	   Chfr	   also	   appears	   to	   be	  modified	   in	   HeLa-­‐Chfr	   cells,	   and	   this	   modification	   is	   reduced	   as	   nocodazole	  treatment	  time	  increases.	   	  As	  nocodazole	  exposure	  increases,	  however,	  nocodazole	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addition	   reduces	   this	   polyubiquitin	   signal	   to	   increase	  Chfr	   levels,	   ensuring	  proper	  checkpoint	   control.	   	   Unlike	   Chfr	   levels,	   Ubc13,	   and	   Mms2/Uev1a	   levels	   remain	  unaffected	  by	   increasing	  doses	  of	  nocodazole	  treatment	   in	  HeLa-­‐Chfr	  cells	  (Figure	  
3-­‐18a).	  	  	  
The	   cellular	   Chfr	   level,	   on	   the	   other	   hand,	   appears	   to	   increase	   upon	  increasing	   nocodazole	   exposure	   to	   counteract	   the	   mitotic	   stress	   (Figure	   3-­‐18a).	  	  	  The	   more	   Chfr	   there	   is,	   the	   less	   modification	   there	   is	   on	   Chfr.	   	   Figure	   3-­‐18b	  indicates	   that	   the	   observed	   Chfr	   modification	   could	   be	   ubiquitination.	   	   This	  experiment	   was	   done	   twice.	   	   This	   indicates	   a	   role	   for	   Chfr	   in	   a	   response	   to	  microtubule	  damage	  because	  the	  Chfr	  level	  increases	  in	  response	  to	  nocodazole,	  and	  is	  in	  line	  with	  a	  recently	  published	  article	  (Kim	  et	  al.,	  2011).	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Figure	   3-­‐17.	   	   Myc-­‐Chfr,	   Ubc13,	   and	   Mms2	   protein	   levels	   at	   the	   G2/M	  
transition	   in	   the	   presence	   or	   absence	   of	   nocodazole.	   	  A	  mitotic	   shake-­‐off	  experiment	   was	   carried	   out	   in	   nocodazole-­‐treated	   and	   untreated	   HeLa-­‐Chfr	  cells.	  	  Cells	  were	  either	  treated	  with	  or	  left	  untreated	  with	  nocodazole	  (for	  O/N),	  and	   the	   rounded	   cells	   were	   shaken	   off,	   separating	   the	   flat	   cells	   from	   the	  rounded	  cells.	  	  	  Lane	  1	  =	  Interphase	  or	  early	  prophase	  cell	  fraction	  +	  nocodazole	  (with	  possible	  rounded,	  late	  prophase	  like	  fraction);	  Lane	  2	  =	  Late	  prophase-­‐like	  cell	  fraction	  +	  nocodazole;	  Lane	  3	  =	  Interphase	  or	  early	  prophase	  cell	  fraction	  –	  nocodazole	   (with	   possible	   rounded,	   late	   prophase-­‐like	   cell	   fraction);	   Lane	  4	   =	  Late	  prophase-­‐like	  cell	  fraction	  –	  nocodazole).	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3.7.2	  The	  two	  molecular	  states	  of	  Chfr	  at	  G2/M	  transition.	  	  Looking	  at	  the	  state	  of	  Chfr	  in	  cell	  populations	  that	  are	  at	  a	  particular	  time	  point	  can	  give	  a	  glimpse	  into	  how	   the	   protein	   could	   function	   at	   a	   molecular	   level.	   	   Our	   data	   indicates	   that	   (a)	  there	   are	   two	   molecular	   states	   of	   Chfr:	   Chfr	   and	   Chfr-­‐Ub;	   that	   (b)	   Chfr	   is	  predominant	  at	  LP,	  whereas,	  Chfr–Ub	  is	  predominant	  at	  INT/EP;	  that	  (c)	  Chfr	  looses	  its	   ubiquitin	   signal	   after	   cells	   pass	   through	   the	   INT/EP	   transition;	   that	   (d)	   Chfr	  protein	   levels	   clearly	   increase	   at	   LP	   in	   response	   to	   extensive	  mitotic	   stress,	   after	  passing	   through	   the	   INT/EP	   stage;	   that	   (e)	   Chfr,	   Ubc13,	   and	   Mms2/Uev1a	   levels	  increase	  at	  INT/EP	  indicating	  their	  importance	  at	  the	  G2/M	  checkpoint	  gate;	  and	  	  that	  f)	  the	  presence	  of	  high	  Ubc13	  and	  Mms2/Uev1a	  levels	  indicates	  the	  possibility	  of	  K-­‐63	  linked	  poly-­‐ubiquitination	  at	  that	  particular	  time	  point.	  	  Figure	  3-­‐17	  shows	  that	   Chfr	   is	   modified.	   	   Figure	   3-­‐18b	   and	   3-­‐18c	   shows	   that	   this	   modification	   is	  ubiquitin.	   	  The	  Chfr	  modification	   is	   associated	  with	   reduced	  pH3	   levels	   in	   the	   cell	  population	  (Figure	  3-­‐18c).	  A	   molecular	   mechanism	   could	   be	   envisioned	   here	   whereby	   Chfr	   auto-­‐ubiquitinates	   itself	   using	   K63-­‐linked	   poly-­‐ubiquitination.	   	   This	   could	   temporarily	  make	   Chfr	   stable	   at	   the	   interphase-­‐to-­‐early	   prophase	   transition.	   	   Chfr-­‐Ub	   at	   this	  stage	  could	  then	  bind	  to	  an	  important	  early	  mitotic	  regulator	  such	  as	  pH3,	  and	  using	  the	   bulky	   K63-­‐linked	   poly-­‐ubiquitin	   signal	   interfere	   with	   further	   condensation	  through	  stearic	  hindrance.	  	  	  This	  could	  temporarily	  alter	  pH3	  activity	  in	  response	  to	  mitotic	   stress	   at	   the	   early	   prophase	   stage	   of	   mitosis.	   	   K-­‐48-­‐linked	   poly-­‐ubiquitination	   could	   then	   function	   to	   reduce	   this	   form	   of	   Chfr	   when	   no	   longer	  necessary,	  promoting	  chromosome	  condensation	  and	  progression	  into	  mitosis.	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3.8	   Ubc13	   may	   interact	   weakly	   with	   phosphorylated	   histone	   H3	   (Figure	   3-­‐
19a).	   	  Ubc13	  was	  pulled	  out	  of	  SAOS2	  cells	  using	  G-­‐sepharose	  beads.	  	  The	  blot	  was	  probed	   for	  Ubc13	  using	   the	  mouse	  4E11	  antibody	  and	  probed	   for	  phosphorylated	  histone	   H3	   (pH3)	   using	   the	   rabbit	   anti-­‐phospho-­‐histone	   H3	   antibody.	  	  Phosphorylated	  histone	  H3	  was	  found	  to	  coimmunoprecipitate	  weakly	  with	  Ubc13	  indicating	   an	   interaction	   between	   these	   two	   proteins.	   	   This	   experiment	  was	   done	  once.	   	   Figure	   3-­‐19b	   and	   3-­‐19c	   further	   support	   this	   interaction.	   	   These	   two	  immunocytochemistry	   figures	  support	   the	   idea	   that	  Ubc13	  binds	  more	  strongly	   to	  mitotic	   chromosomes	   in	   early	   prophase,	   metaphase,	   or	   telophase	   cells	   than	   to	  interphase	   chromatin,	   although	   the	   stronger	   binding	   could	   also	   be	   due	   to	   nuclear	  envelope	  breaking	  down.	  	  	  	  Mitotic	  chromosomes	  are	  rich	  in	  phosphorylated	  histone	  H3.	   Figure	   3-­‐19b	   and	   Figure	   3-­‐19c	   support	   a	   potential	   Ubc13-­‐pH3	   interaction,	  because	   there	   is	   strong	   immunoreactivity	   on	   mitotic	   chromosomes,	   and	   because	  mitotic	   chromosomes	   are	   rich	   in	   phosphorylated	   histone	  H3.	   	   These	   experiments,	  however,	  would	  have	  to	  be	  repeated	  several	  more	  times	  to	  arrive	  at	  a	  more	  definite	  conclusion.	  	  	  	  	  	  
Figure	   3-­‐19a,	   3-­‐19b,	   and	   3-­‐19c	   elucidates	   the	   possible	   role	   of	   Ubc13	   in	  mitosis	  in	  SAOS2	  cells,	  and	  are	  in	  line	  with	  Figure	  3-­‐16a,	  and	  Figure	  3-­‐16b,	  which	  show	  how	  Ubc13	  levels	  increase	  upon	  entry	  into	  mitosis.	  	  	  Figure	  3-­‐17	  also	  shows	  increased	  Ubc13	  levels	  in	  the	  G2/M	  cell	  fraction.	  	  	  
One	  possibility	  for	  the	  function	  of	  Ubc13	  in	  mitosis,	  based	  on	  the	  observation	  presented,	  is	  that	  Ubc13	  serves	  as	  a	  ubiquitin-­‐conjugating	  enzyme	  by	  binding	  to	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Figure	   3-­‐18a.	   	   Effects	   of	   nocodazole	   exposure	   on	   Myc-­‐Chfr	   level	   and	  










	  	   	   73	  
	  
	  
	  	  	  	  	  1	  	  	  	  	  	  	  	  2	  	  	  	  	  	  3	  	  	  	  	  	  4	  	  	  	  	  	  5	  	  	  	  	  6	  
	  
	  	  	  	  Myc-­‐Chfr	  (Low	  exposure)	  
	  
	  
Myc-­‐Chfr	  (Higher	  exposure)	  
	  
	  








Figure	  3-­‐18b.	   	  Effects	  of	  nocodazole	  exposure	  on	  Myc-­‐Chfr	   in	  HeLa-­‐Chfr	  cells.	  	  Extensive	  treatment	  of	  HeLa-­‐Chfr	  cells	  with	  nocodazole	  results	  in	  increased	  levels	  of	  tumor	   suppressor	   protein	   Chfr	   (lanes	   1-­‐3).	   	   Lanes	   1-­‐3	   contain	  whole	   cell	   lysates.	  	  Treatment	  with	  nocodazole	  also	  reduces	  the	  amount	  of	  modified	  form	  of	  Chfr	  in	  the	  HeLa-­‐Chfr	   cell	   population.	   	   Chfr	  was	  pulled	  out	   of	  whole	   cell	   lysate	  using	  Myc-­‐tag	  agarose	   beads	   (lanes	   4-­‐6).	   	   Lanes	   4-­‐6	   contain	   immunoprecipitates.	   	   The	   ubiquitin	  blot	   overlaps	   with	   the	   Chfr	   modification	   indicating	   that	   Chfr	   is	   modified	   through	  ubiquitination.	  	  	  	  
	   	  
	  	  













Figure	   3-­‐18c.	   	   Detecting	   general	   ubiquitin	   and	   K63-­‐linked	   poly-­‐ubiquitin	  
chains	   in	   HeLa-­‐Chfr	   whole	   cell	   lysates.	   	   HeLa-­‐Chfr	   cells	   were	   exposed	   to	  nocodazole	   for	   0,	   9,	   and	   19	   hrs	   (Lanes	   1,	   2,	   and	   3),	   and	   whole	   cell	   lysates	   were	  analyzed	  by	  Western	  blot.	   	  The	  blot	  was	  probed	  with	  a	  rabbit	  antibody	  specific	  for	  K63-­‐linked	   poly-­‐ubiquitin	   chains	   (05-­‐1308).	   	   As	   nocodazole	   increases,	   Chfr	   levels	  increase,	  pH3	   levels	   increase,	   the	  modification	  on	  Chfr	  decreases.	   	  The	  Chfr	  blot	   is	  similar	   to	   the	   ubiquitin	   and	   K63-­‐linked	   poly-­‐ubiquitin	   chain	   blot:	   as	   nocodazole	  exposure	   increases	   the	   Chfr	   modification	   decreases,	   the	   ubiquitin	   modification	  decreases,	   and	   K63-­‐positive	   smears	   decrease.	   	   In	   the	   K63-­‐linked	   poly-­‐ubiquitin	  chain	  blot,	  Lanes	  1	  and	  2	  have	  one	  dark	  smear	  and	  one	  very	  faint	  band,	  respectively;	  lane	  3	  has	  no	  band.	  	  This	  figure	  corresponds	  to	  lanes	  1,	  2,	  and	  3	  of	  Figure	  3-­‐17b.	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Figure	  3-­‐19a.	  	  	  Coimmunoprecipitation	  of	  pH3	  with	  Ubc13-­‐specific	  antibody	  in	  
SAOS2	   cells.	   	  Ubc13	   interacts	  weakly	  with	  phosphorylated	  histone	  H3.	   	   	  Lane	  1	  =	  negative	   control	   (no	   whole	   cell	   lysate;	   beads;	   4E11	   primary	   antibody);	   Lane	   2	   =	  negative	  control	  (whole	  cell	  lysate;	  beads;	  no	  4E11	  primary	  antibody);	  Lane	  3	  =	  CoIP	  (4E11	  primary	  antibody;	  whole	  cell	  lysate;	  beads);	  Lane	  4	  =	  whole	  cell	  lysate.	  	   	  
	  	  







Figure	   3-­‐19b.	   	   Immunocytochemistry	   showing	   SAOS2	   cells	   probed	   with	   the	  
Ubc13	  antibody	  and	   the	  Chfr-­‐CR	  antibody.	  This	  figure	  shows	  an	  early	  prophase	  SAOS2	   cell	   with	   strong	   immunoreactivity	   on	   the	   mitotic	   chromosomes.	   	   Chfr	  localizes	   to	   the	   centrosomes	   brightly.	   	   SAOS2	   cells	   were	   fixed	   and	   permeabilized	  with	  -­‐20°C	  methanol	  for	  5	  minutes,	  and	  were	  then	  incubated	  with	  the	  mouse	  4E11	  Ubc13-­‐specific	  antibody	  and	  the	  rabbit	  Chfr-­‐CR	  antibody	  overnight.	  	  The	  DAPI	  stain	  was	  not	  applied.	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Chfr	  and	  phosphorylated	  histone	  H3	  on	  chromosomes.	  	  Ubc13	  could	  possibly	  attach	  ubiquitin	   chains	  onto	   the	   chromatin	  or	  onto	  Chfr	   itself,	   to	   signal	   a	   conformational	  change,	  promoting	  chromosome	  condensation.	  	  
	  
3.9	  Chfr	  also	  interacts	  with	  phosphorylated	  histone	  H3	  upon	  entry	  into	  mitosis	  
(Figure	  3-­‐20a	  and	  Figure	  3-­‐20b).	  
Chfr	  was	  pulled	  out	  of	  HeLa-­‐Chfr	   cells	  using	   the	  anti	  Myc-­‐tag	  agarose	  bead	  conjugate.	   	   The	   blot	   was	   probed	   for	   Chfr	   using	   the	   rabbit	   Myc-­‐tag	   antibody	   and	  probed	  for	  phosphorylated	  histone	  H3	  (pH3)	  using	  the	  rabbit	  anti-­‐phospho-­‐histone	  H3	  antibody.	   	  Lanes	  1	  and	  2	   in	  Figure	  3-­‐20a	   show	  that	  when	  Myc-­‐Chfr	   is	  present	  and	  is	  pulled	  out	  of	  the	  whole	  cell	  lysate,	  phosphorylated	  histone	  H3	  is	  pulled	  out	  as	  well;	  but	  when	  Chfr	  is	  not	  present	  in	  the	  whole	  cell	   lysate,	  phosphorylated	  histone	  H3	   does	   not	   coimmunoprecipitate.	   	   Lanes	   3	   and	   4	   indicate	   equal	   loading	   of	   both	  HeLa	  and	  HeLa-­‐Chfr	  whole	  cell	  lysates	  to	  the	  beads.	  
A	   second	   experiment	   was	   done	   to	   confirm	   this	   interaction,	   as	   shown	   in	  
Figure	  3-­‐20a.	  	  	  HeLa	  and	  HeLa-­‐Chfr	  whole	  cell	  extracts	  were	  applied	  to	  Myc-­‐tagged	  agarose	  beads	  to	  coprecipitate	  Myc-­‐Chfr	  bound	  to	  phosphorylated	  histone	  H3	  (pH3).	  	  Varying	   amounts	   of	  whole	   cell	   extract	  were	   applied	   to	   the	   beads.	   	   Lanes	   3	   and	   4	  indicate	   that	   endogenous	   phosphorylated	   histone	   H3	   coimmunoprecipitates	   with	  Myc-­‐Chfr	  in	  HeLa-­‐Chfr	  cells.	  	  Lanes	  5	  and	  6	  contain	  HeLa	  and	  HeLa-­‐Chfr	  whole	  cell	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Figure	   3-­‐20b.	   	   Chfr	   interaction	   with	   phosphorylated	   histone	   H3.	   	   HeLa	   and	  HeLa-­‐Chfr	   whole	   cell	   extracts	   were	   applied	   to	   Myc-­‐tagged	   agarose	   beads	   to	  coprecipitate	   Myc-­‐Chfr	   bound	   to	   phosphorylated	   histone	   H3	   (pH3).	   Varying	  amounts	   of	  whole	   cell	   extract	  were	   applied	   to	   the	   beads:	   Lanes	   1	   and	   2,	   528	   μg;	  Lanes	  3	  and	  4,	  1056	  μg;	  Lanes	  7	  and	  8,	  2112	  μg;	  Lanes	  11	  and	  12,	  3168	  μg.	  	  Lanes	  3	  and	  4	   indicate	   that	   endogenous	  phosphorylated	  histone	  H3	  coimmunoprecipitates	  with	  Myc-­‐Chfr	   in	   HeLa-­‐Chfr	   cells.	   	   Lanes	   5,	   6,	   9,	   10,	   13	   and	   14	   contain	  HeLa	   and	  HeLa-­‐Chfr	   whole	   cell	   lysates	   to	   show	   equal	   loading.	   	   Lanes	   3	   and	   4	  were	   chosen	  because	  they	  most	  clearly	  indicate	  the	  difference	  between	  HeLa	  and	  HeLa-­‐Chfr	  cells	  with	  respect	  to	  the	  interaction.	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Figure	   3-­‐20c.	   	   Coimmmunoprecipitation	   of	   Chfr	   and	   phosphorylated	   histone	  
H3	   in	   the	  presence	  of	   nocodazole.	   	   	  HeLa	  and	  HeLa-­‐Chfr	  cell	   lysates	  were	   lysed	  and	  prepared	  for	  Western	  blot	  analysis.	  	  Various	  amounts	  of	  whole	  cell	  lysate	  were	  applied	   to	   the	   beads	   and	   loaded	   onto	   the	   gel	   to	   observe	   pH3	   binding	   to	   Chfr	   at	  various	  applied	  protein	  concentrations.	  	  The	  anti-­‐phospho-­‐histone	  H3	  antibody	  was	  used	   to	  detect	  pH3	  (3:10000).	   	  The	  anti-­‐Myc	   tag	  antibody	  was	  used	   to	  detect	  Chfr	  (3:10000).	   	   Nocodazole	   treatment	   also	   affects	   the	   interaction	   between	   Chfr	   and	  phosphorylated	  histone	  H3.	  	  When	  nocodazole	  is	  present	  the	  amount	  of	  pH3	  in	  Lane	  2,	  for	  example,	  is	  the	  same	  as	  the	  amount	  of	  pH3	  in	  Lane	  1.	  	  This	  is	  in	  contrast	  to	  the	  experiment	  done	  in	  the	  absence	  of	  nocodazole.	  	  Lane	  1	  =	  HeLa	  (30	  μg	  protein);	  2	  =	  HeLa-­‐Chfr	  (30	  μg	  protein);	  3	  =	  HeLa	  whole	  cell	  lysate;	  Lane	  4	  =	  HeLa-­‐Chfr	  whole	  cell	  lysate;	  Lane	  5	  =	  HeLa	  (60	  μg	  protein);	  Lane	  6	  =	  HeLa-­‐Chfr	  (60	  μg	  protein);	  Lane	  7	  =	  HeLa	  whole	  cell	  lysate;	  Lane	  8	  =	  HeLa-­‐Chfr	  whole	  cell	  lysate;	  Lane	  9	  =	  HeLa	  (120	  μg	  protein);	  Lane10	  =	  HeLa-­‐Chfr	   (120	  μg	  protein);	  Lane	  11	  =	  HeLa	  whole	   cell	   lysate;	  Lane	  12	  =	  HeLa-­‐Chfr	  whole	  cell	  lysate;	  Lane	  13	  =	  HeLa	  (240	  μg	  protein);	  Lane	  14	  =	  HeLa-­‐Chfr	  (240	  μg	  protein).	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lysates	  to	  show	  equal	  loading.	  	  Lanes	  3	  and	  4	  were	  chosen	  because	  they	  most	  clearly	  indicate	   the	   difference	   between	   HeLa	   and	   HeLa-­‐Chfr	   cells	   with	   respect	   to	   the	  interaction.	  	  Another	  possible	  alternative	  control	  for	  the	  experiment	  could	  be	  HeLa	  cells	   containing	  Myc-­‐tag	   only.	   	  Figure	   3-­‐20c	   shows	   in	   one	   experiment	   that	  when	  nocodazole	   is	   added	   the	   Chfr-­‐pH3	   interaction	   is	   reduced.	   	   This	   experiment	  would	  have	   to	   be	   repeated	   several	   more	   times	   to	   arrive	   at	   a	   more	   definite	   conclusion.	  	  
Figure	   3-­‐18c	   shows	   how	   nocodazole	   levels	   affect	   Chfr	   and	   pH3	   levels.	   	   As	  nocodazole	  exposure	  increases,	  Chfr	  protein	  level	  increases	  and	  pH3	  level	  increases.	  	  These	   two	   figures	  helps	   to	  point	  out	  what	  happens	   in	   chromosomes	  when	  Chfr	   is	  altered	  through	  nocodazole.	  	  	  	  In	  the	  presence	  of	  nocodazole,	  Chfr	  can	  no	  longer	  bind	  to	  pH3,	  so	  it	  cannot	  affect	  DNA	  structure,	  which	  is	  most	  likely	  why	  pH3	  levels	  rise	  as	  nocodazole	  exposure	  increases.	  
	  
3.10	  Chfr	  appears	  to	  be	  phosphorylated	  upon	  entry	  into	  mitosis.	  
Mitotic	   shake-­‐off	   was	   performed	   on	   nocodazole-­‐treated	   SAOS2	   cells.	  	  Nocodazole	  is	  a	  microtubule	  poison.	  	  SAOS2	  cells	  were	  divided	  into	  adherent	  and	  the	  non-­‐adherent	   cell	   fractions.	   	   The	   adherent	   cell	   fraction	   represents	   interphase	   or	  early	  prophase	  cells,	  whereas	  the	  non-­‐adherent	  cell	  fraction	  represents	  cells	  in	  the	  late	  prophase	  stage	  of	  mitosis.	  	  Figure	  3-­‐21	  clearly	  shows	  that	  as	  cells	  enter	  the	  late	  prophase	  stage	  of	  mitosis,	  the	  single	  Chfr	  band	  turns	  into	  a	  doublet,	  indicating	  that	  Chfr	  is	  modified,	  possibly	  by	  phosphorylation,	  during	  the	  late	  prophase	  stage	  of	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Figure	   3-­‐21.	   	   Western	   blot	   showing	   that	   the	   Chfr	   protein	   maybe	  
phosphorylated	   and	   its	   level	   reduced	   upon	   entry	   into	  mitosis.	   	   Cell	   fractions	  were	   collected	  by	  mitotic	   shake	  off.	   	   Blot	  was	  probed	  with	   a	  Chfr	   rabbit	   antibody	  specific	   for	   the	   C-­‐terminus	   of	   Chfr.	   INT/EP	   =	   interphase	   and	   early	   prophase	   cell	  fraction.	   	   LP	   =	   late	   prophase	   cell	   fraction.	   	   Lane	   1	   =	   SAOS2	   Untreated;	   Lane	   2	   =	  SAOS2	   +	   Nocodazole;	   Lane	   3	   =	   SAOS2	   +	   Nocodazole	   INT/EP;	   Lane	   4	   =	   SAOS2	   +	  Nocodazole	  LP.	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mitosis.	   	  Furthermore,	   the	   levels	  of	  Chfr	  appear	  to	  be	  reduced	  upon	  entry	   into	  the	  later	   stage	   of	   mitosis.	   	   Together,	   these	   findings	   indicate	   that	   Chfr	   may	   be	  phosphorylated.	   	   Kim	   et	   al.	   (2011)	   found	   that	   the	   phosphorylation	   of	   Chfr	   is	  involved	   in	   controlling	   the	   auto-­‐ubiquitinating	   activating	   of	   Chfr.	   When	  phosphorylation	   is	   reduced,	   this	   also	   reduces	   the	   auto-­‐ubiquitinating	   activity	   of	  Chfr.	  
	  
3.11	   Localization	   of	   Ubc13,	   EYFP-­‐Mms2,	   and	   Chfr	   to	   the	   centrosomes	   of	  
interphase	  and	  mitotic	  cells.	  
Interestingly,	   I	   have	   noticed	   that	   Ubc13,	   Mms2,	   and	   Chfr	   localize	   to	   the	  centrosomes	  in	  interphase	  SAOS2	  cells	  and	  in	  mitotic	  SAOS2	  cells	  (Figure	  3-­‐22	  and	  
3-­‐23).	  	  Centrosomes	  are	  structures	  within	  cells	  that	  serve	  as	  microtubule	  organizing	  centers.	   	  Microtubules	   are	   important	   because	   they	   are	   necessary	   to	   pull	   the	   DNA	  matter	  apart	  into	  two	  equal	  halves	  during	  mitosis	  –	  one	  into	  each	  daughter	  cell.	   	  If	  microtubules	  are	  not	  organized	  accurately,	   then	  mitosis	  may	  not	  occur	  accurately,	  resulting	   in	   chromosome	  mis-­‐segregation	   and	   genetic	   instability.	   	   Chfr	   and	  Ubc13	  localize	   to	   these	   structures,	   just	   like	   Aurora	   A	   and	   Plk1	   (Summers	   et	   al.,	   2005),	  which	   promote	   progression	   through	   mitosis	   and	   are	   two	   potential	   Chfr	   target	  proteins.	  	  Furthermore,	  Mms2	  also	  appears	  to	  be	  present	  in	  the	  centrosomes.	  	  Mms2	  is	   a	  Ubc13	   coenzyme	  necessary	   for	   the	  K-­‐63	   linked	  poly-­‐ubiquitination	   activity	   of	  Ubc13.	   	   These	   observations	   imply	   that	   Chfr,	   Ubc13,	   and	   Mms2	   function	   in	   the	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centrosomes	  during	  mitosis	   to	  generate	  K-­‐63-­‐linked	  polyubiquitin	  chains,	  perhaps	  targeting	  proteins	  such	  as	  Aurora	  A	  or	  Plk1.	  
	   The	  Ubc13	  enzyme	  alone	  can	  potentially	  catalyze	  the	  formation	  of	  both	  K63-­‐linked	  and	  K48-­‐linked	  poly-­‐ubiquitin	  chains	  but,	  when	  it	  pairs	  with	  Mms2	  or	  Uev1,	  it	   generates	   K63-­‐linked	   poly-­‐ubiquitin	   chains	   exclusively.	   	   Thus,	   it	   would	   be	  worthwhile	   to	   distinguish	   which	   of	   the	   two	   Uevs	   colocalizes	   to	   the	   centrosomes	  with	  Chfr	  and	  Ubc13.	   	  If	  Mms2	  or	  Uev1	  or	  both	  colocalize	  to	  the	  centrosomes	  with	  Chfr,	  this	  would	  be	  significant	  as	  it	  would	  further	  support	  the	  idea	  that	  Chfr,	  Ubc13,	  and	  Mms2/Uev1	  work	  together	  during	  mitosis	  to	  signal	  cellular	  stress	  through	  K63-­‐linked	  poly-­‐ubiquitination.	  	  	  
	   Figure	   3-­‐22	   illustrates	   Ubc13	   and	   Chfr	   localizing	   to	   the	   centrosomes	   in	  SAOS2	  cells	  via	  immunocytochemistry.	  Immunocytochemistry	  showed	  that	  Chfr	  and	  Ubc13	   localize	   to	   the	   centrosomes	   in	   early	   prophase	   and	   late	   prophase	   SAOS2	  mitotic	  cells.	  	  SAOS2	  cells	  have	  been	  shown	  to	  contain	  a	  functional	  Chfr	  checkpoint.	  	  Two	   different	   immunocytochemistry	   techniques	   were	   used	   to	   visualize	   this	  localization	   to	   small	   round	  structures	   that	  were	  either	   single	  or	   in	  duplicate.	   	  The	  single	   round	   structures	  were	   probably	   centrosomes	   in	   interphase	   cells,	  while	   the	  duplicate	  structures	  were	  duplicated	  centrosomes	  in	  cells	  that	  were	  just	  beginning	  to	  enter	  mitosis	  or	  were	  already	  in	  mitosis.	  	  
	   In	   one	   experiment,	   SAOS2	   cells	   were	   fixed	   with	   4%	   formaldehyde	   for	   30	  minutes	   and	   permeabilized	   with	   methanol	   for	   5	   minutes,	   after	   which	   they	   were	  stained	   with	   the	   rabbit	   CHFR-­‐CR	   antibody	   (Figure	   3-­‐22a).	   In	   the	   second	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experiment,	  SAOS2	  cells	  were	  fixed	  simultaneously	  with	  4%	  formeldahyde	  and	  0.5%	  NP40	  for	  15	  minutes	  on	  ice,	  after	  which	  they	  were	  stained	  with	  the	  rabbit	  CHFR-­‐CR	  antibody	   and	   the	   mouse	   4E11	   antibody	   (Figure	   3-­‐22b).	   	   Ubc13	   and	   Chfr	  localization	   was	   more	   clearly	   observed	   by	   using	   the	   second	   technique.	   	   These	  experiments	   indicate	  that	  Ubc13	  and	  Chfr	   localize	  to	  the	  centrosomes	  of	  early	  and	  late	  prophase	  SAOS2	  cells,	   suggesting	  a	   role	   for	  Ubc13	  and	  Chfr	   in	  mitosis.	  Ubc13	  localization	   to	   the	   centrosomes	   was	   confirmed	   by	   using	   the	   gamma	   tubulin	  antibody.	   	  Figure	   3-­‐22c	   shows	  a	  cell	  with	  Ubc13	   in	   the	  centrosome	  region	  and	   in	  the	   mitotic	   spindle.	   	   At	   this	   particular	   location,	   Chfr	   could	   colocalize	   to	   sense	  microtubule	   damage,	   and	   together	   with	   Ubc13/Mms2	   generate	   signal	   that	   stops	  mitosis.	   	  A	  proper	  Chfr,	  Ubc13,	   and	  Mms2/Uev1	  knockdown	  could	   further	  help	   to	  confirm	   this	   centrosome	   and	   mitotic	   spindle	   localization.	   	   Chfr,	   Ubc13,	   and	  Mms2/Uev1	  could	  localize	  to	  the	  centrosomes	  to	  poly-­‐ubiquitinate	  Aurora	  A	  or	  Plk1	  either	   for	  destruction	   to	  decrease	  protein	   level	  and	  progression	   into	  mitosis,	  or	   to	  alter	  Aurora	  A	  and	  Plk1	  protein	  function	  through	  K63-­‐linked	  poly-­‐ubiquitination.	  
Mms2	   was	   also	   shown	   to	   localize	   to	   the	   centrosomes	   by	   two	   different	  techniques	   (Figure	   3-­‐23).	   In	   one	   experiment,	   SAOS2	   cells	   expressing	   the	   Mms2	  protein	  fused	  to	  an	  enhanced	  yellow	  fluorescent	  protein	  (SAOS2	  pEYFP-­‐Mms2	  cells)	  were	  fixed	  with	  -­‐20ºC	  methanol	  for	  5	  minutes	  and	  were	  then	  stained	  with	  either	  the	  GFP	  antibody	  (Figure	  3-­‐23a,	  3-­‐23b,	  3-­‐23c)	  or	  the	  mouse	  2h11	  antibody	  specific	  for	  Mms2/Uev1	   (Figure	   23d)	   and	   the	   rabbit	   gamma	   tubulin	   antibody.	   	   EYFP-­‐Mms2	  was	  shown	  to	  localize	  to	  the	  centrosomes	  with	  the	  GFP	  antibody	  (Figure	  3-­‐23a,	  3-­‐
23b,	  3-­‐23c),	  and	  also	  with	  the	  2h11	  antibody,	  though	  very	  faintly	  (Figure	  3-­‐23d).	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In	  particular,	  Mms2	  was	  found	  to	  distinctly	  localize	  to	  only	  one	  of	  the	  centrosomes	  in	   Figure	   3-­‐23d,	   indicating	   a	   potential	   role	   for	   this	   protein	   in	   centrosomes	  duplication.	  



















Figure	  3-­‐22a.	   	   Chfr	   and	  Ubc13	  appear	   to	   localize	   to	   the	   centrosomes	   in	  
mitotic	  SAOS2	  cells.	  	  This	  figure	  shows	  the	  two	  proteins	  of	  interest	  localizing	  to	   a	   centrosomes	   in	   late	   prophase.	   SAOS2	   cells	   were	   fixed	   with	   4%	  formaldehyde	  for	  30	  minutes	  and	  permeabilized	  with	  methanol	  for	  5	  minutes,	  after	   which	   they	   were	   stained	   with	   the	   rabbit	   CHFR-­‐CR	   antibody	   and	   the	  mouse	  Ubc13	  antibody.	  	  










Figure	  3-­‐22b.	  	  Chfr	  and	  Ubc13	  appear	  to	  localize	  to	  the	  centrosomes	  in	  





	  	   	   91	  
	  
	  	  	  	  	  	  	  	   	  
	  
Figure	   3-­‐22c.	   	   Ubc13	   localized	  with	   the	   centrosomes	   and	   also	   to	   the	  mitotic	  









Figure	  3-­‐23a.	  	  EYFP-­‐Mms2	  appears	  to	  localize	  to	  the	  mitotic	  spindle	  in	  SAOS2	  
cells	  stably	  expressing	  EYFP-­‐Mms2.	   	  SAOS2	  pEYFP-­‐Mms2	  cells	  were	  fixed	  with	  -­‐20°C	  Methanol	  on	  ice	  for	  5	  minutes,	  after	  which	  they	  were	  stained	  with	  the	  rabbit	  GFP	  antibody	  and	   the	  mouse	  gamma	  tubulin	  antibody.	   	   	   In	   this	   figure	  EYFP-­‐Mms2	  (rabbit	   anti-­‐GFP	   primary	   antibody)	   localizes	   faintly	   not	   only	   to	   the	   centrosome	  region,	  but	  also	  to	  the	  mitotic	  spindle	  apparatus,	  which	  is	  confirmed	  by	  the	  gamma	  tubulin	  stain.	  	  
	   	  
	  	  




Figure	  3-­‐23b.	  EYFP-­‐Mms2	  appears	  to	  localize	  to	  the	  mitotic	  spindle	  in	  SAOS2	  
cells	  stably	  expressing	  EYFP-­‐Mms2.	   	  SAOS2	  pEYFP-­‐Mms2	  cells	  were	  fixed	  with	  -­‐20°C	  Methanol	  on	   ice	   for	  5	  minutes,	  after	  which	  they	  were	  stained	  with	  the	  rabbit	  GFP	  antibody	  and	  the	  mouse	  gamma	  tubulin	  antibody.	  
	   	  
	  	  












Figure	   3-­‐23c.	   	   EYFP-­‐Mms2	   appears	   to	   localize	   to	   the	   centrosomes	   in	   SAOS2	  
cells	  stably	  expressing	  EYFP-­‐Mms2.	  	   	  SAOS2	  cells	  stably	  expressing	  pEYFP-­‐Mms2	  (A)	  and	  SAOS2	  cells	  transiently	  transfected	  with	  the	  pEYFP-­‐C1	  empty	  control	  vector	  (B),	   were	   fixed	  with	   -­‐20°C	  Methanol	   on	   ice	   for	   5	  minutes,	   after	  which	   they	  were	  stained	   with	   the	   rabbit	   GFP	   antibody	   and	   the	   mouse	   gamma	   tubulin	   antibody.	  	  Staining	  is	  reduced	  in	  SAOS2	  cells	  stably	  expressing	  pEYFP-­‐C1.	  	  Non-­‐specific	  binding	  is	  visible,	  but	  the	  cells	  expressing	  pEYFP-­‐Mms2	  have	  a	  noticeably	  brighter	  stain	  both	  in	   general	   throughout	   the	   cell	   and	   also	   in	   the	   centrosome.	   	   The	   gamma	   tubulin	  antibody	  confirms	  the	  centrosome	  localization.	  	  	  
	   	  
	  	  

















Figure	   3-­‐23d.	   	   EYFP-­‐Mms2	   appears	   to	   localize	   to	   the	   centrosomes	   in	   SAOS2	  
cells	  stably	  expressing	  EYFP-­‐Mms2.	   	  SAOS2	  pEYFP-­‐Mms2	  cells	  were	  fixed	  with	  -­‐20°C	  methanol	  for	  5	  minutes	  and	  were	  then	  stained	  with	  the	  Mms2/Uev1a-­‐specific	  mouse	  2H11	  antibody	  and	  the	  rabbit	  gamma	  tubulin	  antibody.	   	  The	  rabbit	  gamma	  tubulin	  antibody	  confirms	  centrosome	  localization.	  	  2H11	  localizes	  in	  one	  of	  the	  two	  centrosomes	  in	  this	  interphase	  cell.	  	  	  
	  
	   	  
	  	  






Figure	   3-­‐23e.	   	   EYFP-­‐Mms2	   appears	   to	   localize	   to	   the	   centrosomes	   in	   SAOS2	  
cells	   stably	   expressing	   EYFP-­‐Mms2.	   SAOS2	   EYFP-­‐Mms2	   cells	   were	   fixed	  simultaneously	   with	   4%	   formeldahyde	   and	   0.5%	   NP40	   for	   15	   minutes	   and	   were	  then	   stained	   with	   the	   rabbit	   GFP	   antibody	   to	   detect	   EYFP-­‐Chfr	   and	   the	   mouse	  gamma	  tubulin	  antibody	  to	  detect	  centrosome	  localization.	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CHAPTER	  4:	  DISCUSSION	  
	  
4.1	   	   Protein	   interactions	   indicating	   involvement	   of	   Chfr,	   Ubc13,	   and	   pH3	   in	  
mitosis.	  Chfr	  binds	  to	  phosphorylated	  histone	  H3	  (pH3),	  a	  protein	  very	  important	  in	  the	   G2/M	   transition.	   	   Histones	   are	   important	   for	   packaging	   DNA	   into	   compact	  chromosomes,	   and	   influence	   chromosome	   condensation	   and	   decondensation.	  	  Phosphorylated	  histone	  H3	  functions	  at	  early	  prophase	  and	  not	  at	  interphase.	  	  It	  is	  a	  mitotic	   protein.	   	   Chfr	   binds	   to	   pH3,	   most	   likely	   through	   its	   FHA	   domain.	   	   The	  literature	   is	   in	   line	   with	   this	   finding	   (Chfr-­‐pH3),	   stating	   that	   whenever	   the	   FHA	  domain	  of	  Chfr	  is	  deleted,	  this	  results	  in	  a	  dysfunctional	  checkpoint,	  probably	  due	  to	  the	   inability	   of	   Chfr	   to	   reduce	   pH3	   levels	   or	   mitotic	   index	   in	   a	   cell	   population	  (Scolnick	  et	  al.,	  2000).	  	  	  A	  possible	  explanation	  for	  the	  Chfr	  disfunction	  caused	  by	  the	  FHA	  deletion	  at	  a	  molecular	   level	   is	   that	   Chfr	   is	   no	   longer	   able	   to	   bind	   to	   pH3	   and	   hence	   cannot	  influence	  or	  remove	  pH3	  from	  DNA,	  resulting	  in	  pH3	  level	  increase,	  which	  indicates	  chromosome	   condensation.	   	   The	   literature	   is	   in	   line	  with	   this	   finding,	   stating	   that	  whenever	   normal	   Chfr	   protein	   levels	   are	   low	   or	   the	   FHA	   domain	   is	   deleted,	   pH3	  levels	  are	  high	  	  (Scolnick	  et	  al.,	  2000).	  Since	  Chfr	  expression	  clearly	  influences	  the	  level	  of	  this	  protein,	  and	  since	  the	  pH3	  protein	   is	  necessary	   for	   chromosome	   condensation,	   a	  Chfr-­‐pH3	   interaction	   is	  not	  surprising.	  	  The	  interaction	  supports	  the	  hypothesis	  that	  Chfr	  interacts	  directly	  with	   DNA	   to	   rapidly	   modulate	   its	   state	   of	   condensation	   at	   the	   interphase-­‐early	  prophase	  transition.	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There	   are	   also	   some	   observations	   that	   indicate	   Ubc13	   binds	   to	   pH3	   in	  mitosis.	   	   Ubc13	   can	  make	   poly-­‐ubiquitin	   chains	  with	   Chfr	   that	   are	   K-­‐63-­‐linked	   in	  nature	  (Bothos	  et	  al.,	  2003).	  	  The	  Chfr-­‐Ubc13,	  Chfr-­‐pH3,	  and	  Ubc13-­‐pH3	  interactions	  support	  the	  idea	  that	  a)	  these	  proteins	  function	  in	  mitosis,	  because	  they	  bind	  pH3;	  b)	   these	   proteins	   function	   together	   in	   mitosis;	   and	   c)	   these	   proteins	   function	  together	   at	   the	   early	   prophase,	   through	   K-­‐63-­‐linked	   or	   K-­‐48-­‐linked	   poly-­‐ubiquitination.	   	   This	   bulky	   polyubiquitination	   chain	   could	   then	   either	   generate	  stearic	   hindrance	   to	   temporarily	   prevent	   proper	   chromosome	   compaction	   or	  prevent	  access	  to	  pH3.	  	  Aurora	  A	  kinases,	  for	  example,	  would	  have	  reduced	  access	  to	  pH3,	   resulting	   in	   a	   higher	   likelihood	   of	   dephosphorylation	   of	   pH3	   and	  decondensation	  of	  chromosomes	  at	  early	  prophase,	  blocking	  mitotic	  progression.	  	  
4.2	   	   Chfr	   localization	   to	   decondensed	   or	   decondensing	   chromatin	   indicating	  
mitotic	  	  function.	  Furthermore,	  an	  over-­‐expressed	  Chfr	  protein	  (EGFP-­‐Chfr)	  in	  U2OS	  cells	  has	  a	  tendency	   to	   accumulate	   at	   higher	   concentrations	   in	   particular	   cellular	   structures,	  most	  notably	   the	  nucleus	  at	   interphase	  and	  telophase.	   	   Interestingly,	   these	  are	   the	  two	   cell	   cycle	   stages	  where	   chromatin	   is	   either	   kept	   in	   a	   decondensed	   state,	   or	   a	  decondensing	   state,	   respectively.	   	   This	   accumulating	   concentration	   of	   the	   Chfr	  protein	   within	   the	   vicinity	   of	   the	   decondensed	   or	   decondensing	   DNA	   indicates	   a	  decondensing	  role	  for	  Chfr.	  	  	  There	   are	   also	   some	   observations	   that	   indicate	   Ubc13	   localizing	   to	  mitotic	  chromosomes,	   also	   including	   telophase.	   	   Such	   visual	   localizations	   are	   significant	  
	  	  
	  	   	   99	  
because	   they	   reflect,	   support,	   and	   help	   to	   elucidate	   some	   of	   the	   earlier	   findings	  about	   the	   molecular	   mechanism	   of	   Chfr.	   	   For	   example,	   Scolnick	   and	   Halazonetis	  (2000)	   showed	   how	   Chfr	   and	   Ubc13	   could	   function	   together	   using	   the	  ubiquitination	  mechanism	  to	  delay	  mitosis.	  
	  
4.3	  	  Chfr,	  Ubc13,	  and	  Mms2/Uev1a	  localization	  to	  mitotic	  structures.	  
Chfr,	  Ubc13,	   and	  Mms2/Uev1a	   localize	   to	   the	   centrosomes.	   	   Localization	  of	  Chfr,	  Ubc13,	  and	  Mms2/Uev1a	  to	  the	  centrosomes	  indicates	  that	  these	  proteins	  are	  involved	  in	  centrosome	  maturation,	  separation,	  and/or	  spindle	  formation.	  	  Aurora	  A	  and	  Plk1,	   two	  mitosis	   promoting	  proteins,	   also	  have	  been	   found	   to	   localize	   to	   the	  centrosome	   structures,	   and	   are	   important	   for	   proper	   cell	   cycle	   progression.	   	   Our	  results	   indicate	   that	   Chfr,	   Ubc13,	   and	   Mms2/Uev1a	   localize	   to	   these	   structures,	  which	   indicates	   that	   they	   may	   possibly	   function	   together	   at	   these	   sites	   to	   send	  signals	   to	   mitotic	   regulators,	   such	   as	   Aurora	   A	   or	   Plk1.	   	   Ubc13	   presence	   at	   the	  centrosomes	   implies	   a	   potential	   K-­‐63-­‐linked	   poly-­‐ubiquitinating	   function	   at	   these	  sites,	   though	   a	   K-­‐48-­‐linked	   function	   is	   not	   excluded.	   	   Ubc13	   and	  Mms2	   have	   also	  been	  found	  in	  the	  mitotic	  spindle	  of	  some	  cells.	  
Summers	  et	  al.	  (2005)	  shows	  how	  Chfr	  expression	  influences	  Aurora	  A.	  	  Chfr	  expression	   in	   cells	   appears	   to	   prevent	   the	   accumulation	   of	   active	  Aurora	  A	   at	   the	  interphase	   centrosomes.	   	   Active	  Aurora	  A	   (Aurora	  pT288)	   is	   only	   present	   in	   cells	  that	   are	   in	   mitosis	   and	   have	   thus	   overcome	   the	   Chfr	   checkpoint.	   	   Perhaps	   Chfr	  functions	   here	   by	   ubiquitinating	   Aurora	   A	   for	   destruction	   by	   K-­‐48-­‐linked	   poly-­‐
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ubiquitination	   at	   interphase,	   and	   at	   late	   prophase	   once	   cells	   squeeze	   through	   the	  G2/M	   checkpoint	   activates	  Aurora	  A	   by	  K-­‐63	   linked	   poly-­‐ubiquitination	   using	   the	  Ubc13-­‐Mms2	   enzyme.	   Cells	   can	   then	   ensure	   that	   their	   centrosomes	   mature	  properly,	   that	   the	   mitotic	   spindle	   is	   properly	   formed,	   and	   that	   mitotic	   progress	  occurs	  securely	  at	  the	  spindle	  checkpoint.	  	  Accurate	  cell	  division	  can	  in	  this	  way	  be	  properly	  carried	  out	  (Summers	  et	  al.,	  2005).	  Toland	  et	  al.	  (2003)	  further	  helps	  to	  confirm	  the	  localization	  of	  Ubc13	  to	  the	  centrosomes	  at	  mitosis.	  	  They	  do	  not	  mention	  Chfr.	  	  However,	  they	  do	  mention	  that	  when	  Aurora	  A	   is	  mutated,	  Ubc13	  does	   not	   colocalize	   to	   the	   centrosomes	  with	   it.	  	  This	  indicates	  that	  Aurora	  A	  may	  recruit	  Ubc13	  into	  the	  centrosomes	  during	  mitosis	  to	  carry	  out	  a	  specific	  function.	  	  This	  report	  together	  with	  our	  results	  indicates	  that	  Ubc13	  functions	  with	  Chfr	  to	  modulate	  Aurora	  A	  function.	  	  Ubc13	  presence	  implies	  the	   possibility	   of	   K-­‐63-­‐linked	   poly-­‐ubiquitination	   (Toland	   et	   al.,	   2003).	   	   The	   Chfr	  checkpoint,	  however,	  most	  likely	  uses	  K-­‐48-­‐linked	  poly-­‐ubiquitin	  chains	  to	  degrade	  or	   inactivate	   Aurora	   A,	   preventing	   centrosome	  maturation	   and	   spindle	   formation	  during	  microtubule	  damage.	   	  Only	  after	  microtubule	  stress	   is	  removed	  can	  the	  cell	  progress	  through	  mitosis.	  	  At	  this	  point	  Ubc13	  could	  use	  K-­‐63-­‐linked	  poly-­‐ubiquitin	  chains	   at	   the	   centrosomes	   to	   activate	   important	   mitotic	   regulators,	   allowing	   for	  centrosome	   maturation,	   spindle	   formation,	   and/or	   proper	   progression	   through	  mitosis.	  	  	  Thus,	  a	  molecular	  mechanism	  can	  be	  envisioned	  here,	  whereby	  Chfr	  localizes	  to	  centrosomes	  with	  Ubc13-­‐Mms2,	  which	  would	  be	  recruited	  by	  Aurora	  A	  (Toland	  et	  al.	  2003).	  	  This	  complex	  could	  then	  generate	  K-­‐48	  linked	  signals	  to	  reduce	  Aurora	  A,	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Plk1,	   or	   alpha-­‐tubulin	   levels	   (Privette	   et	   al.,	   2008b),	   or	   K63-­‐linked	   signals	   to	  influence	   protein	   location	   or	   protein-­‐protein	   interactions	   at	   the	   centrosomes	   and	  microtubule	  location.	  	  	  
4.4	  Chfr	  level	  and	  modification	  at	  the	  G2/M	  mitotic	  entry	  gate.	  Kim	  et	   al.	   (2011)	   shows	  a	   clear	   correlation	  between	  Chfr	  protein	   level	   and	  pH3	  protein	   level,	  as	  cells	  enter	  mitosis	  and	  progress	  through	  mitosis.	   	  This	  group	  clearly	   shows	   that	   when	   Chfr	   expression	   decreases,	   pH3	   levels	   increase,	   which	  indicates	  increased	  entry	  into	  mitosis.	  	  They	  also	  show	  that	  such	  fluctuations	  in	  Chfr	  and	  pH3	  level	  may	  be	  due	  to	  a	  degradative	  ubiquitin	  signal,	  with	  Chfr	  reducing	  itself	  in	  level	  when	  not	  necessary.	  	  
	  
4.4.1	  The	  two	  molecular	  states	  of	  Chfr	  at	  G2/M	  transition.	  	  Looking	  at	  the	  state	  of	  Chfr	  in	  cell	  populations	  that	  are	  at	  a	  particular	  time	  point,	  can	  give	  a	  glimpse	  into	  how	   the	   protein	   could	   function	   at	   a	   molecular	   level.	   	   Our	   data	   indicates	   that	   (a)	  there	  are	  two	  molecular	  states	  of	  Chfr:	  Chfr	  and	  Chfr-­‐Ub;	  (b)	  Chfr	  is	  predominant	  at	  LP,	  whereas,	  Chfr–Ub	  is	  predominant	  at	  INT/EP;	  (c)	  Chfr	  looses	  its	  ubiquitin	  signal	  after	   cells	   pass	   through	   the	   INT/EP	   transition;	   (d)	   Chfr	   protein	   levels	   clearly	  increase	   at	   LP	   in	   response	   to	   extensive	   mitotic	   stress,	   after	   passing	   through	   the	  INT/EP	  stage;	  (e)	  Chfr,	  Ubc13,	  and	  Mms2/Uev1	  levels	  increase	  at	  INT/EP	  indicating	  their	   importance	   at	   the	  G2/M	   checkpoint	   gate;	   and	   f)	   the	  presence	   of	   high	  Ubc13	  and	  Mms2/Uev1	  levels	  indicates	  the	  possibility	  of	  K63-­‐linked	  poly-­‐ubiquitination	  at	  that	  particular	  time	  point.	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4.4.2	  Association	  of	  the	  Chfr	  modification	  with	  chromosome	  condensation.	  Chfr-­‐Ub	  is	  associated	  with	  reduced	  pH3	  levels	  and	  deubiquitinated	  Chfr	  with	  increased	  pH3	  levels	  in	  a	  cell	  population.	  	  The	  ubiquitin	  signal	  could	  be	  either	  K63-­‐linked	   or	   K48-­‐linked	   as	   Ubc13	   can	   generate	   both	   types	   of	   poly-­‐ubiquitin	   chains.	  	  Although	   the	   data	   obtained	   in	   this	   study	   indicate	   a	   potential	   K63-­‐linked	   poly-­‐ubiquitin	  modification,	  this	  does	  not	  exclude	  a	  degradative	  signal,	  particularly	  since	  low	  Chfr	  level	  is	  correlated	  with	  high	  ubiquitination.	  	  	  	  	  Here	  a	  model	  could	  be	  envisioned	  whereby	  the	  E3	  ligase	  functions	  together	  with	   Ubc13	   and	   Mms2	   at	   the	   INT/EP	   checkpoint	   gate	   to	   decondense	   DNA.	   	   The	  ubiquitin	  signal	  could	  be	  either	  K-­‐63-­‐linked	  or	  K-­‐48-­‐linked	  in	  nature.	  	  Chfr-­‐Ub	  could	  bind	   directly	   to	   pH3	   at	   the	   INT/EP	   stage,	   and	   its	   auto-­‐ubiquitin	   signal	   provide	  temporary	   stearic	   hindrance	   to	   interfere	   with	   chromosome	   condensation.	  	  Following	  the	  temporary	  delay	  at	  the	  INT/EP	  transition	  due	  to	  microtubule	  stress,	  Chfr	   could	   then	   destruct	   to	   remove	   stearic	   hindrance	   and	   allow	   chromosome	  condensation,	   using	   its	   temporary	   ubiquitin	   signal.	   	   Stearic	   hindrance	   would	   be	  reduced	  in	  this	  way.	  	  Upon	  passage	  through	  INT/EP,	  Chfr	  clearly	  looses	  its	  ubiquitin	  signal.	  	  As	  a	  result,	  Chfr	  increases	  in	  level	  upon	  entry	  into	  LP;	  and	  this	  could	  serve	  as	  a	  further	  control	  to	  prevent	  progression	  under	  suspicious	  conditions.	  Under	  normal	  conditions,	   Chfr	   would	   be	   expected	   to	   auto-­‐ubiquitinate	   and	   eventually	   destruct	  upon	   entry	   into	  mitosis,	   resulting	   in	   an	   increase	   in	   pH3	   levels.	   	   Temporary	   auto-­‐ubiquitination	  could	   in	   this	  way	  provide	  a	  decondensation	  model	  where	  Chfr	  bind	  pH3,	  auto-­‐ubiquitinates	  self,	  and	  decondenses	  DNA.	  
	  
	  	  
	  	   	   103	  
4.4.3	   Auto-­‐ubiquitination	   versus	   ubiquitination	   of	   substrate	   proteins.	  	  Furthermore,	  Chfr	  could	  bind	  to	  pH3	  and	  generate	  a	  bulky	  K-­‐48/K-­‐63	  linked	  poly-­‐ubiquitin	   stress	   signal	   to	   prevent	   access	   to	   important	   mitotic	   kinases	   that	  phosphorylate	   and	  activate	  H3.	   	   	   Chfr	   could	  poly-­‐ubiquitinate	   either	   itself,	   pH3	  or	  the	  mitotic	  kinases	   themselves	   to	  generate	  stearic	  hindrance.	   	  This	  could	   interfere	  with	   protein	   level,	   protein-­‐protein	   interactions,	   protein	   function,	   or	   protein	  localization.	  Chfr	  could	  influence	  localization	  of	  Aurora	  A	  to	  the	  centrosomes	  (Summers	  et	  al.,	  2005)	  by	  using	  a	  K63-­‐linked	  poly-­‐ubiquitin	  signal.	  	  When	  Chfr	  is	  over-­‐expressed,	  for	  example,	  Aurora	  A	  cannot	  be	  activated	  at	  interphase	  centrosomes	  (Summers	  et	  al.,	   2005).	   	   It	   is	   only	   activated	   later	   on	   in	  mitosis.	   	   Perhaps	  Chfr	   transfers	   a	  bulky	  K63-­‐linked	  ubiquitin	  signal	  onto	  the	  Aurora	  A	  protein	  that	  disables	  Aurora	  A	  from	  localizing	   to	   the	   centrosomes.	   	   Alternatively,	   a	   K48-­‐linked	   poly-­‐ubiquitin	   signal	  could	  degrade	  Aurora	  A	  at	  the	  interphase	  centrosomes	  (Yu	  et	  al.,	  2005;	  Summers	  et	  al.,	  2005).	  	  	  Chfr	   could	   also	   bind	   to	   histone	  H3	   at	   INT/EP,	   generate	   a	   bulky	  K63-­‐linked	  poly-­‐ubiquitin	   signal,	   and	   prevent	   access	   of	   Aurora	   B	   to	   histone	   H3	   at	   this	   stage.	  	  	  Unable	   to	   access	   histone	  H3,	   Aurora	  B	  would	   be	   prevented	   from	  phosphorylating	  histone	   H3	   on	   Serine	   10,	   preventing	   mitotic	   entry.	   	   Aurora	   B	   can	   localize	   to	   the	  kinetochores	  at	  G2	  (Summers	  et	  al.,	  2005).	  	  Kinetochores	  are	  specialized	  regions	  of	  DNA	   that	   contain	   specialized	   histones	   such	   as	   histone	  H3	   variant	   CenH3,	   and	   are	  DNA	  regions	  where	  microtubules	  eventually	  attach	  at	  the	  spindle	  checkpoint.	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Alternatively,	  as	  far	  as	  centrosomes	  are	  concerned,	  Chfr	  could	  degrade	  alpha-­‐tubulin;	  Aurora	  A,	  and	  Plk1	  would	  then	  be	  expected	  for	  targeted	  destruction	  by	  Chfr	  at	   the	   centrosomes.	   It	   could	   degrade	   Plk1	   by	   K48-­‐linked	   poly-­‐ubiquitination,	  activate	  CyclinB1-­‐Cdc2	  and	  promote	  mitotic	  entry.	  	  	  	  
4.4.4	   	  Influence	   of	   nocodazole	   on	   Chfr	  modification.	  Furthermore,	  nocodazole	  which	   is	   a	   form	   of	  microtubule	   stress,	   affects	   the	   observed	   Chfr	  modification.	   	   As	  cells	  are	  exposed	  to	  nocodazole	  for	  a	  longer	  time	  period,	  Chfr	  protein	  levels	  increase	  but	   the	  modification	   on	   this	   protein	   decreases.	   	   Since	   the	  modification	   decreases	  upon	  nocodazole	  exposure,	  this	  indicates	  that	  nocodazole	  exposure	  probably	  results	  in	   Chfr	   deubiquitination.	   	   Cells	   that	   are	   not	   exposed	   to	  nocodazole	   have	   the	  most	  modified	  Chfr,	  and	  the	  least	  Chfr	  protein,	  whereas	  cells	  that	  are	  exposed	  for	  longer	  periods	  have	  less	  modification	  and	  more	  protein.	  	  This	  indicates	  that	  Chfr	  may	  auto-­‐ubiquitinate	  itself	  for	  destruction	  when	  not	  necessary.	  
	  
4.5	  Chfr	  and	  its	  relation	  to	  chromatin.	  As	  far	  as	  chromosomes	  are	  concerned,	  the	  poly-­‐ubiquitin	  chains	  of	  Chfr	  could	  possibly	   serve	   to	   change	   the	   conformation	   of	   the	   chromatin	   and	   increase	   stearic	  hindrance	  at	  the	  early	  prophase	  stage	  of	  mitosis.	  	  This	  is	  in	  line	  with	  the	  observation	  that	  a)	  Chfr	  binds	  to	  pH3,	  which	  is	  an	  early	  mitotic	  protein;	  b)	  Ubc13	  binds	  pH3;	  c)	  Chfr	   binds	   to	   Ubc13,	   which	   is	   a	   ubiquitin-­‐conjugating	   enzyme	   d)	   Chfr	   auto-­‐ubiquitinates	   itself;	  e)	   the	  ubiquitin	  modification	   increases,	  as	  pH3	   levels	  decrease	  in	  nocodazole	  presence;	  and	  f)	  Chfr-­‐Ub	  is	  associated	  with	  INT/EP.	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Nocodazole	  exposure	  can	  regulate	  the	  amount	  of	  Chfr-­‐Ub	  in	  a	  cell	  population,	  and	   the	   amount	   of	   phosphorylated	   histone	   H3	   in	   a	   cell	   population.	   	   Mitotic	  chromosomes	  are	  rich	  in	  phosphorylated	  histone	  H3.	  	  The	  more	  nocodazole,	  the	  less	  polyubiquitinated	   Chfr	   in	   a	   cell	   population,	   the	   more	   Chfr	   there	   is	   in	   the	   cell	  population,	  and	  the	  more	  phosphorylated	  histone	  H3	  there	  is	  in	  nocodazole-­‐exposed	  cells.	   In	  nocodazole	  presence,	   the	  Chfr-­‐pH3	   interaction	  appears	   to	  be	   lost,	   and	   the	  amount	   of	   poly-­‐ubiquitin	   chains	   on	   Chfr	   is	   also	   lost:	   as	   nocodazole	   increases,	  ubiquitinated	   Chfr	   decreases.	   	   This	   could	   reduce	   steric	   hindrance	   potentially	  generated	   by	   the	   ubiquitin	   chains,	   leading	   to	   condensation.	   	   In	   other	  words,	   Chfr	  cannot	   decondense	   the	   chromosomes	   because	   the	   Chfr	   signal	   is	   gone.	   	   In	   the	  presence	   of	   nocodazole,	   Chfr	   can	   no	   longer	   bind	   to	   pH3,	   so	   it	   cannot	   affect	   DNA	  structure,	   which	   is	   most	   likely	   why	   pH3	   levels	   rise	   as	   nocodazole	   exposure	  increases.	  
In	   the	   absence	   of	   nocodazole,	   ubiquitinated	   Chfr	   could	   bind	   histone	   H3	  through	   the	   FHA	   domain	   (Stavridi	   et	   al.,	   2002).	   	   Ubiquitinated	   Chfr	   is	   correlated	  with	  decreased	  amounts	  of	  pH3	  (decreased	  chromosome	  condensation).	  	  The	  bulky	  ubiquitin	  signal	  on	  the	  Chfr	  protein	  bound	  to	  pH3	  could	  serve	  to	  decondense	  DNA	  at	  interphase	  and,	  when	   conditions	  are	   favorable,	   lead	   to	   the	  destruction	  of	   the	  Chfr	  protein	   to	   allow	   entry	   into	  mitosis.	  Figure	   4-­‐1	   summarizes	   the	   discussion.	   	   Since	  pH3	   symbolizes	   chromosome	   condensation	   and	   mitosis,	   the	   correlation	   between	  increased	  Chfr	  ubiquitination	  and	  decreased	  chromosome	  condensation	  (decreased	  pH3	  levels)	  in	  nocodazole	  presence,	  indicates	  a	  mitosis-­‐preventing	  role	  for	  Chfr-­‐Ub.	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Figure	  4-­‐1.	  	  A	  possible	  molecular	  mechanism	  by	  which	  Chfr,	  Ubc13,	  and	  Mms2	  
could	   function	   together	   to	  promote	  accurate	  mitosis.	   	   	  The	  evidence	  presented	  in	   the	   report	   indicates	   that	   Chfr,	   Ubc13,	   and	   Mms2	   localize	   to	   the	   centrosomes	  during	   mitosis.	   	   The	   Chfr-­‐Ubc13-­‐Mms2	   protein	   complex	   could	   possibly	   alter	   the	  level	  or	  behavior	  of	  important	  cell	  cycle	  promoting	  proteins	  in	  the	  centrosomes	  and	  in	   the	  mitotic	   spindle	   to	  halt	  mitosis.	   	  Aside	   from	   the	   centrosome	   localization,	   the	  Chfr-­‐Ubc13-­‐Mms2/Uev1	   complex	   could	   also	   function	   in	   chromosome	  decondensation	  to	  prevent	  mitotic	  progression.	  	  	  (1)	  	  Chfr	  binds	  to	  pH3	  via	  its	  FHA	  domain	   at	   interphase-­‐early	   prophase.	   (2)	   The	   Chfr-­‐Ubc13-­‐Mms2	   complex	   auto-­‐ubiquitinates	  itself	  at	  interphase-­‐early	  prophase.	  	  This	  signal	  could	  be	  either	  K48	  or	  K63-­‐linked.	   	  (3)	  The	  chromatin	  is	  kept	  in	  a	  decondensed	  state	  in	  interphase	  and	  in	  telophase,	  and	  the	  bulky	  ubiquitin	  chain	  interferes	  with	  chromosome	  condensation.	  	  (4)	  The	  Chfr	  protein	  level	  is	  reduced	  through	  degradation,	  which	  is	  the	  reason	  why	  (5)	  chromosomes	  condense	  and	  	  (6)	  mitosis	  occurs.	  	  	  	  Upon	   extensive	   nocodazole	   treatment	   (2),	   the	   Chfr-­‐pH3	   interaction	   is	   lost	  (3),	   the	   ubiquitin	   signal	   is	   reduced	   (4),	   and	   Chfr	   protein	   level	   increases	   in	   late	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prophase	  to	  counteract	  the	  mitotic	  stress	  	  (5).	  	  Chromosomes	  condense	  	  (6)	  because	  Chfr	  can	  no	  longer	  bind	  to	  pH3	  on	  chromosomes	  and	  it	  can	  no	  longer	  use	  the	  bulky	  ubiquitin	   signal	   to	   interfere	   with	   chromosome	   condensation.	   Upon	   temporary	  nocodazole	  exposure	  Chfr	  could	  target	  Plk1,	  Aurora	  A,	  and	  acetylated-­‐alpha-­‐tubulin	  for	  destruction	  at	  the	  centrosomes	  and	  at	  the	  mitotic	  spindle.	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CHAPTER	  5:	  CONCLUSIONS	  
	  
5.1	  Localization	  of	  Chfr,	  Ubc13,	  and	  Mms2	  to	  mitotic	  structures	  indicates	  their	  
function	  in	  mitosis.	  
5.1.1	  Localization	  to	  the	  centrosomes.	  	  Immunocytochemistry	  indicates	  that	  Chfr,	  Ubc13,	   and	   Mms2	   localize	   to	   the	   centrosomes	   in	   interphase	   and	   in	   mitosis.	  Centrosomes	  are	  microtubule-­‐organizing	  centres	   in	  cells,	  and	  their	  proper	  growth,	  maturation,	   duplication,	   and	   separation	   at	   interphase	   and	   early	   prophase	   is	  necessary	   for	   normal	   mitosis.	   	   Localization	   of	   Chfr,	   Ubc13,	   and	   Mms2	   to	   these	  structures,	   thus,	   indicates	   their	   function.	   Colocalization	   of	   Chfr	   and	   Ubc13	   to	   the	  structures	  indicates	  that	  they	  function	  together.	  	  High	  levels	  of	  Chfr-­‐Ub,	  Ubc13,	  and	  Mms2	   at	   the	   interphase-­‐early	   prophase	   stage,	   and	   not	   at	   the	   late	   prophase	   stage,	  further	  helps	  to	  support	  the	  immunocytochemistry	  results	  that	  the	  proteins	  function	  together.	  
Aurora	   A	   and	   Plk1,	   two	   mitosis	   promoting	   proteins,	   also	   localize	   to	   the	  centrosomes	   (Privette	   et	   al.,	   2008b;	   Toland	   et	   al.,	   2003;	   Summers	   et	   al.,	   2005).	  Based	   on	   the	   results	   and	   on	   the	   literature,	   a	   molecular	   mechanism	   can	   be	  envisioned	  whereby	  Chfr,	  Ubc13,	  and	  Mms2/Uev1	  reduces	  the	  level	  of	  Aurora	  A	  or	  Plk1	   in	   the	   centrosomes	   at	   interphase	   through	   K48-­‐linked	   poly-­‐ubiquitination.	  	  Acetylated	  alpha-­‐tubulin	  in	  the	  mitotic	  spindle	  apparatus	  could	  also	  be	  targeted	  for	  destruction.	   	   Auto-­‐ubiquitination	   of	   Chfr	   would	   be	   useful	   here	   in	   modulating	   the	  level	   of	   Chfr:	   auto-­‐ubiquitinating	   itself	   for	   destruction	   when	   not	   necessary	   and	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increasing	   itself	   in	   level	   when	   exposed	   to	   nocodazole.	   	   Once	   the	  mitotic	   stress	   is	  removed	  Ubc13-­‐Mms2	  could	  then	  generate	  K63-­‐linked	  poly-­‐ubiquitin	  chains	  to	  alter	  protein	  function	  of	  Aurora	  A,	  or	  Plk1.	  	  It	  could	  also	  stabilize	  certain	  proteins	  such	  as	  acetylated-­‐alpha	   tubulin.	   	   The	   hypothesis	   was	   that	   Chfr,	   Ubc13,	   and	   Mms2	   are	  involved	   in	  mitosis,	   and	   their	   localization	   to	  mitotic	   structures	   indicates	   that	   the	  results	  agree	  with	  this	  hypothesis.	  	  	  
	  
5.1.2	  Localization	  to	  the	  mitotic	  spindle.	  	  Both	  Ubc13	  and	  Mms2	  have	  been	  found	  to	   localize	   to	   the	   centrosomes	   and	   to	   the	   mitotic	   spindle	   of	   some	   cells.	   	   This	  indicates	   that	   the	   two	   proteins	   are	   involved	   in	   mitosis.	   	   The	   spindle	   checkpoint	  occurs	  at	  the	  metaphase-­‐to-­‐anaphase	  transition	  to	  ensure	  that	  all	  microtubules	  are	  properly	   attached	   to	   the	   kinetochores	   before	   anaphase	   can	   occur.	   	   Chfr	   has	   been	  shown	   to	   bind	   to	   alpha-­‐tubulin,	   and	   to	   ubiquitinate	   this	   protein	   for	   destruction	  (Privette	   et	   al.,	   2008b).	   	   Perhaps	   the	   bulky	   auto-­‐ubiquitin	   signal	   on	   Chfr,	   which	  binds	  to	  alpha-­‐tubulin,	  prevents	  binding	  to	  kinetochores.	  	  Lack	  of	  proper	  attachment	  between	   kinetochores	   and	   microtubules	   could	   then	   further	   alarm	   the	   spindle	  checkpoint	  into	  action.	  
	  
5.1.3	  Localization	  to	  the	  DNA.	  	  Furthermore,	  immunocytochemistry	  indicates	  that	  Chfr	  localizes	  to	  decondensed	  (interphase)	  or	  decondensing	  (telophase)	  chromatin,	  which	   gives	   a	   visual	   representation	   of	   its	   function	   at	   the	   vulnerable	   G2/M	   entry	  gate.	  	  At	  interphase	  the	  nucleus	  is	  full	  of	  Chfr,	  and	  chromatin	  remains	  decondensed.	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After	  cells	  enter	  mitosis,	  Chfr	  no	  longer	  localizes	  to	  DNA,	  dispersing	  throughout	  the	  cytoplasm.	  	  Reaccumulation	  of	  Chfr	  in	  telophase	  confirms	  the	  decondensing	  function	  of	   Chfr	   in	   interphase,	   as	   telophase	   is	   a	   stage	   at	  which	   DNA	   starts	   to	   decondense.	  	  Chfr	  localization	  at	  the	  interphase	  stage	  and	  at	  the	  telophase	  stage	  supports	  the	  idea	  that	  Chfr	   functions	  at	   the	  beginning	  and	  at	   the	  end	  of	  mitosis	   to	  decondense	  DNA,	  which	  supports	   the	  hypothesis	   that	   this	  protein	   is	   involved	   in	  mitosis,	  and	  that	   its	  function	  is	  of	  a	  decondensing	  nature.	  	  	  
Ubc13	   also	   localizes	   to	   DNA.	   	   It	   localizes	   to	   early	   prophase	   chromosomes,	  throughout	  mitosis,	   and	   also	   to	   telophase	   chromatin.	   	   Both	  Ubc13,	   and	  Chfr,	   thus,	  associate	  with	  DNA,	  which	   is	   in	   line	  with	   the	   literature	   that	  states	   that	  Ubc13	  and	  Chfr	  function	  at	  the	  nucleus	  to	  guard	  mitotic	  progression.	  	  	  
	  
5.2.	   High	   Ubc13	   levels	   in	   mitosis	   and	   Ubc13	   interaction	   with	   mitotic	  
chromosomes	  indicates	  a	  mitotic	  function	  for	  Ubc13.	  
Coimunoprecipitation	   indicates	   that	   Chfr	   and	   Ubc13	   may	   interact	   with	  phosphorylated	   histone	  H3.	   	   pH3	   is	   a	   very	   important	   indicator	   of	  mitosis,	   as	   this	  histone	   becomes	   phosphorylated	   very	   early	   on	   in	   mitosis,	   just	   as	   chromatin	   is	  beginning	  to	  condense.	   	   It	   is	  also	  very	  useful	   in	  distinguishing	  early	  prophase	  cells	  from	   interphase	  cells	  and	   late	  prophase	  cells.	   	   	   It	   is	  at	   the	  early	  prophase	  stage	  of	  mitosis,	  where	  the	  Chfr	  protein	  has	  been	  shown	  to	  exert	   its	  effects.	   	  The	  Chfr-­‐pH3	  and	  Ubc13-­‐pH3	  interactions,	  therefore,	  support	  the	  hypothesis	  that	  Chfr	  and	  Ubc13	  play	   a	   role	   in	   mitosis,	   and	   especially	   in	   early	   mitosis.	   	   In	   addition,	   Ubc13	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immunocytochemistry	  shows	  that	  Ubc13	  may	  be	  able	  to	  bind	  mitotic	  chromosomes,	  which	  helps	  to	  verify	  these	  coimmunoprecipitation	  results.	  	  Synchronization	  by	  the	  2xThymidine-­‐1xRO3306	   block	   and	   Western	   blot	   analysis	   further	   confirm	   Ubc13	  involvement	   in	   mitosis	   because	   these	   two	   techniques	   show	   that	   Ubc13	   levels	  increase	  as	  synchronized	  cells	  enter	  mitosis	  following	  the	  G2/M	  block.	  	  In	  summary,	  the	   results	   indicate	   Ubc13	   increases	   in	   mitosis,	   binds	   mitotic	   chromosomes,	   and	  binds	   to	   phosphorylated	   histone	   H3.	   	   These	   results	   indicate	   a	   role	   for	   Ubc13	   in	  regulating	  the	  state	  of	  chromosome	  condensation	  and	  decondensation.	  	  The	  level	  of	  Ubc13	  and	  Mms2	  is	  also	  increased	  at	  the	  interphase-­‐early	  prophase	  time	  point,	  and	  this	  further	  supports	  the	  idea	  that	  Ubc13	  could	  function	  at	  that	  particular	  point	  with	  Chfr,	  during	  the	  Chfr	  checkpoint.	  
	  
5.3.	  Modification	  of	  Chfr	  at	  the	  G2/M	  transition	  is	  correlated	  with	  reduced	  Chfr	  
levels	  and	  chromosome	  condensation.	  
Mitotic	   shake	   off	   and	   coimmunoprecipitation	   indicates	   that	   Chfr	   is	  ubiquitinated	  at	  the	  interphase-­‐early	  prophase	  stage	  of	  mitosis.	  	  This	  signal	  could	  be	  K63-­‐linked	  or	  K48-­‐linked,	  but	   is	  most	   likely	  degradative	   in	  nature	  as	  Chfr	  protein	  levels	  have	  been	  shown	  to	  decrease	  upon	  mitotic	  entry	  to	  allow	  cells	  into	  mitosis.	  	  	  
Our	   results	   indicate	   that	  Chfr	   is	  noticeably	  ubiquitinated	  at	   the	   interphase-­‐early	   prophase	   transition.	   	   The	   ubiquitin	   signal	   is	   clearly	   lost	   as	   cells	   pass	   the	   LP	  stage	   of	   mitosis.	   	   Also,	   in	   the	   presence	   of	   nocodazole,	   Chfr	   protein	   levels	   clearly	  increase	   to	   counteract	   the	   mitotic	   stress.	   	   High	   Ubc13	   and	   Mms2	   protein	   levels	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coincide	  with	   high	   levels	   of	   Chfr-­‐Ub,	   indicating	   that	   they	   function	   together	   at	   this	  time	  point.	  	  The	  Chfr-­‐pH3,	  Ubc13-­‐pH3	  and	  Chfr-­‐Ubc13	  interaction	  helps	  to	  support	  the	  conclusion	  that	  Chfr,	  Ubc13,	  and	  Mms2	  function	  together	  at	  early	  prophase.	  The	  ubiquitin	  signal	  is	  expected	  to	  regulate	  mitotic	  entry	  into	  mitosis.	  	  When	  the	  ability	  of	  Chfr	   to	  auto-­‐ubiquitinate	   itself	   is	  gone,	  Chfr	  expressing	  cells	  enter	  mitosis	  more	  often	   than	   those	   expressing	   normal	   Chfr.	   	   The	   polyubiquitin	   signal	   could	   be	   K63-­‐linked	   or	   K48	   linked.	   	   Perhaps	   Chfr	   uses	   the	   polyubiquitin	   signal	   to	   temporarily	  promote	  a	  decondensed	  state	  of	  chromatin	  at	  interphase-­‐early	  prophase,	  using	  the	  bulky	  signal	  as	  a	  form	  of	  stearic	  hindrance	  at	  the	  histone	  site.	  
	  
5.4	  The	  Chfr,	  Ubc13,	  and	  Mms2	  protein	  complex	  could	  function	  through	  a	  self-­‐
ubiquitination-­‐decondensation-­‐destruction-­‐recondensation	  mechanism.	  In	   summary,	   the	   data	   indicates	   that	   Chfr	   and	   Ubc13	   both	   interact	   with	  phosphorylated-­‐histone	   H3,	   which	   is	   a	   very	   important	   component	   of	   condensing	  chromatin.	   	   Chfr	   and	   Ubc13	   also	   bind	   to	   one	   another.	   	   Based	   on	   our	   research	  findings,	  it	  is	  possible	  that	  Chfr	  and	  Ubc13	  could	  function	  together	  to	  decondense	  or	  keep	  DNA	  in	  a	  decondensed	  state	  by	  binding	  to	  this	  mitotic	  histone,	  using	  its	  auto-­‐ubiquitinating	  signal.	  	  A	  ubiquitin	  molecule	  is	  76	  amino	  acids	  in	  size	  and	  histone	  H3	  is	   136	   amino	   acids	   in	   size.	   	   	   So	   a	   chain	  of	   ubiquitin	   attached	   to	  Chfr,	  which	  binds	  pH3,	   could	   be	   considered	   bulky	   and	   could,	   in	   theory,	   interfere	   with	   compact	  chromatin	  condensation.	  	  	  In	  other	  words,	  auto-­‐ubiquitination	  of	  Chfr	  could	  lead	  to	  dynamic	   decondensation,	   and	   then	   destruction	   of	   the	   Chfr-­‐Ub	   protein	   (and	   the	  bulky	  ubiquitin	  signal),	  leading	  to	  recondensation	  and	  mitosis.	  	  When	  nocodazole	  is	  
	  	  
	  	   	   113	  
added	   to	   such	   a	   situation,	   Chfr	   levels	   increase	   to	   counteract	   the	   mitotic	   stress.	  However,	   this	   also	   results	   in	   loss	  of	   the	  Chfr-­‐pH3	   interaction,	   and	   loss	  of	  Chfr-­‐Ub,	  indicating	   loss	   of	   bulky	   ubiquitin	   chains	   near	   the	   chromatin,	   resulting	   in	  chromosome	  condensation	  and	  forced	  entry	  into	  mitosis.	  	  Chfr	  could	  also	  localize	  to	  centrosomes	   and	   the	   mitotic	   spindle	   upon	   temporary	   nocodazole	   exposure	   to	  reduce	   acetylated	   alpha-­‐tubulin,	   Plk1,	   and	   Aurora	   A.	   	   Figure	   4-­‐1	   explains	   the	  molecular	  mechanism	  by	  which	  Chfr,	  Ubc13,	  and	  Mms2	  could	   function	  together	   to	  promote	  accurate	  mitosis.	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APPENDIX	  (Antibodies,	  solutions,	  buffers,	  media,	  chemicals,	  reagents):	  
	  
Dithiothreitol	  (DTT)	  BP	  172-­‐5	  Fisher	  scientific	  	  
Deoxycholic	  Acid	  D-­‐6750	  SIGMA	  	  
Igepal	  CA-­‐630	  (Nonindet	  P40)	  SIGMA-­‐ALDRICH	  13021-­‐100	  ml	  	  
Iodoacetamide,	  SigmaUltra	  	  I1149	  	  SIGMA	  	  
N-­‐Ethylmaleimide	  	  E1271-­‐5G	  	  SIGMA-­‐ALDRICH	  	  
N,N,Nʹ′ ,Nʹ′-­‐Tetramethylethylene-­‐diamine,	  	  
for	  electrophoresis,	  approximately	  99%	  T9281-­‐25	  ml	  SIGMA	  	  
Acrylamide/Bis-­‐acrylamide	  	  A6050-­‐100	  ml	  	  SIGMA	  	  
Thimerosal,	  SigmaUltra	  	  T8784-­‐1G-­‐25	  ml	  SIGMA	  
	  
Lipofectamine	  RNAiMAX	  Reagent	  13778-­‐030	  Invitrogen	  	  
OPTI-­‐MEM®1	  31985-­‐062	  GIBCO	  Invitrogen	  	  
	  
	  	  
	  	   	   117	  
R03306	  217-­‐699	  CALBIOCHEM	  
	  
Monoclonal	  Anti-­‐β Actin	  antibody	  Produced	  in	  mouse	  Clone	  AC-­‐74,	  ascites	  fluid	  SIGMA	  A5316	  -­‐	  0.5	  ml	  
	  
Anti-­‐phospho-­‐histone	  H3	  antibody	  (Ser10)	  Mitosis	  Marker	  06-­‐570	  MILLIPORE	  
	  
GFP	  Antibody	  sc-­‐8334	  rabbit	  polyclonal	  IgG	  Santa	  Cruz	  Biotechnology	  
	  
2H11	  ascites	  	  α-­‐hMMS2	  Feb	  19/01	  	  
Anti-­‐Ubiquitin,	  Lys	  63-­‐Specific	  antibody	  Clone	  Apu3	  (rabbit	  monoclonal)	  05-­‐1308	  MILLIPORE	  	  
Mouse	  Gamma	  Tubulin	  antibody	  05-­‐565	  UPSTATE	  	  
Anti-­‐Myc	  Tag	  antibody	  clone	  4A6	  agarose	  conjugate	  16-­‐219	  Millipore	  	  
Anti-­‐Myc	  Tag	  antibody	  rabbit	  polyclonal	  IgG	  06-­‐549	  UPSTATE	  
	  
Goat	  anti-­‐mouse	  IgG	  HRP	  conjugate	  antibody	  UPSTATE	  	  12-­‐349	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goat	  anti-­‐rabbit	  IgG	  HRP	  conjugate	  antibody	  sc-­‐2004	  	  HRP	  conjugated	  Santa-­‐Cruz	  Biotechnology	  	  
goat	  anti-­‐mouse	  IgG	  HRP	  conjugate	  antibody	  12-­‐349	  UPSTATE	  
	  
Anti-­‐Xpress	  antibody	  46-­‐0528	  Invitrogen	  
	  
Chfr	  	  (H-­‐300)	  sc-­‐28263	  Rabbit	  polyclonal	  IgG	  Santa	  Cruz	  Biotechnology	  
	  
	  
0.05%	  Trypsin-­‐EDTA	  25300-­‐062	  Invitrogen	  GIBCO	  
	  
FBS	  	  10437	  GIBCO	  Invitrogen	  
	  
Bio-­‐Rad	  Protein	  Assay	  BIORAD	  	  500-­‐0006	  	  
Acrylamide/Bis-­‐acrylamide,	  37:1	  SIGA-­‐ALDRICH	  A6050-­‐100	  ml	  
	  
Iodoacetamide	  Sigma	  Ultra	  SIGMA	  	  I1149-­‐5	  g	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Methanol	  	  A412-­‐4	  Fisher	  scientific	  
	  
Lysis	  Solution:	  200	  μl	  of	  phosphate	  buffer	  (0.2	  g	  KCl,	  0.2	  g	  KH2PO4,	  1.15	  g	  Na2HPO4,	  50	  ml	  ddH2O)	  54.8	  μl	  5M	  NaCl	  	  20	  μl	  of	  phosphate	  inhibitory	  cocktail	  	  20	  μl	  1	  M	  NEM	  in	  DMSO	  	  40	  μl	  10%	  SDS	  	  40	  μl	  10%	  deoxycholate	  	  1625	  ml	  water	  	  	  	  
IP	  diluent:	  1000	  μl	  of	  phosphate	  buffer	  274	  μl	  5	  M	  NaCl	  100	  μl	  phosphate	  inhibitory	  cocktail	  100	  μl	  1	  M	  NEM	  dissolved	  in	  DMSO	  8526	  ml	  of	  water	  	  
Elution	  buffer:	  125	  μl	  loading	  buffer	  25	  μl	  phosphate	  buffer	  	  50	  μl	  10%	  SDS	  (1%	  final)	  5	  μl	  1M	  DTT	  295	  μl	  autoclaved	  ddH2O	  6	  μl	  0.5	  M	  iodoacetamide	  per	  tube	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
